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General introduction 
Urogenital system, pathologies and current treatment options
The urogenital system is composed of the reproductive organs and the urinary 
system. These organ systems are often grouped together due to their common 
embryological origin, their proximity and the use of organs like the male urethra 
for both organ systems [1]. This thesis focuses on three organs from this system: 
The ureter, the urinary bladder and the urethra (figure 1). Like most organs, these 
are susceptible to acquired or congenital pathologies.
The ureter
The ureter is a muscular hollow tube that actively transports urine from the kidney 
to the urinary bladder through peristalsis [2]. Valves at the entrance to the bladder 
prevent reflux of urine. Ureteral damage mainly results from acquired pathologies 
such as injury, tumors or iatrogenic injury during surgical procedures [3]. A large 
retrospective analysis between 2002 and 2006 showed that 2,6% of all urogenital 
traumas involved the ureter [4]. While ureteral injury is relatively uncommon, 
failing to recognize the injury can lead to severe side effects, including sepsis or 
loss of renal function [5]. Specific anatomic characteristics of the ureter, such as 
the segmental vascular supply and the lack of native tissue, limits surgical ureteral 
reconstruction. Several surgical techniques have been introduced to repair long 
ureteral defects. Common procedures include a ureteroneocystostomy, a Boari 
flap, ileal interposition and renal autotransplantation. When these procedures 
fail, an undesirable nephrectomy often is the only option [6, 7]. 
Figure 1. Schematic overview of the urinary tract. Urine is produced by the kidneys and is transported 
through the ureters to the urinary bladder. The urinary bladder collects the urine, which is voided 
through the urethra when full.
The urinary bladder
The urinary bladder is a hollow muscular organ located in the pelvic floor. It 
collects and stores up to 300-500ml urine produced by the kidneys [2]. Acquired 
pathologies of the urinary bladder often result from tumors and can require 
complete resection of the urinary bladder [8]. Congenital anomalies can result 
from diseases such as bladder exstrophy or a neuropathic bladder [9]. Patients with 
congenital anomalies often require bladder augmentation to increase the volume 
of the bladder. Augmentation is most often performed using gastrointestinal 
tissue. The use of this tissue can be problematic due to a lack of tissue or result in 
side effects such as metabolic abnormalities, infections or stone formation [10, 11]. 
The urethra
The urethra is a hollow muscular tube that is used to void urine from the urinary 
bladder [2]. Congenital defects of the urethra, such as hypospadias, and acquired 
defects, such as strictures are major clinical problems. Hypospadias occur in 1 
in 300 live male births and 1 in 1000 men > 65 years of age develop strictures [12-
14]. Current treatment usually involves surgery and often requires graft tissues 
such as local tissue flaps or buccal mucosa [15-17]. The use of autologous grafts is 
often associated with donor site morbidity and complications such as infections 
or recurrent strictures [18]. 
Tissue engineering
While treatment options are available for most acquired and congenital pathologies 
of the urogenital system, there is a clear need for new treatment options to reduce 
side effects and recurrences. Tissue engineering and regenerative medicine aims 
at repairing or replacing damaged organs or tissues [19]. These newly formed 
tissues should provide similar functionality as the native organ or tissue. In 
general tissue engineered material can be produced by decellularization of donor 
tissue or by de-novo preparation from natural or synthetic materials [20-22]. 
Currently, no superior material has been identified. Several attempts have been 
made to improve these materials. These include the culture of stem) cells in the 
materials or the addition of biologically active materials such as growth factors 
and glycosaminoglycans (figure 2) [23, 24]. 
The ureter
While the literature on urogenital tissue engineering is quite extensive, the ureter 
is relatively understudied. This may suggest that the ureter is a challenging tissue 
to reconstruct due to the complexity of creating an actively contractile and tubular 
tissue [7]. Another reason may be the relatively low number of patients that need 
a tissue engineered ureter. In chapter 2 of this thesis it was demonstrated that the 
evidence in the literature was inconclusive about the optimal tissue engineering 
approach to treat long ureteral injuries. Clearly, there is still a need to develop 
new tubular constructs for ureteral repair. 
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The urinary bladder
Contrary to the ureter, tissue engineering of the urinary bladder has been 
studied more extensively. Atala et al. performed the first clinical trial using tissue 
engineering to improve bladder capacity [25]. While these results were promising, 
they could not be replicated in a phase 2 study [26]. Another clinical study showed 
that it was possible to improve bladder capacity, but the primary clinical endpoint 
of improved dry intervals was not reached [27]. This shows that improvements to 
the design of the tissue engineered constructs are still required before clinical 
trials can be considered again [28]. A systematic review of pre-clinical studies 
showed animal models with dysfunctional bladders in large animal models are 
required to properly test new tissue engineered constructs [29]. 
The urethra
The urethra is probably the most studied organ of the urogenital tract regarding 
tissue engineering. More than 20 clinical studies have been published using 
different materials and techniques as shown in chapter 4 of this thesis. Despite 
promising results, tissue engineering is still not routinely applied in clinical 
practice. This may be explained by insufficient quality of reporting in pre-clinical 
studies and a lack of proper control groups. To improve clinical translation, the 
quality of pre-clinical studies and their design should be improved. 
Figure 2. Schematic overview of tissue engineering approaches. In general, biomaterials are used 
as a scaffold or template to support the function of the organ while the tissue is regenerating. These 
materials can be enhanced with (stem) cells or bioactive molecules which may improve tissue 
regeneration. Before a material can be implanted into a patient, sterilization is required. 
Design of tissue engineered constructs
Scaffold design has a major impact on the in vivo performance of tissue engineered 
constructs. Obviously, the shape, size and mechanical requirements depend 
on the organ that is being treated. The materials, cells and other factors used 
show great similarities between urogenital tissue engineering applications as 
these organs share many features e.g. they are hollow, their function depends on 
smooth muscle tissue and urothelium protects the surroundings (figure 3). 
Materials
The first consideration when designing a tissue engineered construct is which 
material to use. The material is the major component of the constructs and acts 
as a permanent or temporary scaffold during the regeneration process of the body 
[30]. Ideally, the materials should be biocompatible, biodegradable and stimulate 
tissue regeneration. Materials should have similar biomechanical properties to 
the tissue that is being repaired to prevent fibrosis or extrusion of the material 
[31]. Many different materials have been studied, either alone or in combination, 
to achieve the desired properties. Common materials for soft tissues include 
decellularized tissues such as small intestinal submucosa and acellular bladder 
matrix, natural materials such as collagen or synthetic materials like polyglycolic 
acid and poly(lactic-co-glycolic acid) [32-36]. 
Every type of material has its own advantages and disadvantages. 
Decellularized tissues generally have an intact native architecture and may 
present naturally occurring bioactive molecules to improve regeneration [37], 
but molding in the desired dimensions may be difficult. In contrast, constructs 
produced in the laboratory from natural materials like collagen are highly tunable 
and material properties can be adjusted towards the application at hand. Finally, 
synthetic materials offer most control over material properties such as degradation 
speed and mechanical strength [38]. However, these materials are foreign to the 
body and may induce a more severe immune response than natural materials. 
Figure 3. A histological cross section of the ureter showing the two most important functional 
tissues in the urogenital organs. The smooth muscle tissue is responsible for active transport of urine 
through contraction. The urothelium forms a barrier between the toxic urine and the surrounding 
tissues. Scalebar = 400µm.
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This thesis mainly focused on the use of collagen and collagen combined with 
poly(lactic-co-glycolic acid) to control the mechanical and degradation properties. 
Implantation techniques
In urological tissues, the urothelial cells and smooth muscle cells are specifically 
important for the function of the organs [39]. When designing tissue engineered 
constructs, it is possible to culture cells on the biomaterial before implantation. 
Initially, primary cells were mainly isolated from autologous tissue. These cells 
however, are not always sufficiently available and may be compromised in case of 
malignant disease. Therefore, it was recently shown that mesenchymal stem cells 
derived from e.g. bone marrow or adipose tissue are a promising cell source as 
they are abundantly available and can differentiate to multiple cell types [40-43]. 
Pre-conditioning of constructs with cells may be used to improve the regeneration 
outcome [44, 45]. 
Currently, tissue constructs without cells are mostly directly implanted 
to repair the damaged organ or tissue as an off-the-shelve solution. While 
this is generally possible for small defects, it may become problematic when 
large constructs are needed because vascularization is absent [46]. Without 
vascularization of the tissue, oxygen and nutrients can only reach the tissue 
construct by diffusion, risking necrosis and central fibrosis [47]. Several methods 
have been described to improve the vascularization of tissue engineered 
constructs, including the addition of growth factors that play a key role in the 
formation and maturation of blood vessels [48]. Other options include pre-
implantation of the construct whereby the host body is used to generate a 
vascularized graft. In this approach, the engineered construct is implanted in a 
non-functional location such as the omentum, peritoneum or subcutis. After a 
few weeks, the tissue is then transplanted to the functional location. By using this 
technique, partial remodeling including blood vessel formation and the initial 
immune response can occur without negatively impacting the function of the 
tissue [25, 49-52]. While the use of cells and pre-implantation techniques has 
shown promising results, it may not always be applicable due to the incubation 
times. In these cases, off-the-shelve solutions are still required. 
Animal models and clinical translation
The use of animal models is a critical step in the evaluation of the safety and 
performance of tissue engineered constructs as the complexity of a body during 
remodeling cannot be simulated in vitro yet [53]. Choosing the right animal 
model and using proper experimental design are paramount to successful clinical 
translation as shown in chapter 4 of this thesis. Moreover, for tissue engineered 
constructs to be implemented in a clinical setting it needs to meet all regulatory 
requirements related to medical devices [54]. This includes sterilization for which 
multiple techniques are available. Common techniques include autoclaving, 
gamma irradiation and ethylene oxide gas. Not all techniques are compatible with 
materials. Autoclaving at high temperatures may degrade the biomaterials [55]; 
gamma irradiation can create or break cross-links in the material, adjusting the 
intrinsic material properties and ethylene oxide can leave residues that are toxic 
[56-68]. It is therefore critical to take the clinical regulations and demands into 
account in the design of tissue engineered constructs and experiments. 
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Thesis objective and outline
The aim of this thesis was to develop new technologies and medical devices to 
treat patients with severe urogenital trauma as an alternative to current graft 
tissues in reconstructive surgery.  
In this thesis, new urogenital tissue engineering and regenerative medicine 
applications are described. In the first part the current state-of-art for ureteral and 
urethral tissue engineering through (systematic) literature searches is discussed. 
In the second part, the use of newly developed tubular and flat collagen based 
(hybrid) constructs in vivo and in vitro is presented.  
Part 1: A comprehensive overview of urogenital tissue engineering
The first part of this thesis was focused on identifying the current state-of-art in 
urogenital tissue engineering.
In chapter 2 a literature review on ureteral tissue engineering was performed. 
In this review, a trend was identified showing a shift from non-degradable 
synthetic materials to degradable natural biomaterials such as collagen and 
decellularized tissues. 
Chapter 3 focused on new developments in ureteral tissue engineering in 
the last 3 years. Where mainly simple constructs without cells were previously 
used, most new studies focused on the use of stem cells seeded on decellularized 
tissues. In addition, the constructs were often implanted in a non-functional 
location such as the subcutis or the omentum for preconditioning. While these 
techniques showed promising results, there were only few studies published in 
the field of ureteral tissue engineering. 
Chapter 4 systematically reviews the most studied field of urogenital tissue 
engineering for pre-clinical and clinical studies: the urethra. In this study the 
relation between preclinical and clinical studies was investigated, identifying 
current strengths and weaknesses in study design and execution.  
Part 2: New hybrid biomaterials in urogenital tissue engineering
After having identified the current state-of-art in urogenital tissue engineering, 
new collagen based medical devices were developed and evaluated in vitro and in 
vivo. First, relatively simple flat constructs were evaluated. 
In chapter 5 porcine smooth muscle and urothelial cells were cultured on 
flat collagen constructs comparing traditional static cell culture and dynamic cell 
culture in a bioreactor. By mimicking normal tissue conditions, proliferation and 
differentiation of the cells could be influenced. 
In chapter 6 the performance of flat collagen patches to increase the total 
bladder capacity was evaluated in a pig model. Multiple constructs were used 
to increase the total surface area of the bladder. Three conditions were studied: 
constructs containing collagen only, collagen with heparin and collagen with 
heparin and growth factors.
Next, more complex tubular constructs were developed and evaluated in 
vivo. Chapter 7 describes the outcome of the repair of a created critical five-
centimeter-long ureteral defect in pigs using tubular collagen-Vicryl constructs. 
Half of the constructs were loaded with growth factors FGF-2 and VEGF to 
improve vascularization and smooth muscle cell ingrowth. Unfortunately, the 
outcome was sub-optimal. Because of the size and weight of pigs, young animals 
had to be used. These animals grew rapidly during the experiments, which may 
have influenced the regeneration process. 
Therefore, a similar approach was tested in an adult goat model. In chapter 8 
the first experiences with the goat model are described. Technical complications 
were encountered due to anatomical differences. By employing clinical protocols 
for stent placement, these complications could be avoided. 
Chapter 9 describes the results of ureteral reconstruction in goats. In light of 
recent advancements in the field of tissue engineering, collagen-Vicryl constructs 
that were directly implanted in the ureter were compared to constructs that were 
first implanted in the subcutis for one month. This pre-implantation helps to 
partially replace the construct with native tissue and increases vascularization. 
Finally, the results and conclusions are summarized in chapter 10. In addition, 
future perspectives for the development of tissue engineered constructs for 
urogenital applications are described. 
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Abstract
In the field of regenerative medicine, various types of biodegradable and 
nonbiodegradable scaffolds have been developed for urinary tract tissue-
engineering applications. Naturally derived or synthetic materials have 
been tested to determine their properties and their effectiveness. However, 
the majority of the current literature focuses on the reconstruction of the 
urethra, urinary diversion, and urinary bladder, while limited data have been 
published regarding the use of biomaterials in ureteral reconstruction. Tissue 
engineering might offer alternative and less invasive therapeutic options 
for long ureteral defects compared with the current surgical reconstructive 
techniques and their potential complications. In this article, we aimed to 
review the literature regarding ureteral tissue engineering through a Medline 
search and describe new potential options for future clinical applications. We 
concluded that the available literature is inconclusive since the superiority of 
a specific scaffold has not been demonstrated and the latest developments of 
regenerative medicine have not been evaluated in ureteral tissue engineering 
yet.
Introduction
Damages to the ureters are caused either by an injury or a pathologic situation that 
may result in stricture formation, such as urolithiasis or chronic inflammation. 
Most ureteral injuries are iatrogenic due to surgical procedures or radiation 
therapy [1]. If identified, many of these lesions can be repaired primarily, but if 
left unrecognized, they can lead to sepsis or loss of renal function [2]. About 73% 
of all ureteral injuries occur during gynecological operations, most often during 
hysterectomy [3-7]. What is of great importance is that these complications 
often remain unrecognized (33% to 87.5% of cases) at the time of the surgery 
[8-10]. Oncological, vascular, and general surgery procedures can also result in 
intraoperative ureteral injuries [11]. Intra- and postoperative complications of 
endourological  procedures have also been increased due to the increased number 
of diagnostic or therapeutic ureteroscopies performed worldwide during the last 
years. Ureteroscopy results in ureteral avulsion in 0.3% and perforation in 2% 
to 6% of cases. The perforation rates are lowest in series using smaller caliber 
ureteroscopies [12-15]. Long-term data regarding stricture formation due to 
endourological procedures are lacking. Injuries to the ureter by an external cause 
such as gunshot wounds, stab wounds, or blunt injuries are relatively uncommon 
(less than 1%) and in the majority of cases are combined with other organ lesions 
[15]. Penetrating traumas result in ureteral injury twice as often as blunt traumas. 
The mortality rates for penetrating and blunt ureteral traumas were 6% and 9%, 
respectively [16].
The site and the length of the affected ureter are of great importance for the 
surgical repair [17]. The classical surgical techniques for long ureteral defects (Boari 
flap, Psoas hitch, transureteroureterostomy, reimplantation, Blandy cystoplasty, 
and ileal interposition) are not always applicable and they also carry their own 
risks for complications such as recurrent strictures, urinary leakage, metabolic 
complications, and donor tissue harvesting problems. Since traditional surgical 
procedures for ureteral repair have their own limitations and complication rates, 
new therapeutic approaches are needed in ureteral surgery. Tissue engineering 
may contribute to ureteral  reconstruction by developing new suitable tubular 
biomaterials that could serve as a ureter, and thus preserve the normal renal 
function.
In this article, we review the literature regarding ureteral tissue-engineering 
applications. A Medline search was performed for articles published between 1983 
and February 2013 regarding ureteral tissue-engineering applications. Combined 
MeSH terms were ureter, biomaterials, tissue scaffolds, tissue engineering, 
regenerative medicine, and growth factors. Articles that examine the etiology 
and assessment of ureteral lesions were also included in the article. Finally, we 
propose new potential options for future clinical applications.
Ureteral Tissue Engineering Overview
The underlying supposition of tissue engineering is that the employment of 
the natural biology of the system will allow for greater success in developing 
therapeutic strategies aimed at the replacement, repair, maintenance, and/
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or enhancement of the tissue function [17]. The biomaterials involved must 
maintain the physiological anatomy and functionality of the original tissue and 
have the proper mechanical and structural properties. They should also provide 
a microenvironment capable of supporting certain cell types. Under these 
conditions, cells will be able to differentiate and regenerate tissues according to 
their tissue of origin. Alternatively, smooth muscle cells (SMCs) and urothelial 
cells (UCs) may be seeded onto scaffolds to enhance tissue regeneration. In time, 
cells produce new extracellular molecules, which gradually replace the initial 
structured scaffold leading to a healing and regenerative process. Autologous 
cells are preferred due to biocompatibility, and thus, avoidance of tissue rejection. 
In the field of regenerative medicine, ureteral tissue engineering remains an 
underreported topic so far. This could be due to either the smaller percentage of 
ureteral lesions or cross-over knowledge from the urinary bladder and urethral 
tissue-engineering studies. In Table 1, we present the ureteral tissue-engineering 
studies with regard to the type of construct used, animal model, scaffold length, 
regeneration outcome, and tubular or onlay application of the biomaterial. 
Authors Animal model Scaffold Seeded Length
Regeneration 
outcome Technique
Tachibana [1985]18 Dog Collagen No 5cm UC/F T
Dahms [1997]19 Rat Collagen No 0.3-0.8cm UC/SMC T
Baltaci [1998]20 Dog Gore-Tex No 5-8cm none T
Sabanegh [1996]21 Dog Gore-Tex No 10cm UC (minimal 
in growth)
T
Osman [2004]22 Dog AM No 3cm UC/SMC T
Liatsikos [2001]23 Pig SIS No 7cm UC/SMC O
Smith [2002]24 Pig SIS No 2cm UC/SMC/F O
Shalhav [1999]25 Mini pig AM, SIS No 1.5-2.8cm UC/SMC/F T*
Duchene [2004]26 Pig SIS No 2cm UC/F T*
Sofer [2002]27 Pig SIS No 2cm UC/SMC/F T*
El-Assmy [2004]28 Dog SIS No 4cm UC/SMC/F T*
El-Hakim [2005]29 Pig, Dog SIS
AM
DSB
Yes 3-5cm F
UC/SMC/F
UC/BM
T*
Table 1. Preclinical studies regarding ureteral tissue engineering applications. AM= Acellular 
Matrix, DSB= Decellularized Small Bowel, T= Tubular, T*=Tubularized, O= Onlay, UC=Urothelial 
Cells, SMC=Smooth Muscle Cells, F=Fibrosis, BM=Bowel Mucosa 
One of the first reported attempts to replace a ureteral segment with 
biomaterials was performed by Tachibana et al. They concluded that 
approximately 5-cm-long tubular collagen sponges in the canine ureter could 
promote the regeneration of UC layers with coeval SMCs regeneration present 
only at the junctional area between the primary ureter and the graft. No severe 
hydronephrosis was observed in six dogs where a ureteral stent was used, while 
in the remaining two dogs where no stent was used, severe strictures of the 
anastomotic sites were observed [18]. Another study by Dahms et al. examined 
the use of acellular collagen tubular scaffolds in a rat model. SMCs and nerve 
fibers were noticed at 10 and 12 weeks, respectively, while at 3 months, SMCs 
had assumed a regular configuration in a lower density compared to the normal 
contralateral ureter. The SMCs were arranged in parallel rows in the longitudinal 
direction with a decrease from the end to the central part of the scaffold. The 
ureteral segment that was replaced ranged from 0.3 to 0.8 cm. An examination 
of the specimens showed various degrees of hydronephrosis and this might be 
attributed to the migration of the stent to the distal ureter in all animals [19]. 
Baltaci et al. tested a 5- to 8-cm Gore-Tex ureteral graft in a canine model, 
but advanced hydronephrosis, atrophy of the renal parenchyma with calcium 
deposits, and no cellular growth was noted in all five animals. Although the 
lumen of the proximal and distal ureter was not obstructed, there was severe 
fibrosis and strictures at the proximal and distal anastomotic sites. The ureteral 
mucosa proximal to the Gore-Tex tubular graft revealed squamous metaplasia 
[20]. Gore-Tex was also evaluated in a canine model by Sabanegh et al. They used 
a 10-cm tubular graft and reported the absence of hydronephrosis in five of the 
total eight animals at 6 months or 1 year. Histology revealed a marked acute and 
chronic inflammatory reaction surrounding the graft, but the luminal diameter 
remained unaffected. Also, minimal cellular migration was noticed through the 
scaffold to the lumen [21]. 
Osman et al. tested a 3-cm tubular acellular matrix in a canine model. 
The constructs were prepared from heterologous canine ureters after cell lysis. 
Hydronephrosis, shrinkage of the graft and strictures with narrowing of the graft 
lumen were observed [22]. Small intestinal submucosa (SIS) has also been used 
for ureteral reconstruction. Liatsikos et al. replaced two-thirds of the diameter of 
a 7-cm ureteral segment in a pig model with SIS. They demonstrated epithelial 
regeneration supported by a prominent submucosal neovascularization. SMCs 
did not exhibit the normal organization found in the original ureter [23]. 
Smith et al. replaced half the diameter of a 2-cm-long ureteral segment in a pig 
model with SIS as an onlay patch laparoscopically. After 9 weeks, a primarily 
transitional epithelium was observed at the SIS graft with focal intestinal 
metaplasia. The submucosa and ureteral musculature appeared histologically 
normal [24]. Shalhav et al. also laparoscopically replaced a 1.5–2.8-cm ureteral 
segment with either the acellular matrix (prepared from mini pigs or domestic 
pigs) or tubularized SIS. They reported regeneration of urothelium, but also bone 
metaplasia with dense fibrosis and obstruction of the neo-ureter in all animals 
[25]. These findings were confirmed by Duchene et al. in a pig study, where a 2-cm 
ureteral segment was replaced laparoscopically by SIS. In contrast to tubularized 
SIS, where all animals demonstrated hydro-ureteronephrosis or renal atrophia, 
partial replacement of the ureteral wall with an SIS patch as onlay led to re-
epithelization and normal appearance of the kidney [26]. Sofer et al. tested a 2-cm 
SIS graft tubularized over a 10F ureteral stent in a pig model. The histological 
evaluation demonstrated regeneration of both the urothelial and smooth muscle 
layers over the graft. However, this regeneration was associated with an intense 
fibrotic and inflammatory process resulting in complete ureteral obstruction 
and secondary hydronephrosis at 12 weeks postoperatively. In addition, mucous 
metaplasia of the epithelium, metaplastic bone and dystrophic calcification 
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of sloughed luminal fragments and mucosal ulceration were observed [27]. El-
Assmy et al. replaced a 4-cm-long ureteral segment with a tubularized one-layer 
SIS graft in mongrel dogs. Regeneration of urothelial and smooth muscular layers 
was noticed with associated intense fibrosis and inflammation resulting in hydro-
ureteronephrosis [28]. El-Hakim et al. published three sets of experiments. In the 
first set, they compared a 5-cm-long nonseeded versus seeded with autologous 
urothelial and SMC tubularized SIS in pigs. In the second set, they compared 
a 3-cm decellularized porcine ureteral segment seeded with autologous bladder 
cells versus nonseeded decellularized porcine ureteral segment in beagles. In 
the third set, they examined a 4-cm-long deepithelialized small bowel segment 
seeded with autologous cells, which was retubularized transversely (Monti) in 
one mongrel dog. Successful outcomes were reported only in the last set, but 
bowel mucosa regeneration was noticed in the histology [29]. 
Ureteral regeneration has also been evaluated without in situ implantation 
of the scaffolds. Zhang et al. implanted an 8 Fr Silastic tube in the peritoneal 
cavity of female beagles. Within 3 weeks after implantation, the tubes had been 
completely encapsulated by a tubular tissue capsule. Histological analysis showed 
transversely arranged myofibroblasts embedded in homogenous collagen bundles 
and an outer layer of mesothelial cells. The tissue was everted and was used 
to replace a 3-cm ureteral segment. At 12 weeks, the urothelial lining, smooth 
muscle bundles, and surrounding fibrous adventitia became similar to the normal 
ureteral wall [30]. Matsunuma et al. demonstrated successful seeding of the canine 
decellularized ureteral matrix with the stratified urothelium and bone marrow-
derived mononuclear cells using the subcutaneous tissue of nude mice or the 
omentum of rats as a natural bioreactor [31]. Baumert et al. reported successful 
urothelial regeneration upon a multilayer smooth muscle connective tissue 
by placing an SIS patch seeded with autologous cells shaped around a silicone 
drain in the omentum of female pigs [32]. Shi et al. evaluated the differentiation 
potential of human adipose-derived stem cells (hADSCs) into urothelial lineage 
after seeding in a hybrid polylactic acid collagen scaffold. These scaffolds were 
implanted subcutaneously in athymic mice for a period of 2 weeks. They reported 
differentiation of the hADSCs into UCs, which were maintained after the in vivo 
implantation [33]. ADSCs were also reported to differentiate into SMCs after 
proper induction. Zhao et al. used the decellularized Vessel Extracellular Matrix 
(VECM) from abdominal rabbit aortas. The VECM was seeded with inducted 
stem cells and replaced with an approximately 3-cm-long ureteral segment. At 16 
weeks after implantation, the stratified epithelium and organized muscle bundles 
were observed that were similar to the native tissue [34]. Fu et al. constructed an 
electrospun composite poly(L-lactic acid)-collagen and examined the outcomes 
of seeded with UCs versus nonseeded scaffolds after subcutaneous implantation 
in nude mice. They also tested cell distribution after seeding with regard to the 
centrifugal or static seeding method. They concluded that this type of scaffold 
seeded with the centrifugal technique could be used as a biomatrix for UC 
growth [35]. Xu et al. prepared a spiral poly(L-lactic acid) scaffold and implanted 
it subcutaneously in Wistar rats. The scaffolds were harvested after 1, 2, and 3 
weeks, decellularized, and finally seeded with autologous UCs. The entrapped 
cells grew well and UCs lined up in a continuous layer at all time points. Besides 
the cytocompatibility, neovascularization was also noticed [36]. Nevertheless, the 
functionality of these matrices remains to be evaluated.
Clinical implication and future Perspectives
The primary goal of the engineered ureter is to maintain the safe transportation 
of urine from the kidney to the bladder. The ureter is an active, contractile tissue 
that generates peristaltic waves and its role is critical in preserving the normal 
renal function and avoiding the development of hydronephrosis. In the porcine 
midureter, the propagation velocity of these peristaltic waves is 2.1 – 1.0 cm/s with 
a length of pressure peak 5.9 – 1.3 cm [37]. The native ureter is composed of two 
smooth muscle layers, an inner longitudinal and an outer circular, and therefore, 
the regenerated tissue should exhibit the same anatomic and functional properties 
as much as possible. 
There is a clear difference in the outcome of published studies depending 
whether a partial or a complete ureteral segment is replaced. This can be 
justified by the fact that ureteral regeneration warrants cell migration from the 
original ureter onto and into the scaffold. Regeneration of the entire length and 
circumference of the scaffolds is challenging since it requires cell migration over 
a longer distance than in onlay techniques. When increasing the ureteral defect 
or the implanted scaffold, the cell growth and regeneration of acellular scaffolds 
decreases. Since current surgical techniques can be used to repair short ureteral 
defects, ureteral tissue engineering should contribute to the reconstruction of 
longer lesions. 
This issue can be potentially managed by seeding scaffolds with cells or loading 
them with growth factors. In urethral tissue engineering, cell seeding is critical 
for the avoidance of stricture formation when collagen scaffolds are used [38, 
39]. When acellular tubular scaffolds were evaluated in urethral reconstruction, 
normal tissue regeneration was only noticed for 0.5-cm-long defects [40]. In a 
recent study regarding urinary diversion, Geutjes et al. reported that UC seeding 
may not provide any advantage to the development of urothelium [41]. On the 
other hand, the cytotoxicity of urine and also its negative influence in tissue 
regeneration has been demonstrated [42]. To protect the cells during ingrowth and 
tissue remodeling after in situ implantation, seeding UCs in the luminal surface 
might be beneficial (Fig. 1) [43]. In studies where scaffolds are preimplanted into 
the peritoneal cavity, the toxic effect of urine is absent and further data regarding 
regeneration after in situ implantation would be interesting. 
The construction of cell-seeded scaffolds involves cell harvesting, culture, 
and seeding onto the scaffold. Ideally, the scaffolds should also be tested in a 
bioreactor for their mechanical properties before implantation to ensure adequate 
mechanical strength, and thus avoid intra- and postoperative complications. With 
tensile and flow studies, it is possible to study the cell response to the forces that 
are normally applied to the ureter. This is a procedure that consumes time, work 
hours, and also increases the costs. Cell distribution after seeding is another issue 
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that has to be determined before implantation. Sun et al. examined cell ingrowth 
in collagen and hybrid scaffolds of different collagen concentrations [ranging from 
0.3% to 0.8% (w/v)]. They concluded that a hybrid scaffold prepared from 0.4% 
collagen strengthened with knitting achieved the best cellular distribution [44]. 
Autologous cells are preferred since their use ensures a minimal inflammatory 
response and biocompatibility [45]. To obtain these cells, in most cases, an 
additional surgery is necessary and this can cause additional morbidity. The 
technique used for seeding cells should provide equal distribution of living cells. 
Static, dynamic, and spinning seeding methods are most often used currently 
[46, 47]. The time needed to perform the aforementioned procedures may be a 
limitation in their use. Consideration should be given to determine whether the 
advantages of a cellular construct outweigh these disadvantages, the increased 
cost, and possibly decreased clinical applicability.
Figure 1. A. Scanning electron microscopy image of the porous surface of a collagen 0.5% scaffold. B. 
Scanning electron microscopy image of the surface of a cell-seeded collagen 0.5% scaffold. A dense 
layer of cells cover the surface of the collagen scaffold forming a potential barrier between urine and 
the scaffold. 
Growth factors can be an alternative to attract cells inside the ureteral 
scaffolds. They are known to have a stimulatory effect on various cellular 
processes, including cell influx, angiogenesis, and proliferation, thus improving 
the regenerative capacity of the scaffold [48]. Growth factors can be incorporated 
in biomaterials through a variety of methods, including entrapment within gel 
matrices, hydrophobic scaffolds, or microparticles, through affinity binding sites 
and covalent binding to matrices [49]. In ureteral tissue engineering, different 
growth factors are needed to stimulate different cell populations. The vascular 
endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2) are 
involved in angiogenesis and blood vessel maturation [50]. The epidermal growth 
factor (EGF) is known to play a key role in urothelial regeneration [51]. These 
growth factors are heparin binding growth factors. Heparin can be incorporated 
in many different biomaterials to create controlled release systems [52]. In a 
study regarding urethral reconstruction using tubular collagen scaffolds loaded 
with growth factors (VEGF, FGF-2, and EGF) in a rabbit model, Nuininga et al. 
demonstrated narrowing of the lumen due to urothelium ingrowth. This may be 
prevented by loading the EGF only in the inner (luminal) side of the scaffold [48]. 
The insulin-like growth factor-1 (IGF-1) has been explored in an array of tissues, 
including skeletal and cardiac muscle, nerve, cartilage and bone. Lorentz et al. 
reported an engineered IGF-1 that improved SMC regeneration [53]. The main 
disadvantage of IGF-1 is that it does not bind to heparin. The main advantage 
of scaffolds loaded with growth factors is that they can be used off the shelf in 
urgent cases. 
Stem cells (SCs) appear to be a promising area of research in urological 
regenerative medicine. Their use in tissue regeneration has been tested in bladder 
augmentation and detrusor regeneration in animal studies and in the treatment 
of stress urinary incontinence in clinical trials [54, 55]. Studies regarding ureteral 
regeneration by using SCs are still lacking [56]. Autologous urine-derived SCs 
exhibit a high expansion rate and capability of differentiating into both urothelial 
and SMCs [57]. Supplementation of growth factors in vivo promoted the survival 
of urine-derived SCs and their differentiation into muscle cells. Enhancement of 
nerve regeneration and native cell attraction were also noticed [58]. Issues that 
need further research are the control of SC proliferation rate, differentiation into 
the desirable line, and also their behavior in the long term [59]. 
Collagen currently seems to be the biomaterial of choice in the construction 
of small diameter tubular scaffolds. Type-I collagen is the most abundant 
type of collagen in organs and provides strength and structural integrity to 
tissues. Allogenic collagen, like bovine, exhibits excellent biocompatibility 
and low immunogenicity in humans [60-62]. Highly purified type-I collagen 
is commercially available and it is technically feasible to prepare up to 10-cm-
long tubular scaffolds. The major disadvantage of collagen scaffolds is their poor 
physical strength [63]. Chemical crosslinking can enhance their mechanical 
properties [64]. By experience of our institution, suturability of these scaffolds in 
vitro in a porcine ureteral model is satisfactory and patency is achieved without 
complications. Another option may be the use of high degradable polymer-
collagen scaffolds to increase the physical strength and ease of application. 
Further research regarding the development of small diameter hybrid scaffolds 
is required. 
The animal model for preclinical studies is also a factor that may affect the 
outcome of the experiment. The natural algorithm for animal studies—which 
dictates the use of small animals before proceeding into large animal studies—
cannot always be followed strictly as in the case of ureteral tissue engineering. 
Crossover knowledge from urethral tissue engineering studies can provide data 
for the regeneration of scaffolds up to 2 cm long [65]. In ureteral reconstruction, 
a lesion of this length is clinically insignificant since it can be repaired by the 
available surgical techniques. In longer defects, and to mimic the clinical situation 
and extrapolate the preclinical data as much as possible, the animal model should 
have an abdominal and ureteral anatomy analogue to that of a human. This offers 
the advantages of testing the feasibility of such a procedure, the applicability of 
the scaffold, and the outcome of the regenerative process. The pig model seems 
to be the best alternative [66, 67]. Nevertheless, from the ethical perspective, 
it is important to perform extensive in vitro- and ex vivo-related experiments 
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before animal testing, for example, pressure–flow experiments to characterize 
the mechanical properties and suturability of the construct. 
The ideal scaffold should have a high regenerative capacity, ease of 
construction, and direct availability in urgent cases. Developing tubular scaffolds 
for ureteral reconstruction will be of great importance for both the patient and 
the surgeon. The simplified surgical technique may lead to a less invasive surgery, 
lower complication rates, and a reduction in health care costs. From this point of 
view, the evaluation of tubular collagen scaffolds loaded with growth factors seems 
to be promising. Finally, as in every tissue-engineering application, considerations 
should be made to bring these new options to applicable techniques in the clinical 
situation. However, the exact requirements and methods for conducting clinical 
trials should be defined [68]. 
Conclusions
Current literature regarding ureteral tissue engineering is lacking evidence 
as for the determination of a suitable biomaterial. Furthermore, progresses 
in regenerative medicine, like cell-seeded scaffolds, scaffolds loaded with 
growth factors, or the use of SCs have not been efficiently evaluated in ureteral 
reconstruction yet. Further, preclinical research is required to develop a suitable 
scaffold and improve the tissue- engineering applications for this domain of 
urological regenerative medicine.
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Abstract
Reconstruction of long ureteral defects often warrants the use of graft tissue 
and extensive surgical procedures to maintain the safe transport of urine 
from the kidneys to the urinary bladder. Complication risks, graft failure 
related morbidity and the lack of suitable tissue are major concerns. Tissue 
engineering might offer an alternative treatment approach in these cases, 
but ureteral tissue engineering is still an underreported topic in current 
literature. In this review, the most recent published data regarding ureteral 
tissue engineering are presented and evaluated, with a focus on cell sources, 
implantation strategies and (bio)materials. 
Introduction
Advances in endourology led to an increase in the number of ureteroscopies and 
nephroscopies during the last two decades worldwide. The complications of these 
procedures are often underreported, possibly due to lack of early recognition 
or short term postoperative follow-up [1-3]. Strictures after ureteroscopy occur 
with an estimated frequency up to 3.5%, which is more often than avulsion or 
major perforation [4-6]. In around 1% of the gynaecological procedures a ureteral 
injury occurs, which is estimated to account for up to 73% of all ureteral injuries 
[3, 7, 8]. In addition to these iatrogenic injuries, trauma can result in ureteral 
damage. A large retrospective analysis in the United States showed that 2,6% 
of all urogenital traumas involved the ureter between 2002 and 2006 [9]. The 
specific anatomic characteristics of the ureter, such as the segmental vascular 
supply, can be easily damaged, and the lack of native tissue limits surgical 
ureteral reconstruction. To repair the long ureteral defects, where an end-to-
end anastomosis is not feasible for the urologist, several techniques have been 
introduced such as a ureteroneocystostomy, a Boari flap, ileal interposition and 
renal autotransplantation. Ultimately, when surgical expertise is not available or 
the aforementioned techniques do not succeed, an undesirable nephrectomy is 
the only option [10, 11].  
Tissue engineering might offer new treatment approaches in ureteral 
reconstruction to optimize the outcome in complicated cases, which currently 
have complication rates up to 25% [12]. The number of published manuscripts 
dealing with tissue engineering applications of the urinary system is quite 
extensive, particularly for urinary bladder reconstruction, but the number of 
research groups that focus on tissue engineering of the ureter is limited, which 
suggests that the development of an artificial construct suitable for ureteral 
reconstruction is challenging. Additionally, there might be less incentive to 
investigate tissue engineering approaches as the incidence of long ureteral injuries 
is lower than urethra or bladder injuries. 
Ureteral tissue engineering
In a recent review on ureteral tissue engineering [13] it was demonstrated that the 
evidence in the literature was inconclusive about the optimal tissue engineering 
approach to treat long ureteral injuries. Furthermore, compared to other parts of 
the urogenital tract, very few tissue engineering studies were performed. Most 
studies focused on tubular(ized) small intestinal submucosa (SIS) without cellular 
pre-seeding [14-20]. Other materials included collagen [21, 22] and Gore-Tex [23, 
24]. In general, collagen and SIS, but not Gore-Tex, were capable of facilitating 
some degree of urothelium and smooth muscle regeneration. However, fibrosis 
occurred in most cases. 
In this review we present recent developments in ureteral tissue engineering 
and discuss currently used materials, construct design, cell sources, and 
implantation techniques. In addition to the recent literature reviews on ureteral 
tissue engineering, a Medline search was performed for papers published in the 
last 3 years using a previously published tissue engineering filter [25] combined 
 3
Chapter 3 Recent advances in ureteral tissue engineering
44 45
with the MeSH term ureter. An overview of the recent studies is presented in 
table 1 in which we focused on the early post implantation complications and the 
presented solutions. 
Ureteral defect repair
To study the effect of a tissue engineered construct on the regeneration of 
the ureter, it is imperative to test the constructs in a ureteral defect model. 
Nevertheless, in three recent studies the authors refrained from implantation of 
tissue engineered constructs in an induced ureteral defect model. Instead, the 
authors performed subcutaneous implantations in rats (Xu, et al. [26]) and mice 
(Shi, et al. [27] and Fu, et al. [28]). While these studies showed the potential of 
pre-implantation for ureteral replacement, information about the behavior of the 
construct as ureteral replacement is lacking. In the intracorporeal environment 
constructs are exposed to the toxic effects of urine and various mechanical forces 
[5]. All three studies used a similar spiral PLLA stent as the backbone of their 
construct. Xu, et al. [26] implanted the spiral PLLA stents in the subcutis and used 
the body as a natural bioreactor to generate a tissue fleece around the stent. The 
newly formed tissue was then decellularized and re-seeded with primary urinary 
bladder urothelial cells. Cell proliferation was similar compared to SIS. Shi, et al. 
[27] and Fu, et al. [28] combined the same PLLA stent with electrospun collagen to 
improve cell attachment and cell proliferation. Before subcutaneous implantation 
in athymic mice, the final constructs were seeded with human adipose derived 
stem cells (hADSC) (Shi, et al. [27]) or human urothelial cells (hUC) (Fu, et al. [28]). 
Both authors were able to detect viable human cells 2 weeks post-implantation, 
demonstrating that the cells could survive the procedure.  These studies solely 
indicate that the subcutis might be a suitable pre-implantation site to generate 
a tubular pre-vascularized autologous tissue, which may prevent fibrosis when 
attempting to repair the ureter.
Authors Animal 
model
Biomaterial Cell 
Seeded
Length Tech-
nique
Outcome
Xu, et al.[26] Rats (M) PLLA No 0.9 cm S,T  I1, V
Shi, et al.[27] Mice (F) PLLA, Collagen hADSC - S,T hUC
Fu, et al.[28] Mice (M) PLLA, Collagen hUC 1.0-1.5 cm S,T hUC
Zhang, et al.[29] Dogs (F) Autologous graft No 3.0 cm P,T UC, SMC, V
Salehipour, et al.[30] Dogs (M) AM No 3.0 cm T* L, H, F, I2
Zhao, et al.[31] Rabbits (F) VECM ADSC 3.0 cm T UC, SMC
Liao, et al.[32] Rabbits (M) BAM MSC, SMC 4.0 cm P, T* I1,UC, SMC
De Jonge and 
Simaioforidis, et 
al.(unpublished)
Pigs(F) Collagen UC, SMC 5.0cm T UC, SMC, L, 
F, H
Table 1. Recent ureteral tissue engineering studies. PLLA, Poly(L-lactic acid); AM, Amniotic 
membrane; VECM, Vessel extracellular matrix; BAM, bladder acellular matrix; (h)ADSC, (human) 
adipose derived stem cell; MSC, Mesenchymal stem cell; (h)UC, (human) urothelial cell; SMC, 
Smooth muscle cell; S, subcutaneous implantation; P, Pre-implantation; T, Tubular; T*, Tubularized; 
I, Inflammation (I
1
: mild, I2: severe); V, Vascularization; F, Fibrosis; H, Hydronephrosis; L, Urine 
leakage.
Cell sources
The use and necessity of cell seeding of tissue engineered constructs has been a 
matter of debate, but once it is considered many options exist. Embryonic stem 
cells are highly controversial due to their origin and the risk of tumor formation. 
A safer and less controversial option is the use of autologous cells when available. 
Tissue biopsies can yield differentiated primary cells or multipotent cells like 
mesenchymal or adipose derived stem cells. Most early studies in ureteral tissue 
engineering used bare scaffolds and almost all of them resulted in fibrosis, which 
may indicate the necessity of cell seeding [14-19, 21-24, 33]. This is supported by 
previous statements that cell seeding is required for large defects (> 1.0cm from 
the wound edge) to promote tissue regeneration and to prevent scar formation 
[34]. In most recent studies, cell seeding or pre-implantation of the scaffolds was 
explored to improve regeneration [27-29, 31, 32]. 
Fu, et al. [28] used primary urothelial cells, isolated from patients that 
underwent nephrectomy, which were seeded on spiral PLLA stents and 
subcutaneously implanted in a nude mouse model for 2 weeks. The grafts resulted 
in a thin tissue capsule in which the seeded cells were still present and viable. 
This successful approach is relatively straight forward, albeit time consuming 
since it takes 4 weeks before ureter reconstruction can be performed; the cells are 
expanded for 2 weeks, followed by pre-implantation for 2 weeks. 
A faster approach would be the implantation of only the cell seeded 
construct. To investigate this approach we implanted 5.0 cm long highly porous 
tubular 0,5% type-I collagen constructs to repair a full ureteral defect in 11 female 
Landrace pigs (unpublished data). In brief, primary urothelial (UC) and smooth 
muscle cells (SMC) were isolated from porcine urinary bladder biopsies [35]. First, 
the scaffolds were homogenously seeded with urinary bladder derived SMCs, 
followed by luminal seeding of urinary bladder derived UC. The right ureter was 
approached and mobilized through a midline incision and a 5.0 cm segment of the 
ureter was removed and replaced with an equally sized scaffold. A 6 Fr double-J 
stent was placed to facilitate urinary flow and animals were followed up to 4 
weeks. In 7/11 pigs, abdominal swelling due to urine leakage was observed after 
2-3 weeks. The other animals developed strictures and hydronephrosis despite 
the presence of the stent. Upon analysis it became clear that the urine leakage 
could be attributed to insufficient mechanical strength of the collagen scaffolds, 
which resulted in ruptures or dissections of the scaffolds. In the animals where 
the scaffold remained patent, the scaffold was mostly covered by a single layer 
of urothelial cells. Extensive neovascularization and some SMC ingrowth was 
observed (Fig 1). Although the collagen construct with primary urinary bladder 
cells was suitable for ureteral reconstruction, we can conclude that back-bone 
biodegradable synthetic materials are needed to bear mechanical loads when 
attempting to repair an unsupported, mobile organ like the ureter. 
One of the major disadvantages of primary cells, especially for urothelium, is 
that the cells cannot safely be harvested in case of possible malignancies [36]. Also, 
suitable tissue may not always be available for cell isolation. Therefore, alternative 
cell sources are being explored with a focus on mesenchymal (MSC) and adipose 
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derived stem cells (ADSC). These cells can differentiate into multiple cell lineages, 
including muscle and epithelium, without the risk of tumor formation [37-40]. 
Additionally, they are associated with anti-inflammatory properties and the 
capability to produce several cytokines that are associated with normal wound 
healing [41].
Zhao, et al. [31] isolated ADSC from rabbits and differentiated these towards 
a SMC phenotype before cell seeding and implantation. The cells were seeded on 
decellularized rabbit abdominal aorta to prepare a vascular extracellular matrix 
(VECM). Cell seeded scaffolds were used to replace a 3.0 cm long defect of the 
rabbit ureter. After 16 weeks the defect was characterized by a well-organized 
muscle layer and stratified urothelium similar to native tissue. Strictures and 
hydronephrosis were absent. The authors attributed the positive results to the 
stimulating effect of ADSC on SMC proliferation and differentiation, and the use 
of a graft containing many natural occurring growth factors [42]. Additionally, 
Shi, et al. [27] showed that human ADSC can survive and maintain their 
phenotype for at least 2 weeks when implanted subcutaneously in nude mice, 
showing the possibility to use these cells for their stimulating properties in time. 
Alternatively, MSC can be used. These cells possess similar properties as ADSC, 
but are isolated from the bone marrow. The harvesting procedure of these cells 
is painful, the differentiation potential decreases with age, and the number 
isolated cells is limited compared to ADSC [43, 44]. Liao, et al. [32] used MSC in 
combination with SMC seeded on bladder acellular matrix (BAM) to repair a 4.0 
cm ureteral defect in rabbits. The BAM was seeded with bone marrow derived 
mesenchymal stem cells (MSCs) on one side and urinary bladder derived SMCs 
on the other side to create tissue-engineered tubular grafts (TETG). The TETG 
was tubularized around a catheter and pre-implanted in the omentum of rabbits 
for 2 weeks. During this pre-implantation, the MSC differentiated and formed 
a single-cell layered epithelium. Next, the ureteral defect was repaired, where 
a multilayer urothelium with central neovascularization was observed after 16 
weeks. No strictures or hydronephrosis was observed, even though the ureteral 
catheter was removed 6 weeks post-operatively. Without MSC the ureter repair 
resulted in scar formation and severe hydronephrosis. The investigators reasoned 
that the formation of the single layered epithelium during the pre-implantation 
phase might have protected the surrounding tissue against urine. 
These examples show the potential of stem cells as an alternative cell source 
for ureteral tissue engineering when insufficient donor tissue is available. 
Full circumference ureteral defect repair
Major ureteral reconstructions are required when a complete segment of the 
ureter needs to be replaced. Onlay graft repair is most often impossible and can 
only be applied in stricture repair. It is therefore not surprising that the majority 
of the studies focus on the repair of long (relative to the total length of the ureter) 
defects using tubular or tubularized constructs. Zhang, et al. [29] used 3.0 cm 
long tubular autologous connective tissue that was formed after the implantation 
of silicon tubes in the peritoneal cavity of dogs. By maintaining one third of the 
Figure 1. Implantation strategy and outcome after ureteral reconstruction using tubular collagen 
scaffolds. A,B: Macroscopic overview of a tubular 0.5% type-I collagen scaffold (length = 6 cm, Ø = 6 
mm). C: SEM overview of the scaffold surface, which was highly porous, facilitating cell penetration 
into the scaffold (scale bar = 500 µm) D: Immunofluorescent staining for collagen (green), nuclei 
(blue) and RCK103 (red) of a cell seeded scaffold. Urothelial cells (RCK103 positive) were lining the 
scaffold (scale bar = 400 µm). E: Immunofluorescent staining for collagen (green), nuclei (blue) and 
α smooth muscle actin (red) of a cell seeded scaffold. Smooth muscle cells (α smooth muscle actin 
positive) were found throughout the scaffold (scale bar = 400 µm). F: The scaffolds were implanted by 
end-to-end anastomosis. G,H: Ureteral regeneration was evaluated after 1 month. 4 animals showed 
intact ureters (G), while 7 animals presented with defects or dissections (H). I: Histological overview 
of a regenerating ureter (scale bar = 5 mm). Black dotted lines indicate the anastomosis sites. Specific 
locations are highlighted (J-O). J: Haematoxylin and eosin (HE) staining of the native ureter (scale 
bar = 400 µm). K: Inflammatory response in the regenerating tissue near scaffold remnants (red 
arrows). Mostly lymphocytes, a few granulocytes and some multinucleated giant cells (black arrows) 
were observed (scale bar = 200 µm). L: Pancytokeratin staining in the middle of the neo-ureter, 
indicating the presence of (multilayered) urothelium (scale bar = 400 µm). M: Smoothelin staining 
near the anastomosis site, indicating ingrowth and maturation of smooth muscle tissue into the neo-
ureter (scale bar = 400 µm). N: Masson’s trichrome staining of the native ureter (scale bar = 400 µm). 
O: Masson’s trichrome staining near the anastomosis site, indicating the ingrowth of new muscle 
tissue (scale bar = 400 µm). 
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ureter the investigators kept adequate vascularization and they managed to 
generate new tissue which was similar to the normal ureter. After 12 weeks, 
the tubular construct was completely lined by multilayered urothelium, and 
presented with an organized muscle layer and mucosal folds. While these results 
are very promising, one has to realize that it is unlikely that one third of healthy 
ureter is present in the clinical situation, e.g. in case of severe adhesions or 
prolonged avascularity. It is generally accepted that tissue ingrowth after 1.0 cm 
becomes increasingly difficult and is likely to be accompanied by fibrosis [34]. By 
maintaining the ureteral segment, the authors avoided this challenge. 
Pre-implantation
The lack of functional urothelium and adequate vascularization may contribute 
to stricture formation and fibrosis as urine can freely damage the regenerating 
tissue [5, 45]. Pre-implantation promotes vascularization and helps to maintain 
the viability of the seeded cells in vivo. Different pre-implantation sites have been 
used for various applications, including the omentum [46, 47], peritoneum [48, 
49] and subcutis [49, 50]. Zhang, et al. [29] and Liao, et al. [32] took advantage 
of pre-implantation before repairing a ureteral defect. Zhang, et al. exploited 
pre-implantation to create a tubular scaffold from the fibrous capsule which was 
formed in the peritoneal cavity. Liao, et al. [32] used omental pre-implantation as 
an in vivo bioreactor to increase neo-vascularization in the construct. Additionally, 
it allowed the formation of a one-layer epithelial structure which may protect the 
construct after implantation in the toxic urine-rich environment. 
Ideally, when harvesting the pre-implanted material, the newly formed 
blood vessels should remain intact. A mobile pre-implantation site close to the 
ureteral defect repair site, like the greater omentum, might be suitable for this 
as flaps can easily be mobilized most of the time. Although pre-implantation 
techniques are promising, it is time consuming and requires a second surgical 
procedure. Therefore, it may not always be applicable in case of acute problems 
and unplanned procedures, which is often the case with ureteral trauma.
Decellularized tissue and synthetic polymers
A variety of materials has been used as scaffolding material. Most studies used 
decellularized tissues as opposed to “man-made” scaffolds in the past decades. 
The advantages of decellularized tissues include preservation of the native 
tissue architecture and inclusion of tissue specific growth factors and other 
signaling molecules [42]. In the past, SIS has been the decellularized tissue of 
choice. The results, however, were not optimal in ureteral tissue engineering. 
Recently, Salehipour, et al. [30] used amniotic membrane (AM), which is known 
for its anti-inflammatory properties, as a biomaterial to reconstruct long ureteral 
defects. In dogs a 3.0 cm segment of the ureter was replaced by tubularized 
decellularized AM. Two out of seven animals died due to urine leakage and 
another animal showed severe hydronephrosis, acute and chronic inflammation, 
and the formation of granulation tissue. The other animals presented with mild 
pelvicaliectasis and fibrosis of the reconstructed segment with lymphatic and 
granulocytic infiltration. Where Koziak, et al. [51] showed encouraging results 
when AM was used as an onlay graft in 2007, the authors of this study concluded 
that AM did not act as a favorable material when used in full defects. This result 
was similar to a previous study by Osman, et al. in 2004 [33]. Decellularized blood 
vessels and bladder acellular matrix have recently been used with promising 
results, but these results may also be caused by the use of stem cells and pre-
implantation techniques, something that was not done in combination with SIS 
for the ureter [31, 32]. 
Besides decellularized tissues, “man-made” scaffolds can be used. The 
advantage of these scaffolds is a higher degree of plasticity, good mechanical 
properties, and they are well defined. Most materials can be prepared in any shape 
(e.g. flat, film or tube) or size, and different proteins and bioactive molecules 
can be added as demonstrated in the recent publications using spiral PLLA 
stents in combination with collagen and our tubular collagen scaffolds. When 
improvements such as increased mechanical strength are required, these man-
made scaffolds can easily be tailored compared to decellularized tissue. 
Animal models
In recent ureteral replacement animal studies rabbits [31, 32], dogs [29, 30] and in 
our case pigs (unpublished), were used, while subcutaneous implantation studies 
were performed in rats [26] or mice [27, 28]. The pig is the preferred model because 
the abdominal anatomy of pigs and humans is similar [52, 53]. Nevertheless, the 
lack of recent pig studies might be associated with the high incidence of fibrosis 
and fast growth of the animal, as mostly fast growing young pigs are used. This 
may influence tissue regeneration and cause mechanical stress on the tissue 
constructs. The ideal animal should have a similar size and abdominal anatomy 
as humans, be fully grown, and have similar wound healing characteristics. 
Potential candidate animals include goats, sheep, cattle and horses. In general, 
randomized controlled trials preceded by extensive toxicity studies are required 
before a new technique is widely used in the clinic. However, in tissue engineering 
it is unethical to perform safety studies in healthy patients and there is often a 
lack of golden standard treatments. Therefore, choosing the right animal models 
is critical to predict the expected clinical outcome as good as possible [54]. 
Conclusions
Ureteral reconstruction should focus on the maintenance of safe urine transport 
from the kidney to the bladder. Fast development of a vascular system, a functional 
smooth musculature, and a urothelial barrier are critical for the success of 
constructs as the lack of these layers may result in strictures and hydronephrosis, 
even when stents are used. In the past few years, clear advancements have been 
made in ureteral tissue engineering. Specifically, the cell source, implantation 
techniques and new biomaterials have improved the tissue engineering of the 
ureter. Decellularized tissues or scaffolds with added natural proteins and other 
molecules may perform better than simple scaffolds, however, these were only 
studied in the context of stem cells. Despite these advancements, published 
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research in the area of ureteral tissue engineering is scarce.  Many recent studies 
do not address the behavior of the constructs in a ureteral replacement setting. 
To increase our knowledge on the effect of different materials, cells sources and 
implantation techniques, future studies should attempt to repair a full ureteral 
defect. Current literature suggests that the use of mesenchymal and adipose 
derived stem cells, seeded on any type of mechanically suitable bioactive 
material, is optimal for ureteral regeneration. In addition, pre-implantation of 
these constructs in the omentum may improve the final outcome by increasing 
vascularization and triggering stem cell differentiation. However, when using the 
body as an in vivo bioreactor, the long incubation time may be problematic in 
ureteral repair. Finally, different pre-clinical animal models should be evaluated 
to prevent species-related result bias prior to commencing clinical trials. 
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Abstract
Context: Urethra repair by tissue engineering has been extensively studied in 
laboratory animals and patients, but is not routinely used in clinical practice.
Objective: To systematically investigate pre-clinical and clinical evidence 
of the efficacy of tissue engineering for urethra repair in order to stimulate 
translation of pre-clinical studies to the clinic.
Evidence Acquisition: A systematic search strategy was applied in PubMed 
and EMBASE. Studies were independently screened for relevance by two 
reviewers, resulting in 80 pre-clinical and 23 clinical studies of which 63 
and 13 were selected for meta-analysis to assess side-effects, functionality, 
and study completion. Analyses for pre-clinical and clinical studies were 
performed separately. Full circumferential and inlay procedures were 
assessed independently. Evaluated parameters included seeding of cells and 
type of biomaterial.
Evidence Synthesis: Meta-analysis revealed that cell seeding significantly 
reduced the probability of encountering side-effects in pre-clinical studies. 
Remarkably though, cells were only sparsely used in the clinic (4/23 studies) 
and showed no significant reduction of side-effects. ln 21 out of 23 clinical 
studies, decellularized templates were used, while in pre-clinical studies 
other biomaterials showed promising outcomes as well. No direct comparison 
to current clinical practice could be made due to the limited number of 
randomized controlled studies.
Conclusion: Due to a lack of controlled (pre-)clinical studies, the efficacy of 
tissue engineering for urethra repair could not be determined. Meta-analysis 
outcome measures were similar to current treatment options described in 
literature. Surprisingly, it appeared that favorable pre-clinical results, i.e. 
inclusion of cells, were not translated to the clinic. Improved (pre-)clinical 
study designs may enhance clinical translation. 
Patient Summary: We reviewed all available literature on urethral tissue 
engineering to assess the efficacy in pre-clinical and clinical studies. We 
show that improvements to (pre-)clinical study design is required to improve 
clinical translation of tissue engineering technologies.
Introduction
Congenital birth defects of the urethra, such as hypospadias (1 in every 300 births) 
[1, 2], and acquired urethral abnormalities, such as urethral strictures (1 in every 
1,000 men >65 years of age [3]), represent major clinical entities. Treatment usually 
involves a surgical procedure with risk of (recurrence of) strictures or fistula 
requiring additional care or reintervention. Whenever possible, local tissue flaps 
or stricture resection in combination with end-to-end anastomosis are used for 
urethra reconstruction [4, 5]. Generally, two surgical approaches exist for urethral 
reconstruction: partial replacements using onlay or inlay techniques or the full 
circumferential procedure, which is used in rare cases with significant urethral 
scarring or lichen sclerosis. Depending on patient and local factors, procedures 
can be performed as one-stage procedure or as planned multistage procedure [3]. 
Autologous tissue transplantation such as buccal mucosa or free skin grafts 
are the standard treatments [6-9]. However, due to the limited quantity of available 
donor tissue, accompanying donor site morbidity (16 to 32% for buccal mucosa 
grafts) and complications (e.g. recurrences or infections), alternative treatment 
options are needed to improve long-term outcome [10]. Tissue engineering may 
overcome some of the aforementioned disadvantages by providing a temporary 
template to guide tissue regeneration [11]. In general, tissue engineered templates 
include decellularized tissue or de-novo prepared materials from natural or 
synthetic origin [12-14]. Templates can be seeded with (stem) cells from the 
patient prior to implantation. These cells may stimulate tissue remodeling by 
excreting cytokines and growth factors and contributing to cellular population 
of the template [15, 16]. 
Despite the potential of tissue engineering shown in in vitro research and pre-
clinical studies, clinical translation is limited. To improve translation, an evidence-
based approach, such as systematic reviews, can be applied when designing new 
tissue engineering strategies. This will avoid unnecessary replication of studies 
and will help to select the most optimal experimental design and model. We are 
the first to perform a comprehensive systematic review of evidence for the efficacy 
of urethral tissue engineering in pre-clinical and clinical studies. A meta-analysis 
was used to compare different experimental designs based on clinically relevant 
outcomes. This systematic review aims to improve the translation of urethral 
tissue engineering from bench to bedside.
Evidence acquisition
Literature search
To identify all available studies on urethral tissue engineering published and 
indexed up until June 1, 2016, a systematic search strategy was applied in PubMed 
(Appendix 1) and Embase (via OvidSP; Appendix 2). This strategy combined a 
tissue engineering search component containing synonyms for tissue engineering 
related terms [17] with a customized search component for urethra or urethra-
related diseases. MeSH terms and EMTREE terms were used in PubMed and 
Embase, respectively, together with separate words or word combinations in title 
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or abstract. Next, either an animal filter designed by Hooijmans et al. (PubMed) 
[18] or de Vries et al. (Embase) [19] was applied (Appendix 1 and 2, search 
component 3A) or a custom filter for clinical studies (Appendix 1 and 2, search 
component 3B). In addition, retrieved reviews were screened for primary studies 
not found using the search strategy. Clinical studies found during animal search 
strategy were marked and screened for relevance and vice versa.
Study selection
Duplicates in retrieved articles were removed in EndNote (Version X7.2, Thomson 
Reuters). Studies were assessed independently by LV and PdJ. First, clearly 
irrelevant studies were excluded based on title. Next, titles and abstracts of 
the remaining articles were screened for relevance in Early Review Organizing 
Software (EROS, Buenos Aires, Argentina, www.eros-systematic-review.org) 
using the following exclusion criteria: 1) no urethra, 2) no tissue engineering, 3) no 
animals or patient, 4) no primary study. A study was considered to be about tissue 
engineering when a processed template was used. Studies on tissue transplants or 
reconstructive surgery without the use of a template or without a urethra defect 
were excluded. Of the remaining studies full texts were screened using the same 
exclusion criteria. Articles not available as full text were excluded at this stage. 
No language restrictions were applied in the screening phase. If necessary, Google 
translate was used. Retrieved studies from search updates were directly screened 
in Endnote according to the same principles. In all stages of the selection process, 
discrepancies between reviewers were discussed until consensus was reached.
Study characteristics
From all included studies, general information (author, year) and study 
characteristics (age range of patients, animal species, sex, surgical procedure, 
type of biomaterial, type of cells) were extracted and listed in Table 1 for pre-
clinical studies and Table 2 for clinical studies. For languages other than English, 
German and French, Google Translate was used to retrieve study characteristics. 
Extraction outcome data
Three outcome measures were used to evaluate study outcome: 1) incidence of 
side effects, e.g. strictures, stenosis, fistulae, and infections, 2) functionality, 
defined as the ability to void with continence, and 3) study completion, for 
animals defined as survival until predetermined endpoint and for clinical studies 
as available for follow-up or no additional urethroplasty required. Only English, 
German and French studies were considered for quality assessment and meta-
analysis. When critical information needed (e.g. surgical procedure or number 
of animals/patients) was incomplete, studies were excluded. As only two studies 
used rats these were also excluded at this stage.
Table 1: Study characteristics of all 80 pre-clinical studies sorted on inclusion in meta-analysis, surgical 
procedure and biomaterial.
Author Year Animal 
model
# of 
ani-
mals 
Sex Surgical 
Procedure 
(defect length 
in mm)
Biomaterial (category) Type of added cells Quality 
Assess-
ment + 
Meta-
analysis
1 Feng, C. 2011 Rabbit 28 M Inlay (15) Acellular corpus spongiosum, 
porcine (D)
Autologous corporal SMC’s and 
lingual keratinocytes
Yes
2 Ayyildiz, A. 2006 Rabbit 10 M Inlay (5) Alloderm® + acellular 
pericardium, bovine (D)
- Yes
3 Chen, F. 1999 Rabbit 10 M Inlay (10) BAM, porcine (D) - Yes
4 Chun, S.Y. 2015 Rabbit 10 M Inlay (20) BAM, porcine (D) Autologous minced urethral 
muscle and urothelial tissue
Yes
5 Sayeg, K. 2013 Rabbit 18 M Inlay (35) BAM, porcine (D) Autologous bladder SMC’s Yes
6 Huang, J.W. 2014 Rabbit 30 M Inlay (15) BAM, rabbit (D) - Yes
7 Li, C. 2008 Rabbit 24 M Inlay (20) BAM, rabbit (D) Autologous oral keratinocytes Yes
8 Li, C. 2013 Rabbit 27 M Inlay (20) BAM, rabbit (D) Autologous oral kereatincytes 
and TGF-β siRNA transfected 
fibroblasts
Yes
9 Li, H. 2014 Rabbit 36 M Inlay (20) BAM, rabbit (D) Epithelial-differentiated rabbit 
adipose-derived stem cells
Yes
10 Wang, F. 2014 Rabbit 12 M Inlay (10) Denuded amnion, human (D) Rabbit urothelial cells Yes
11 Kajbafzadeh, 
A.M. 
2014 Rabbit 12 M Inlay  (5) Preputial acellular matrix, 
human (D)
- Yes
12 Kawano, P.R. 2012 Rabbit 24 M Inlay  (10) SIS, 1- and 4 –layer, porcine (D) - Yes
13 Guo, H. 2015 Rabbit 24 M Inlay (20) SIS, porcine (D) Autologous keratinocytes 
and TIMP siRNA transfected 
fibroblasts
Yes
14 Kropp, B.P. 1998 Rabbit 8 M Inlay(10) SIS, porcine (D) - Yes
15 Rotariu, P. 2002 Rabbit 7 M Inlay (25) SIS, porcine (D) - Yes
16 Villoldo, G.M. 2013 Rabbit 15 M Inlay(10) SIS, porcine (D) - Yes
17 Shokeir, A. 2003 Dog 21 M Inlay (30) UAM, dog (D) - Yes
18 Huang, J.W. 2015 Rabbit 30 M Inlay (20) Cellulose (N) Rabbit Lingual keratinocytes Yes
19 Xie, M. 2013 Dog 10 F Inlay (50) Silk fibroin (N) Autologous oral keratinocytes 
and fibroblasts
Yes
20 Xie, M. 2013 Dog 9 F Inlay (30) Silk fibroin (N) Dog urothelial cells Yes
21 Sun, D. 2014 Rabbit 21 M Inlay (5) Subcutaneous implanted 
autologous minced muscle (N)
Human umbilical cord MSC’s Yes
22 Xu, Y. 2014 Rabbit 21 M+F Inlay (5) Subcutaneous implanted 
autologous muscle microsomes 
(N)
Human umbilical cord MSC’s Yes
23 Zhang, K. 2015 Rabbit 12 M Inlay (20) P(LA/CL) + type I collagen 
in combination with ICG-001 
(Wnt-pathway inhibitor) (S)
Rabbit bladder urothelial cells Yes
24 Wang, D.J. 2015 Rabbit 24 M Inlay (5) Polylactid acid (S) Rabbit AdSC’s Yes
25 Kelami, A. 1971 Dog 10 M Inlay (30) PTFE (S) + lyophilized dura, 
human (D)
- Yes
26 Chung, Y.G. 2014 Rabbit 8 M Inlay (20) Silk fibroin (N) + SIS (D) - Yes
27 Lv, X. 2016 Rabbit 18 M Inlay (15) Silk-Keratin-Gelatin-Calcium 
peroxide (N) + SIS, porcine (D)
- Yes
28 Nuininga, J.E. 2003 Rabbit 18 M Inlay (10) SIS, 1 - and 4 - layer, porcine 
(D) + Type I collagen (N)
- Yes
29 Zhang, Q. 2008 Rabbit 12 M Full (10) Acellular amnion, human (D) Homologous endothelial 
progenitor cells
Yes
30 Parnigotto, P.P. 2000 Rabbit 12 M Full (10) Acellular aorta, rabbit (D) - Yes
31 DeFilippo, R.E 2002 Rabbit 24 M Full (10) BAM (D) Autologous bladder SMC’s and 
urothelial cells
Yes
32 El-Tabey, N. 2012 Dog 14 F Full (30) BAM (D) Autologous bladder SMC’s and 
urothelial cells
Yes
33 Wang, J.H. 2013 Rabbit 18 M Full (30) BAM with polylactid acid –
glycolic acid with VEGF (D)
- Yes
34 DeFilippo, R.E. 2015 Rabbit 15 M Full (30) BAM, porcine (D) Autologous bladder SMC’s and 
urothelial cells
Yes
35 Dorin, R.P 2008 Rabbit 12 M Full (5-30) BAM, porcine (D) - Yes
36 Orabi, H. 2012 Dog 21 M Full (60) BAM, porcine (D) Autologous bladder SMS’s and 
urothelial cells
Yes
37 Fu, Q. 2007 Rabbit 18 M Full (15) BAM, rabbit (D) Autologous foreskin epidermal 
cells
Yes
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38 Fu, Q. 2008 Rabbit 18 M Full (15) BAM, rabbit (D) Autologous foreskin epidermal 
cells
Yes
39 Gu, G.I. 2012 Rabbit 18 M Full (15) BAM, rabbit (D) Autologous mesothelial cells Yes
40 Li, C.L. 2013 Rabbit 30 M Full (30) BAM, rabbit (D) Autologous bone-marrow 
derived MSC’s and SMC’s
Yes
41 Li, B. 2013 Rabbit 12 M Full (15) Frozen-thawed bladder muco-
sa, dog (D)
- Yes
42 Kjaer, T.B. 1976 Dog 9 M Full (30) Lyophilized vein, dog (D) - Yes
43 Shokeir, A. 2004 Dog 14 M+F Full (30) UAM, dog (D) - Yes
44 Sievert, K.D. 2001 Rabbit 14 M Full (8-11) UAM, dog and rabbit (D) - Yes
45 Sievert, K.D. 2000 Rabbit 30 M Full (8-11) UAM, rabbit (D) - Yes
46 Lv, X. 2016 Dog 18 F Full (20) Bacterial cellulose + potato 
starch (N)
Dog lingual muscle cells Yes
47 Gu, G.I. 2010 Rabbit 9 M Full (15) De-novo created tissue in 
peritoneal cavity (N)
- Yes
48 Jia, W. 2015 Dog 10 M Full (50) Type I collagen scaffold +/- 
3VEGF (N)
- Yes
49 A. Da Silva, L.F. 2014 Rabbit 16 M Full (10) Type I collagen, bovine (N) Autologous bladder SMC’s Yes
50 Nuininga, J.E. 2010 Rabbit 32 M Full (10) Type I collagen, bovine (N) - Yes
51 Kanatani, I. 2007 Rabbit 28 M Full (15) Type I collagen, porcine + 
P(LA/CL) (N)
- Yes
52 Micol, L.A. 2012 Rabbit 16 M Full (10) Type I collagen, rat tail (N) Autologous bladder SMC’s Yes
53 Mikami, H. 2012 Dog 10 M Full (20) Type I collagen, rat tail (N) Autologous oral epithelial and 
muscle cells
Yes
54 Italiano, G. 1997 Rabbit 14 M Full (15) Hyaluronan benzyl ester (S) - Yes
55 Italiano, G. 1998 Rabbit 4 M Full (15) Hyaluronan benzyl ester (S) - Yes
56 Fu, Q. 2014 Dog 18 M Full (15) PGA (S) Oral mucosal epithelial cells 
and AdSC’s
Yes
57 Hakky, S.I. 1977 Dog 15 M Full (50) Polyethylene terephthalate (S) - Yes
58 Hakky, S.I. 1977 Dog 9 M Full (50) Polyethylene terephthalate (S) - Yes
59 Olsen, L. 1992 Dog 6 M Full (30-40) Polyglactin fiber coated with 
polyhydroxybutyric acid (S)
- Yes
60 Anwar, H. 1984 Dog 10 ? Full (25) PTFE (S) - Yes
61 Dreikorn, K. 1979 Dog 12 M Full (30-80) PTFE (S) - Yes
62 Xie, H. 2007 Rabbit 34 M Inlay + Full (15) Elastin and collagen, porcine 
(N)
- Yes
63 El-Assmy, A. 2004 Rabbit 18 M Inlay + Full (15) SIS (D) - Yes
64 Wang, Y.Q. 2005 Rabbit 14 M Inlay (10) BAM, human (D) - No (CN)†
65 Beintker, M. 2007 Rat 20 M Inlay (?) SIS (D) - No*
66 Glybochko, P.V. 2014 Rabbit Un-
known
M Full (?) Acellular artery, human (D) - No (RU)†
67 Peng, W.B. 2013 Rabbit Un-
known
M Full (25) BAM (D) Rabbit hair follicle stem cells No (CN)†
68 Hu, Y.F. 2008 Rabbit 30 M Full (10-15) UAM, rabbit (D) - No‡
69 Hu, Y.F. 2009 Rabbit 20 M Full (10-15) UAM, rabbit (D) - No (CN)†
70 Yang, S.X. 2004 Rabbit 30 M Full (10-15) UAM, rabbit (D) - No‡
71 Lebret, T. 1994 Rat 7 F Full (?) Type IV collagen, human (N) - No*
72 Fu, W.J. 2009 Rabbit 32 M Full (10-15) PLLA (S) Autologous urothelial cells No‡
73 Verit, A. 2003 Dog 2 M Full (10) PTFE (S) - No (TR)†
74 Huang, X. 2006 Rabbit 12 M Inlay + Full (?) SIS, porcine (D) - No (CN)†
75 Fu, Q. 2006 Rabbit 12 M Unclear (10-30) BAM, rabbit (D) - No (CN)†
76 Xu, L.S. 2007 Rabbit 48 M Unclear (?) UAM, porcine (D) - No‡
77 Han, P. 2009 Rabbit 24 M Unclear (20) UAM, rabbit (D) Rabbit bladder SMC’s No (CN)†
78 Huang, H.J. 2007 Rabbit 48 M Unclear (?) UAM, rabbit (D) Rabbit bone marrow derived 
MSC’s
No (CN)†
79 Zhang, Y. 2011 Rabbit Un-
known
M Unclear (?) Silk fibroin (N) Rabbit AdSC’s No (CN)†
80 Liu, C. 2008 Dog 12 M Unclear (15-30) Silk fibroin (N) - No (CN)†
† Excluded from meta-analysis due to language restrictions defined in section 2.5. 
* Excluded from meta analysis because only two studies used rats (insufficient for statistical analysis).
‡ Excluded from meta analysis due to unclear experimental setup.
? = unclear, AdSC = adipose-derived stem cells, BAM = bladder acellular matrix, CN = Chinese, D = 
decellularized, MSC = mesenchymal stem cells, N = natural, P(LA/CL) = copoly(L-lactide/ɛ-caprolactone), 
PTFE = Polytetrafluoroethylene, RU = Russian, S = synthetic, SIS = small intestinal submucosa, SMC = 
Smooth muscle cell, TR = Turkish, UAM = urethral acellular matrix, VEGF = vascular endothelial growth 
factor.
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Quality assessment
Due to the non-randomized, non-controlled nature of most pre-clinical and clinical 
studies, no standard risk of bias analysis could be performed as validated tools are 
unavailable for these types of studies. Instead, overall quality was independently 
scored by PdJ and LV based on the reporting of specific key information (Fig. 2, 
Results section). Discrepancies were discussed until agreement was reached.
Meta-analysis
The following main research question was considered: “What is the evidence for 
the efficacy of urethral tissue engineering in pre-clinical and clinical studies?” 
Sub-questions included the effects of the addition of (stem) cells to the template, 
the type of biomaterial, as well as potential differences between animal species 
on the separate outcome measures. Analyses for pre-clinical and clinical studies 
were conducted separately, as were full circumferential and inlay procedures. 
Statistical analyses were performed with SAS/STAT® software v9.2 for Windows, 
copyright© 2002-2008 by SAS Institute Inc., Cary, NC, USA.
Pre-clinical studies
The following pre-clinical data were extracted for all available time points per 
study: the total number of animals as well as the number of animals without 
side effects, with functionality, and alive at the study endpoint. Time points were 
categorized in three periods: 0-4 weeks, 5 11 weeks and 12 weeks or longer. 
Per study, the probability of response (e.g. having no side effects) with 
a corresponding 95% exact (Clopper-Pearson) confidence interval (CI) was 
estimated per outcome. An additive random-effects logistic meta-regression 
model was fitted by means of a generalized linear mixed model approach. The 
number of responding animals out of the total was used as outcome parameter. In 
addition, the following independent parameters were used: treatment (combining 
the addition of cells and the type of biomaterial) and animal species. Random 
effects for study and for treatment grouped by study, were added. The Akaike 
Information Criterion [20] showed that models based on combined study data 
were preferable to models based on the period data (period as factor), therefore all 
time points per study were combined. When possible, the maximum likelihood 
approach with adaptive quadrature was used as estimation method. If this did 
not converge, the maximum likelihood with the Laplace approximation was 
applied. The resulting estimated odds were backtransformed into percentages 
and corresponding 95% CIs. In addition, the marginal effects of the treatments 
were estimated by combining the estimated percentages for rabbits and dogs, 
including 95% logit-based CIs, as described by Zou [21]. P-values were based on 
these confidence intervals.
Clinical studies
For the analyses of the clinical outcomes, the following data per study were 
extracted: total number of patients, and numbers of patients without side effects, 
with functionality, and completing the study. No separate time points were 
analyzed in the human studies. For each study, the probability of response with 
corresponding 95% exact CIs was estimated per outcome. Due to limited study 
diversity, meta-regression models similar to pre-clinical studies were only fit for 
inlay repair and biomaterial type ‘decellularized’. A compound symmetry random 
effect was added for the addition of cells, grouped by study. Estimated odds from 
meta-regression were backtransformed into probabilities and corresponding 95% 
CIs.
Evidence synthesis
Literature search and screening
Figure 1A and B show the results of the literature search and screening of collected 
studies. After the search, 1,524 unique pre-clinical and 5,361 unique clinical 
studies were identified. During title and abstract screening of these studies, 1,349 
and 5,282 were excluded, respectively. After full text screening, 80 pre-clinical 
studies and 23 clinical studies were included in the study characteristics table 
(see section 3.2). Only 63 pre-clinical and 13 clinical studies were eligible for the 
quality assessment (section 3.3) and meta-analysis (section 3.4).
Figure 1A. Flowchart of search and screening process of pre-clinical studies. The search was updated 
until June 1, 2016. 
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Figure 1B. Flowchart of search and screening process of clinical studies. The search was updated 
until June 1, 2016. 
Study characteristics
Pre-clinical studies
Pre-clinical study characteristics are summarized in Table 1 (see Appendix 3 for 
references of listed studies). Only three animal species, rabbits (59/80), dogs 
(19/80) and rats (2/80) were used, which were predominantly males (72/80). Full 
circumferential repair was investigated in 41 studies, inlay repair in 30 studies, 
both methods in three, while the procedure was unclear in the remaining studies 
(6/80). In dogs, primarily full defect repairs were performed (14 full vs. 4 inlay), 
while in rabbits both inlay (25) and full repairs (26) were employed.
Due to the wide variety of materials used, they were categorized into 
three categories: decellularized templates (46/80), de novo prepared templates 
from natural materials (18/80), and de novo prepared templates from synthetic 
materials (12/80). Four (4/80) studies used multiple material types in 
different groups and these were assessed separately in the meta-analysis. 
Synthetic materials were almost exclusively used for full repair (10 full vs. 3 inlay). 
Cells were incorporated into templates in 34 studies, of which bladder smooth 
muscle cells (SMCs) and urothelial cells were mostly used (13/34), followed by 
keratinocytes and fibroblasts from oral tissue (6/34) or a combination thereof 
(2/34), foreskin epidermal cells (2/34) and omental mesothelial cells (1/34). Stem 
cells, mostly derived from adipose tissue, bone marrow or human umbilical cord, 
were used in 10 studies. 
Clinical studies
Study characteristics of clinical studies are listed in Table 2 (see Appendix 4 for 
references of listed studies). Clinical studies were performed with males, except 
for one study (Table 2, #22). From 23 studies, 16 used an inlay approach, two a 
full circumferential procedure, one used both approaches, while in four studies 
the procedure was unclear. The majority of studies (21/23) used decellularized 
templates, while natural and synthetic templates were both used once. Four 
studies used cell-seeded templates; 2/23 buccal mucosa keratinocytes and/or 
fibroblasts and 2/23 bladder SMCs and/or urothelial cells.
Quality assessment
The quality of reporting was assessed for 63 pre-clinical and 13 clinical studies 
from which outcome data could sufficiently be extracted for inclusion in the 
meta-analysis (Fig. 2). Results per study are listed in Appendix 5. Reporting of 
information regarding included animals/patients, such as species and strain, 
sex, number of animals/patients, age/weight and patient inclusion criteria, were 
generally well described.
Overall quality of the experimental setup was poor. Although the different 
experimental groups were well described, hardly any control groups were present, 
and randomization and blinding were seldom mentioned in both pre-clinical 
and clinical studies. Also, clinical study protocols were not published. However, 
surgical procedure, composition, size and preparation of the implants were clearly 
described in most studies. Reporting of outcome measures was good for both pre-
clinical and clinical studies with respect to the description of outcome measures, 
follow-up time and side effects. The number of drop-outs was clearly mentioned 
in clinical studies, but only in half of the pre-clinical studies. For pre-clinical 
studies, histological sampling location and representativeness of the results were 
poorly described.
Meta-analysis
Pre-clinical studies
For full circumferential repair (Fig. 3A), the addition of cells significantly reduced 
the probability of side effects, independent of the type of biomaterial used 
(p=0.001). Exact point estimates including CI are given in Appendix 6. Regarding 
the type of biomaterial, when no cells were used, estimates show that synthetic 
materials had a higher probability for having no side-effects compared to 
decellularized and natural materials. With cells seeded, estimated probabilities 
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were similar for all materials. For functionality and study completion, estimated 
probabilities were similar for all study conditions.
For inlay repair (Fig. 3B), the addition of cells significantly reduced the 
probability of side effects (p=0.003), albeit less than for full repair. Estimated 
probabilities were similar for all types of biomaterial regardless of the addition 
of cells. For functionality and study completion, estimated probabilities were 
similar for all study conditions. It was impossible to estimate study completion 
probability per biomaterial as almost all animals survived inlay repair (statistical 
model did not converge).
Although estimated probabilities for dogs and rabbits were slightly different, 
differences were not statistically significant. Consequently, the animal species 
had only marginal influence on outcome (data not shown). 
Clinical studies
For clinical studies, a similar meta-analysis was performed (Fig. 3C). Only inlay 
repair using decellularized materials with or without cells could be analyzed 
due to the limited number of other combinations. No statistically significant 
differences were found for the inclusion of cells for any of the outcome measures 
(p=0.5 for side-effects, p=0.7 for functionality and p=0.08 for study completion).
When comparing pre-clinical and clinical estimated probabilities, point 
estimates for absence of side-effects after inlay repair seem to be higher in 
clinical studies for both acellular and cellular templates. For functionality, the 
point estimates were similar. The estimated probability for study completion 
was much lower in clinical studies compared to pre-clinical studies regardless 
of the addition of cells, but these cannot be directly compared due to distinctive 
definitions for study completion and differences in disease status.
Discussion 
Reconstructive surgery using biomaterials has been studied as an alternative 
approach for urethral repair since the early seventies and efforts along these 
lines expanded rapidly in the nineties when the term ‘Tissue Engineering’ 
was introduced (Fig. 4) [11]. Nowadays, pre-clinical studies have been readily 
performed, but clinical studies have not followed this trend. Although many 
(pre-)clinical studies have been performed, tissue engineering is not used as an 
alternative treatment in routine clinical practice, except for a select patient group 
with a history of failed repairs [22-24]. In this systematic review, all (pre-)clinical 
publications on urethra tissue engineering until June 2016 were analyzed to assess 
the evidence for the efficacy. For clinical studies, the term “effectiveness” may be 
more suitable, as most studies included in this review showed a heterogeneous 
patient population [25]. However, we used the term “efficacy” for pre-clinical 
and clinical studies throughout this systematic review. For both pre-clinical 
and clinical studies, tissue engineering had a high probability for functionality, 
defined as voiding with continence. Study completion was high in pre-clinical 
studies, but not in clinical studies. This may be related to the difference in our 
definition of study completion and in study design. In pre-clinical studies, animals 
generally only need to survive for several months to study the tissue regeneration 
process, compared to patients that need to show a good long term outcome 
without reintervention and without being lost in follow-up. Most patients had 
a history of failed repairs using conventional techniques, while healthy animals 
were used. As randomized clinical studies were lacking, e.g. comparison with 
gold standard treatments (free skin graft or buccal mucosa urethroplasty) [3], 
no direct comparisons with current clinical practice could be made. Available 
literature about complex two-stage urethroplasty shows complication-free rates, 
functionality and study completion of approximately 62%, 67% and 36% [26], 
similar to the outcome of tissue engineered urethras (based on point estimates). 
This suggests that tissue engineered urethras may perform adequately and may 
be a valid alternative. Clearly, randomized controlled clinical trials are needed to 
clarify this issue. 
Application of cells
There is no consensus on the potential beneficial effects of cell seeding of tissue 
engineered constructs for the urogenital system. For tissue engineering of the 
bladder, the addition of cells did not give an overall beneficial effect on tissue 
regeneration [27], while others claim that cells are required for urethra repair 
of constructs >0.5 cm [28]. For urethra tissue engineering, the inclusion of cells 
significantly reduced side effects in pre-clinical studies for both full (p=0.001) and 
inlay (p=0.003) defects. In other, less comprehensive systematic reviews, a similar 
outcome regarding the effectiveness of the addition of cells was shown [29, 30]. 
For full defects, cell addition has more added value, which may be explained by 
the fact that cells can only infiltrate from the two urethra edges, while in inlay 
repair cell ingrowth can also occur from the sides, boosting cell coverage.
The effects of cell addition on functionality and study completion were not 
significant, regardless of surgical procedure. This may be caused by the short 
follow-up period underestimating long-term complications, such as complete 
strictures. Meta-analysis of clinical studies showed no significant effect of cells 
for any of the outcome measures. Consequently, the use of cells for the repair of 
urethra in the clinic remains debatable.
Type of biomaterial 
Meta-analysis showed no differences in estimated probabilities for the 
different materials in most of the conditions, with the exception of synthetic 
materials showing better estimated probabilities than natural materials in full 
circumferential repair without cells regarding side-effects. For inlay repair in pre-
clinical studies, synthetic materials did not perform as well as in full repair, but 
only a limited number of studies was reported. 
Decellularized materials were used in the vast majority of clinical studies. 
This may be related to the experience with decellularized materials in other 
fields of tissue engineering, such as skin tissue engineering [31]. Which type of 
biomaterial is superior to the current state-of-the-art remains to be established.
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Figure 2. Quality assessment of pre-clinical and clinical studies. All studies included for meta-
analysis were scored on clear reporting of several key parameters (Q1-Q21) showing that study design 
such as inclusion of proper control groups, associated randomization and blinding, reporting of key 
parameters such as representativeness of shown results and drop-outs needs to be improved in pre-
clinical studies.
Figure 3. Estimated probability including 95% confidence intervals for the absence of side effects, 
functionality and study completion for A) full circumferential repair and B) inlay repair in pre-
clinical studies, both categorized for the use of cells and the type of biomaterial. C) For the clinical 
studies, only decellularized material with or without cells could be analyzed. The effect of cells on the 
three outcome measures was calculated in estimated probabilities. Overall differences for cellular 
vs. acellular templates were determined for each outcome measure for both full and inlay repair: * 
p=0.003, ** p=0.001, all other differences were not significant (p>0.05). Specific point estimates and 
confidence interval are given in Appendix 6.
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Figure 4. Number of publications per year for pre-clinical and clinical studies included in this 
systematic review. After several single studies between 1971 and 1994, the number of publications 
increased. Peaks in both clinical and pre-clinical studies were seen around 2005-2008 and again 
between 2012-2015.
Selection of animal species
The choice of animal species is often based on financial issues, experience of the 
researchers, ethical arguments and practical restrictions [32-34]. An evidence-
based approach can aid in selection of the most appropriate model. In this review, 
differences between treatment were not notably influenced by the choice for 
rabbit or dog, however a higher statistical power would strengthen this claim.
Clinical relevance and limitations of pre-clinical and clinical studies
Quality of the experimental designs and reporting of pre-clinical studies was 
generally low. Proper control groups, such as sham operation groups and gold 
standard treatment groups, were often lacking. Instead, the experimental 
material without cells was generally considered the control. In addition, 
outcome measures and drop-outs were not specifically reported for each animal, 
complicating data interpretation. Also, representativeness of presented data was 
often not mentioned. This may have hampered clinical translation of these pre-
clinical findings. To improve this, all design parameters and outcomes should 
be specifically documented for individual animals similar to patients in clinical 
studies. The “Gold standard publication checklist to improve the quality of animal 
studies” by Hooijmans et al. would be helpful for the design and reporting of pre-
clinical studies [35].
Another limitation for the level of evidence provided by the pre-clinical 
studies is the use of healthy animals, in which a created defect is immediately 
closed, compared to patients with a history of stricture, lichen sclerosis or 
hypospadias. From the patients in clinical studies 75% had one or more previous 
treatments, e.g. dilation, urethrotomy or urethroplasty, before attempting the 
tissue engineered constructs. The requirement of animal models with injury or 
disease has been shown in other fields [36] and should also be considered in tissue 
engineering, in this particular situation by inducing strictures. 
Clinical studies provided a low level of evidence due to their setup, making the 
true effect of tissue engineering as surrogate for the current standard treatment 
unclear. Only El-Kassaby et al. (Table 2, #3) performed a small randomized 
controlled study. To improve the level of evidence, more randomized controlled 
studies are needed, preferably with larger numbers of patients and longer follow-
up. Compared to the pre-clinical studies, reporting of important parameters was 
much better, notably regarding drop-outs and adverse events. Nevertheless, to 
further improve the quality of the clinical studies, the study protocol should be 
published with the manuscript and a detailed description of patient inclusion 
criteria (e.g. sex, age and medical history) should be provided.
The level of evidence is further limited by original research’s susceptibility 
to publication bias [37], which may lead to overestimation of the treatment effect 
in pre-clinical studies. Recognition of this bias may partly explain the poor 
translation of tissue engineering techniques to the clinic. 
Furthermore, pre-clinical studies should better support the clinical need: 
the majority of pre-clinical studies involves full circumferential repair, where 
clinicians mainly perform inlay repair [3]. This may be explained by pre-clinical 
researchers attempting to prove the effectiveness of the experimental treatment 
for the most problematic (circumferential) procedures, assuming that it will also 
be effective in less complicated (inlay) approaches.
Finally, inclusion of cells remains challenging in a clinical setting as no 
beneficial effect was seen (in 11 patients), even though this significantly improved 
pre-clinical outcome. It is possible that inclusion of cells was perceived as too 
problematic, despite better results in a pre-clinical setting and that in the final 
assessment the choice was driven by parameters other than pre-clinical outcome. 
To consider cells for clinical applications, its efficacy has to be proven as the use 
of cells involves extensive regulatory requirements which may hamper clinical 
application [38-40]. In addition, the costs of cellular implants will be higher 
compared to off-the-shelf acellular implants, since two procedures are needed 
(cell harvesting in urine or biopsy, and urethroplasty) and in vitro cell expansion 
may be needed [41, 42]. 
Conclusions
The efficacy of tissue engineering for urethra repair could not be determined due 
to a lack of controlled (pre-)clinical studies. However, meta-analysis outcomes 
(side-effects, functionality and study completion) were comparable to current 
treatment options described in literature, indicating the potential of tissue 
engineering for urethra repair. The findings of this systematic review may result 
in improved study design which may aid the translation of tissue engineered 
urethras to the clinic as an alternative for autografts. 
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Appendix 1
Search strategy to retrieve all relevant literature using PubMed. Individual search 
components for tissue engineering, urethra, pre-clinical- and clinical studies were 
designed using relevant MeSH terms and other relevant synonyms and related 
terms. Search components 1, 2 and 3A were combined to retrieve all relevant pre-
clinical studies, while search components 1,2 and 3B were combined to retrieve all 
clinical studies.
Search component 1: Tissue Engineering
tissue engineering [MeSH] OR tissue culture techniques [MeSH] OR organ 
culture techniques [MeSH] OR organoids [MeSH] OR guided tissue regeneration 
[MeSH] OR regenerative medicine [MeSH] OR artificial organs [MeSH] OR tissue 
scaffolds [MeSH] OR biocompatible materials [MeSH] OR bioreactors [MeSH] OR 
(regenerative [tiab] AND (medicine [tiab] OR medicines [tiab])) OR ((decellularized 
[tiab] OR acellular [tiab] OR cell-free [tiab] bioartificial [tiab] OR bio-artificial 
[tiab] OR artificial [tiab] OR tissue [tiab] OR tissues [tiab] OR organ [tiab] OR 
organs [tiab] OR culture [tiab] OR cultures [tiab]) AND (autograft [tiab] OR 
autografts [tiab] OR graft [tiab] OR grafts [tiab] OR matrix [tiab] OR matrices [tiab] 
OR biomatrix [tiab] OR biomatrices [tiab] or biomaterial [tiab] OR biomaterials 
[tiab] OR scaffold [tiab] OR scaffolds [tiab] OR scaffolding [tiab] OR engineering 
[tiab] OR engineer [tiab] OR culture [tiab] OR cultures [tiab] OR regeneration 
[tiab] OR regenerated [tiab] OR regenerating [tiab] OR reconstruction [tiab] OR 
reconstructed [tiab] OR reconstructing [tiab])) OR tissue-engineered [tiab] OR 
tissue engineering [tiab] OR bio-engineering [tiab] OR bioengineering [tiab] OR 
bioengineered [tiab] OR bio-engineered [tiab] OR organoids [tiab] OR organoid 
[tiab] OR bioartificial [tiab] OR bio-artificial [tiab] OR artificial [tiab] OR scaffold 
[tiab] OR scaffolds [tiab] OR scaffolding [tiab] OR matrix [tiab] OR matrices [tiab] 
OR biomatrix [tiab] OR biomatrices [tiab] OR biomaterial [tiab] OR biomaterials 
[tiab] OR bioreactor [tiab] OR bioreactors [tiab]
Search component 2: Urethra
urethra [MeSH] OR urethral diseases [MeSH] OR urethra [tiab] OR urethral [tiab] 
OR urethras [tiab] OR urethrotomy [tiab] OR urethrotomies OR ureterotomy 
[tiab] OR ureterotomies [tiab] OR urethrotomia [tiab] OR urethroplasty OR 
urethroplasties [tiab] OR ((stricture [tiab] OR strictures [tiab]) AND (urology 
[tiab] OR urinary [tiab] OR urine [tiab] OR urological [tiab])) OR hypospadias 
[tiab] OR epispadias [tiab] OR urethritis [tiab] OR (meatus [tiab] AND (urology 
[tiab] OR urinary [tiab] OR urine [tiab] OR urological [tiab])) OR chordee [tiab] 
OR (perineal [tiab] AND (urology [tiab] OR urinary [tiab] OR urine [tiab] OR 
urological [tiab]))
Search component 3A: preclinical studies
(“animal experimentation”[MeSH Terms] OR “models, animal”[MeSH Terms] 
OR “invertebrates”[MeSH Terms] OR “Animals”[Mesh:noexp] OR “animal 
population groups”[MeSH Terms] OR “chordata”[MeSH Terms:noexp] OR 
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“chordata, nonvertebrate”[MeSH Terms] OR “vertebrates”[MeSH Terms:noexp] 
OR “amphibians”[MeSH Terms] OR “birds”[MeSH Terms] OR “fishes”[MeSH 
Terms] OR “reptiles”[MeSH Terms] OR “mammals”[MeSH Terms:noexp] 
OR “primates”[MeSH Terms:noexp] OR “artiodactyla”[MeSH Terms] OR 
“carnivora”[MeSH Terms] OR “cetacea”[MeSH Terms] OR “chiroptera”[MeSH Terms] 
OR “elephants”[MeSH Terms] OR “hyraxes”[MeSH Terms] OR “insectivora”[MeSH 
Terms] OR “lagomorpha”[MeSH Terms] OR “marsupialia”[MeSH Terms] 
OR “monotremata”[MeSH Terms] OR “perissodactyla”[MeSH Terms] OR 
“rodentia”[MeSH Terms] OR “scandentia”[MeSH Terms] OR “sirenia”[MeSH 
Terms] OR “xenarthra”[MeSH Terms] OR “haplorhini”[MeSH Terms:noexp] OR 
“strepsirhini”[MeSH Terms] OR “platyrrhini”[MeSH Terms] OR “tarsii”[MeSH 
Terms] OR “catarrhini”[MeSH Terms:noexp] OR “cercopithecidae”[MeSH 
Terms] OR “hylobatidae”[MeSH Terms] OR “hominidae”[MeSH Terms:noexp] 
OR “gorilla gorilla”[MeSH Terms] OR “pan paniscus”[MeSH Terms] OR 
“pan troglodytes”[MeSH Terms] OR “pongo pygmaeus”[MeSH Terms]) OR 
((animals[tiab] OR animal[tiab] OR mice[Tiab] OR mus[Tiab] OR mouse[Tiab] OR 
murine[Tiab] OR woodmouse[tiab] OR rats[Tiab] OR rat[Tiab] OR murinae[Tiab] 
OR muridae[Tiab] OR cottonrat[tiab] OR cottonrats[tiab] OR hamster[tiab] 
OR hamsters[tiab] OR cricetinae[tiab] OR rodentia[Tiab] OR rodent[Tiab] OR 
rodents[Tiab] OR pigs[Tiab] OR pig[Tiab] OR swine[tiab] OR swines[tiab] OR 
piglets[tiab] OR piglet[tiab] OR boar[tiab] OR boars[tiab] OR “sus scrofa”[tiab] 
OR ferrets[tiab] OR ferret[tiab] OR polecat[tiab] OR polecats[tiab] OR “mustela 
putorius”[tiab] OR “guinea pigs”[Tiab] OR “guinea pig”[Tiab] OR cavia[Tiab] OR 
callithrix[Tiab] OR marmoset[Tiab] OR marmosets[Tiab] OR cebuella[Tiab] OR 
hapale[Tiab] OR octodon[Tiab] OR chinchilla[Tiab] OR chinchillas[Tiab] OR 
gerbillinae[Tiab] OR gerbil[Tiab] OR gerbils[Tiab] OR jird[Tiab] OR jirds[Tiab] 
OR merione[Tiab] OR meriones[Tiab] OR rabbits[Tiab] OR rabbit[Tiab] OR 
hares[Tiab] OR hare[Tiab] OR diptera[Tiab] OR flies[Tiab] OR fly[Tiab] OR 
dipteral[Tiab] OR drosophila[Tiab] OR drosophilidae[Tiab] OR cats[Tiab] OR 
cat[Tiab] OR carus[Tiab] OR felis[Tiab] OR nematoda[Tiab] OR nematode[Tiab] 
OR nematodes[Tiab] OR sipunculida[Tiab] OR dogs[Tiab] OR dog[Tiab] OR 
canine[Tiab] OR canines[Tiab] OR canis[Tiab] OR sheep[Tiab] OR sheeps[Tiab] 
OR mouflon[Tiab] OR mouflons[Tiab] OR ovis[Tiab] OR goats[Tiab] OR goat[Tiab] 
OR capra[Tiab] OR capras[Tiab] OR rupicapra[Tiab] OR rupicapras[Tiab] OR 
chamois[Tiab] OR haplorhini[Tiab] OR monkey[Tiab] OR monkeys[Tiab] OR 
anthropoidea[Tiab] OR anthropoids[Tiab] OR saguinus[Tiab] OR tamarin[Tiab] 
OR tamarins[Tiab] OR leontopithecus[Tiab] OR hominidae[Tiab] OR ape[Tiab] 
OR apes[Tiab] OR “pan paniscus”[Tiab] OR bonobo[Tiab] OR bonobos[Tiab] OR 
“pan troglodytes”[Tiab] OR gibbon[Tiab] OR gibbons[Tiab] OR siamang[Tiab] OR 
siamangs[Tiab] OR nomascus[Tiab] OR symphalangus[Tiab] OR chimpanzee[Tiab] 
OR chimpanzees[Tiab] OR prosimian[Tiab] OR prosimians[Tiab] OR “bush 
baby”[Tiab] OR bush babies[Tiab] OR galagos[Tiab] OR galago[Tiab] OR 
pongidae[Tiab] OR gorilla[Tiab] OR gorillas[Tiab] OR “pongo pygmaeus”[Tiab] 
OR orangutan[Tiab] OR orangutans[Tiab] OR lemur[Tiab] OR lemurs[Tiab] OR 
lemuridae[Tiab] OR horse[Tiab] OR horses[Tiab] OR equus[Tiab] OR cow[Tiab] 
OR calf[Tiab] OR bull[Tiab] OR chicken[Tiab] OR chickens[Tiab] OR gallus[Tiab] 
OR quail[Tiab] OR bird[Tiab] OR birds[Tiab] OR quails[Tiab] OR poultry[Tiab] OR 
poultries[Tiab] OR fowl[Tiab] OR fowls[Tiab] OR reptile[Tiab] OR reptilia[Tiab] OR 
reptiles[Tiab] OR snakes[Tiab] OR snake[Tiab] OR lizard[Tiab] OR lizards[Tiab] 
OR alligator[Tiab] OR alligators[Tiab] OR crocodile[Tiab] OR crocodiles[Tiab] 
OR turtle[Tiab] OR turtles[Tiab] OR amphibian[Tiab] OR amphibians[Tiab] 
OR amphibia[Tiab] OR frog[Tiab] OR frogs[Tiab] OR bombina[Tiab] OR 
salientia[Tiab] OR toad[Tiab] OR toads[Tiab] OR “epidalea calamita”[Tiab] 
OR salamander[Tiab] OR salamanders[Tiab] OR eel[Tiab] OR eels[Tiab] OR 
fish[Tiab] OR fishes[Tiab] OR pisces[Tiab] OR catfish[Tiab] OR catfishes[Tiab] OR 
siluriformes[Tiab] OR arius[Tiab] OR heteropneustes[Tiab] OR sheatfish[Tiab] 
OR perch[Tiab] OR perches[Tiab] OR percidae[Tiab] OR perca[Tiab] OR 
trout[Tiab] OR trouts[Tiab] OR char[Tiab] OR chars[Tiab] OR salvelinus[Tiab] 
OR minnow[Tiab] OR cyprinidae[Tiab] OR carps[Tiab] OR carp[Tiab] OR 
zebrafish[Tiab] OR zebrafishes[Tiab] OR goldfish[Tiab] OR goldfishes[Tiab] OR 
guppy[Tiab] OR guppies[Tiab] OR chub[Tiab] OR chubs[Tiab] OR tinca[Tiab] 
OR barbels[Tiab] OR barbus[Tiab] OR pimephales[Tiab] OR promelas[Tiab] 
OR “poecilia reticulata”[Tiab] OR mullet[Tiab] OR mullets[Tiab] OR eel[Tiab] 
OR eels[Tiab] OR seahorse[Tiab] OR seahorses[Tiab] OR mugil curema[Tiab] 
OR atlantic cod[Tiab] OR shark[Tiab] OR sharks[Tiab] OR catshark[Tiab] OR 
anguilla[Tiab] OR salmonid[Tiab] OR salmonids[Tiab] OR whitefish[Tiab] OR 
whitefishes[Tiab] OR salmon[Tiab] OR salmons[Tiab] OR sole[Tiab] OR solea[Tiab] 
OR lamprey[Tiab] OR lampreys[Tiab] OR pumpkinseed[Tiab] OR sunfish[Tiab] 
OR sunfishes[Tiab] OR tilapia[Tiab] OR tilapias[Tiab] OR turbot[Tiab] OR 
turbots[Tiab] OR flatfish[Tiab] OR flatfishes[Tiab] OR sciuridae[Tiab] OR 
squirrel[Tiab] OR squirrels[Tiab] OR chipmunk[Tiab] OR chipmunks[Tiab] OR 
suslik[Tiab] OR susliks[Tiab] OR vole[Tiab] OR voles[Tiab] OR lemming[Tiab] 
OR lemmings[Tiab] OR muskrat[Tiab] OR muskrats[Tiab] OR lemmus[Tiab] OR 
otter[Tiab] OR otters[Tiab] OR marten[Tiab] OR martens[Tiab] OR martes[Tiab] 
OR weasel[Tiab] OR badger[Tiab] OR badgers[Tiab] OR ermine[Tiab] OR 
mink[Tiab] OR minks[Tiab] OR sable[Tiab] OR sables[Tiab] OR gulo[Tiab] OR 
gulos[Tiab] OR wolverine[Tiab] OR wolverines[Tiab] OR mustela[Tiab] OR 
llama[Tiab] OR llamas[Tiab] OR alpaca[Tiab] OR alpacas[Tiab] OR camelid[Tiab] 
OR camelids[Tiab] OR guanaco[Tiab] OR guanacos[Tiab] OR chiroptera[Tiab] 
OR chiropteras[Tiab] OR bat[Tiab] OR bats[Tiab] OR fox[Tiab] OR foxes[Tiab] 
OR iguana[Tiab] OR iguanas[Tiab] OR xenopus laevis[Tiab] OR parakeet[Tiab] 
OR parakeets[Tiab] OR parrot[Tiab] OR parrots[Tiab] OR donkey[Tiab] OR 
donkeys[Tiab] OR mule[Tiab] OR mules[Tiab] OR zebra[Tiab] OR zebras[Tiab] OR 
shrew[Tiab] OR shrews[Tiab] OR bison[Tiab] OR bisons[Tiab] OR buffalo[Tiab] 
OR buffaloes[Tiab] OR deer[Tiab] OR deers[Tiab] OR bear[Tiab] OR bears[Tiab] 
OR panda[Tiab] OR pandas[Tiab] OR “wild hog”[Tiab] OR “wild boar”[Tiab] OR 
fitchew[Tiab] OR fitch[Tiab] OR beaver[Tiab] OR beavers[Tiab] OR jerboa[Tiab] 
OR jerboas[Tiab] OR capybara[Tiab] OR capybaras[Tiab]) NOT medline[sb])
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Search component 3B: clinical studies
(((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH 
Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR 
random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading])) 
OR ((Human[tiab] OR humans[tiab] OR patient[tiab] OR patients[tiab]) AND 
(study[tiab] OR studies[tiab] OR research[tiab] OR investigat*[tiab] OR clinic*[tiab] 
OR therapy[tiab] OR treatment[tiab] OR surgery[tiab] OR surgical[tiab]))
Appendix 2
Search strategy to retrieve all relevant literature using Embase. Individual search 
components for tissue engineering, urethra, pre-clinical- and clinical studies 
were designed using relevant EMTree-terms and relevant synonyms and related 
terms. Search components 1, 2 and 3A were combined to retrieve all relevant pre-
clinical studies, while search components 1,2 and 3B were combined to retrieve all 
clinical studies.
Search component 1: Tissue Engineering
Exp tissue engineering/ OR Exp tissue culture/ OR Exp organ culture/ OR Exp 
tissue regeneration/ OR Exp regenerative medicine/ OR Exp artificial organ/ OR 
Exp tissue scaffold/ OR Exp biomaterial/ OR Exp bioreactor/ OR (regenerative 
AND (medicine OR medicines)).ti,ab. OR ((decellularized OR acellular OR cell-
free bioartificial OR bio-artificial OR artificial OR tissue OR tissues OR organ 
OR organs OR culture OR cultures) AND (autograft OR autografts OR graft OR 
grafts OR matrix OR matrices OR biomatrix OR biomatrices OR biomaterial OR 
biomaterials OR scaffold OR scaffolds OR scaffolding OR engineering OR engineer 
OR culture OR cultures OR regeneration OR regenerated OR regenerating 
OR reconstruction OR reconstructed OR reconstructing)).ti,ab. OR (tissue-
engineered OR tissue engineering OR bio-engineering OR bioengineering OR 
bioengineered OR bio-engineered OR organoids OR organoid OR bioartificial 
OR bio-artificial OR artificial OR scaffold OR scaffolds OR scaffolding OR matrix 
OR matrices OR biomatrix OR biomatrices OR biomaterial OR biomaterials OR 
bioreactor OR bioreactors).ti,ab.
Search component 2: Urethra
Exp urethra/ OR Exp urethra disease/ OR Exp urethra surgery/ OR urethra.ti,ab. 
OR urethral.ti,ab. OR urethras.ti,ab. OR urethrotomy.ti,ab. OR urethrotomies.
ti,ab. OR ureterotomy.ti,ab. OR ureterotomies.ti,ab. OR urethrotomia.ti,ab. OR 
urethroplasty.ti,ab. OR urethroplasties.ti,ab. OR ((stricture OR strictures) AND 
(urology OR urinary OR urine OR urological)).ti,ab. OR hypospadias.ti,ab. OR 
epispadias.ti,ab. OR urethritis.ti,ab. OR (meatus AND (urology OR urinary OR 
urine OR urological)).ti,ab. OR chordee.ti,ab. OR (perineal AND (urology OR 
urinary OR urine OR urological)).ti,ab.
Search component 3A: preclinical studies 
exp animal experiment/ or exp animal model/ or exp experimental animal/ 
or exp transgenic animal/ or exp male animal/ or exp female animal/ or exp 
juvenile animal/ OR animal/ OR chordata/ OR vertebrate/ OR tetrapod/ OR 
exp fish/ OR amniote/ OR exp amphibia/ OR mammal/ OR exp reptile/ OR exp 
sauropsid/ OR therian/OR exp monotremate/ OR placental mammals/ OR exp 
marsupial/ OR Euarchontoglires/ OR exp Afrotheria/ OR exp Boreoeutheria/ 
OR exp Laurasiatheria/ OR exp Xenarthra/ OR primate/ OR exp Dermoptera/ 
OR exp Glires/ OR exp Scandentia/ OR Haplorhini/ OR exp prosimian/ OR 
simian/ OR exp tarsiiform/ OR Catarrhini/ OR exp Platyrrhini/ OR ape/ OR exp 
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Cercopithecidae/ OR hominid/ OR exp hylobatidae/ OR exp chimpanzee/ OR exp 
gorilla/ OR exp orang utan/ OR (animal OR animals OR pisces OR fish OR fishes 
OR catfish OR catfishes OR sheatfish OR silurus OR arius OR heteropneustes OR 
clarias OR gariepinus OR fathead minnow OR fathead minnows OR pimephales 
OR promelas OR cichlidae OR trout OR trouts OR char OR chars OR salvelinus 
OR salmo OR oncorhynchus OR guppy OR guppies OR millionfish OR poecilia 
OR goldfish OR goldfishes OR carassius OR auratus OR mullet OR mullets OR 
mugil OR curema OR shark OR sharks OR cod OR cods OR gadus OR morhua OR 
carp OR carps OR cyprinus OR carpio OR killifish OR eel OR eels OR anguilla 
OR zander OR sander OR lucioperca OR stizostedion OR turbot OR turbots 
OR psetta OR flatfish OR flatfishes OR plaice OR pleuronectes OR platessa OR 
tilapia OR tilapias OR oreochromis OR sarotherodon OR common sole OR dover 
sole OR solea OR zebrafish OR zebrafishes OR danio OR rerio OR seabass OR 
dicentrarchus OR labrax OR morone OR lamprey OR lampreys OR petromyzon 
OR pumpkinseed OR pumpkinseeds OR lepomis OR gibbosus OR herring OR 
clupea OR harengus OR amphibia OR amphibian OR amphibians OR anura OR 
salientia OR frog OR frogs OR rana OR toad OR toads OR bufo OR xenopus OR 
laevis OR bombina OR epidalea OR calamita OR salamander OR salamanders OR 
newt OR newts OR triturus OR reptilia OR reptile OR reptiles OR bearded dragon 
OR pogona OR vitticeps OR iguana OR iguanas OR lizard OR lizards OR anguis 
fragilis OR turtle OR turtles OR snakes OR snake OR aves OR bird OR birds OR 
quail OR quails OR coturnix OR bobwhite OR colinus OR virginianus OR poultry 
OR poultries OR fowl OR fowls OR chicken OR chickens OR gallus OR zebra 
finch OR taeniopygia OR guttata OR canary OR canaries OR serinus OR canaria 
OR parakeet OR parakeets OR grasskeet OR parrot OR parrots OR psittacine OR 
psittacines OR shelduck OR tadorna OR goose OR geese OR branta OR leucopsis 
OR woodlark OR lullula OR flycatcher OR ficedula OR hypoleuca OR dove OR 
doves OR geopelia OR cuneata OR duck OR ducks OR greylag OR graylag OR 
anser OR harrier OR circus pygargus OR red knot OR great knot OR calidris 
OR canutus OR godwit OR limosa OR lapponica OR meleagris OR gallopavo 
OR jackdaw OR corvus OR monedula OR ruff OR philomachus OR pugnax OR 
lapwing OR peewit OR plover OR vanellus OR swan OR cygnus OR columbianus 
OR bewickii OR gull OR chroicocephalus OR ridibundus OR albifrons OR great 
tit OR parus OR aythya OR fuligula OR streptopelia OR risoria OR spoonbill 
OR platalea OR leucorodia OR blackbird OR turdus OR merula OR blue tit OR 
cyanistes OR pigeon OR pigeons OR columba OR pintail OR anas OR starling 
OR sturnus OR owl OR athene noctua OR pochard OR ferina OR cockatiel OR 
nymphicus OR hollandicus OR skylark OR alauda OR tern OR sterna OR teal 
OR crecca OR oystercatcher OR haematopus OR ostralegus OR shrew OR shrews 
OR sorex OR araneus OR crocidura OR russula OR european mole OR talpa OR 
chiroptera OR bat OR bats OR eptesicus OR serotinus OR myotis OR dasycneme 
OR daubentonii OR pipistrelle OR pipistrellus OR cat OR cats OR felis OR catus 
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Appendix 5
Quality assessment score per study for (A) pre-clinical studies and (B) clinical 
studies. Quality was scored based on 19 questions for pre-clinical studies and 17 
questions for clinical studies (see Fig. 2). Detailed scores per study are available 
upon request.
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Appendix 6
Numerical data on which Figure 3 is based. Estimated probability including 
95% confidence intervals for the absence of side effects, functionality and study 
completion for A) full circumferential repair and B) inlay repair in pre-clinical 
studies, both categorized for the use of cells and the type of biomaterial. C) For 
the clinical studies, only decellularized material with or without cells could be 
analyzed. The effect of cells on the three outcome measures was calculated in 
estimated probabilities. Overall differences for cellular vs. acellular templates 
were determined for each outcome measure for both full and inlay repair: 
* p=0.003, ** p=0.001, all other differences were not significant (p>0.05).
A. Pre-clinical studies – Full circumferential repair
Point estimate and 95% CI [lower:upper]
Biomaterial type No side-effects Functionality Study completion
A
ce
llu
la
r Decellularized 0.04 [0.001:0.46] 0.76 [0.09:0.99] 1.0 [0.63:1.0]
Natural 0.24 [0.07:0.57] 0.87 [0.04:1.0] 0.95 [0.26:1.0]
Synthetic 0.80 [0.56:0.93] 0.96 [0.25:1.0] 0.98 [0.49:1.0]
Overall 0.36 [0.26:0.48] 0.81 [0.14:0.99] 0.98 [0.66:1:0]
C
el
lu
la
r Decellularized 0.99 [0.68:1.0] 0.77 [0.01:0.99] 1.0 [0.58:1.0]
Natural 0.73 [0.19:0.97] 1.0 [0.59:1.0] 1.0 [0.52:1.0]
Synthetic 1.0 [0.00:1.0] unable to estimate 1.0 [0.03:1.0]
Overall 0.91 [0.59:0.99] 0.87 [0.07:1.0] 1:0 [0.88:1.0]
B. Pre-clinical studies – Inlay repair
Point estimate and 95% CI [lower:upper]
Biomaterial type No side-effects Functionality Study completion
A
ce
llu
la
r Decellularized 0.49 [0.26:0.73] 0.98 [0.88:1.0] unable to estimate
Natural 0.74 [0.04:1.0] 1.0 [0.36:1.0] unable to estimate
Synthetic 0.26 [0.22:0.29] 0.73 [0.26:0.95] unable to estimate
Overall 0.50 [0.20:0.80] 0.90 [0.66:0.98] 1.0 [0.92:1.0]
C
el
lu
la
r
Decellularized 0.85 [0.03:1.0] 1.0 [0.34:1.0] unable to estimate
Natural 1.0 [1.0:1.0] 1.0 [0.42:1.0] unable to estimate
Synthetic 0.40 [0.29:0.52] 0.86 [0.31:0.99] unable to estimate
Overall 0.75 [0.44:0.92] 0.95 [0.66:0.99] 1:0 [0.75:1.0]
C. Clinical studies – Inlay repair
Point estimate and 95% CI [lower:upper]
Biomaterial type No side-effects Functionality Study completion
D
e-
ce
l. Acellular 0.70 [0.49:0.85] 0.84 [0.64:0.94] 0.55 [0.18:0.87]
Cellular 1.0 [0.20:1.0] 0.94 [0.43:1.0] 0.04 [0.002:0.43]
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Abstract
Purpose: Pre-conditioning of a cell seeded construct may improve the 
functional outcome of a tissue engineered construct for augmentation 
cystoplasty. The precise effects of mechanical stimulation on urinary bladder 
cells in vitro is not clear. In this study we investigate the effect of a cyclic 
uniaxial strain culture on urinary bladder cells which were seeded on a type 
I collagen scaffold.
Methods: Isolated porcine smooth muscle cells or urothelial cells were 
seeded on a type I collagen scaffolds and cultured under static and dynamic 
conditions. A uniform cyclic uniaxial strain was applied to the seeded 
scaffold using a Bose Electroforce Bio-Dynamic bioreactor. Cell proliferation 
rate and phenotype were investigated, including SEM analysis, RT-PCR and 
immunohistochemistry for α-Smooth muscle actin, Calponin-1, desmin and 
RCK103 expression to determine the effects of mechanical stimulation on 
both cell types.
Results: Dynamic stimulation of smooth muscle cell seeded constructs 
resulted in cell alignment and enhanced proliferation rate. Additionally, 
expression of α-Smooth muscle actin and calponin-1 was increased suggesting 
differentiation of smooth muscle cells to a more mature phenotype. 
Conclusions: Mechanical stimuli did not enhance the proliferation and 
differentiation of urothelial cells. Mechanical stimulation i.e., preconditioning 
may improve the functional in vivo outcome of smooth muscle cell seeded 
constructs for flexible organs such as the bladder.
Introduction
For patients who need bladder reconstruction, a tissue engineered bladder may 
be an alternative to current procedures in which autologous bowel tissue is used. 
The first clinical studies with cell seeded bladder-sized constructs illustrated 
that scaffolds implanted in patients who had a normal bladder cycle regenerated 
properly, while patients with abnormal cycles responded poorly [1]. Bladder 
regeneration studies in animals indicated slow smooth muscle cell ingrowth in 
scaffolds, probably due to the limited migration from adjacent tissue [2]. This 
suggests that adequate conditioning of the tissue engineered construct may be 
needed to improve the functional outcome of the regenerated tissue for flexible 
organs.
It has become clear that mechanical stimulation is equally important 
in cellular behavior as genetic and chemical signals [3]. By providing 
mechanotransduction, cell proliferation and differentiation can be influenced 
and it may lead to extracellular matrix (ECM) production [4-6]. Therefore, it is 
important to investigate the behavior and phenotype of cells in constructs while 
under defined mechanical strain before implantation.
A bioreactor can apply mechanical stimuli under controlled in vitro conditions 
[7, 8]. Initially vacuum suction (Seliktar et al., 2000) and mechanical stretch was 
used [5]. Thereafter different bioreactor systems using hydrostatic pressures 
have been developed and used to study urinary bladder tissue engineering [9]. 
Hydrostatic pressure on human bladder smooth muscle cells on aligned nano 
fibrous scaffolds resulted in functional improvement of the engineered tissue 
[10]. Although this setting simulated in vivo conditions, the exact impact of 
the mechanical stimulation on the urinary bladder cells is not clear. Moreover, 
whether mechanical stimulation of cells seeded on other materials such as 
collagen also leads to functional improvement is currently unclear. In this study 
we investigated the effect of a long-term controlled cyclic uniaxial strain on 
urinary bladder cells which were seeded on a type I collagen scaffold mimicking 
the filling and emptying of the bladder to assess whether this pre-conditioning 
step is beneficial in urinary bladder tissue engineering.
Material and Methods
Products were purchased from Life technologies (Carlsbad; US) unless otherwise 
indicated.
Scaffolds preparation and characterization
For the construction of collagen scaffolds, insoluble type I collagen fibrils were 
purified from pulverized bovine Achilles tendon, as previously described [11]. 
In short, a 0.5% (w/v) type I collagen suspension was made by swelling and 
subsequent homogenization in 0.25 M acetic acid at 4°C. The collagen suspension 
was deaerated, poured into six-well plates, frozen at -20 °C and lyophilized. The 
dried collagen matrices were stabilized using 1-ethyl-3-(3-dimethyl aminopropyl) 
carbodiimide (Fluka, Sigma-Aldrich; St Louis, US) and N-hydroxysuccinimide 
(Fluka, Sigma-Aldrich; St Louis, US) crosslinking in 50 mM 2-morpholinoethane 
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sulphonic acid (MES, pH5,0) containing 40% (v/v) ethanol for 4 h at 21°C. After 
cross-linking, the scaffolds were washed consecutively in 0.1M Na2HPO4, 1M 
NaCl, 2M NaCl, demineralized water, disinfected by 70% ethanol washings and 
stored at -20°C. The degree of crosslinking of the scaffolds was determined by 
2,4,6-trinitrobenzene sulfonic acid (TNBS) analysis in triplicate [12]. Collagen 
strips were cut to match the bioreactor dimensions (length 2.5 cm, width 1 cm), 
and washed in 70% ethanol (at least 2 times 1 h and 1 time overnight (o/n)), 
followed by washings in sterile phosphate-buffered saline (PBS; pH 7.4, at least 2 
times 1 h and 1 time o/n), and an o/n incubation in medium.
Cell isolation
Porcine bladders were collected from a local abattoir. After opening the bladder, 
~1 cm2 pieces were collected under aseptic conditions and tissue specimens 
were transferred to transport medium (HBSS+Mg+Ca, 10 mM HEPES; pH 7.6, 
aprotinin 1 μg/ml (Roche; Basel, Switzerland), 100 U/ml penicillin and 100 μg/
ml streptomycin (P/S). Tissue specimens were incubated 16 h at 4°C in stripper 
medium (HBSS-Mg-Ca, 10 mM HEPES; pH 7.6, aprotinin 1 ug/ml (Roche; Basel, 
Switzerland), P/S and 2.4 U/ml dispase II (Sigma-Aldrich; St Louis, US). Urothelial 
cells (UC) were isolated by scraping the urothelial sheet using tweezers. Urothelial 
sheets were collected in a 15 ml tube and incubated for 20 min at 37°C with 100 
U/ml collagenase type IV (Sigma-Aldrich; St Louis, US) prepared in transport 
medium. Cells were collected by centrifugation at 400g for 8min. and seeded 
in Primaria flasks (BD Falcon®, US; 1 T75 per cm2 tissue specimen). Cells were 
cultured in keratinocyte serum-free medium (KSFM) supplemented with 50 μg/
ml bovine pituitary extract, 5 ng/ml epidermal growth factor, 30 ng/ml cholera 
toxin (Sigma-Aldrich; St Louis, US) and P/S (UC medium).
For the isolation of SMC, the remaining tissue was cut into small pieces (~2 
mm2) and incubated for 1.5 h at 37°C with 1.5 U/ml liberase enzyme (Roche; Basel, 
Switzerland) diluted in HBSS+Ca+Mg and P/S. After vigorous resuspension, the 
material was pushed through a 70 μm cell strainer (BD Falcon®, US) to remove 
undigested particles. Cells were collected by centrifugation and cultured in 
smooth muscle cell medium (SMCM, Sciencell; Carlsbad, US), supplemented 
with 2% (v/v) fetal bovine serum, 1% (v/v) smooth muscle growth supplement 
and P/S (2 T75 per cm2 tissue specimen). Cultures were maintained at 37°C in a 
humidified atmosphere of 5% (v/v) CO2 in air. Medium was changed three times a 
week and cells were split when 100% confluence was reached. Cells harvested from 
one porcine bladder were used to prevent the influence of individual differences 
between animals.
Cells from passage 1 to 3 were used. 
Bioreactor culture
Collagen scaffold strips were placed in a 6 well plate and seeded statically with 
1 to 1.5 x106 SMC or UC in a volume of 100 μl of SMC medium or UC medium. 
After 1 hour the volume was increased to 2.5 ml SMCM medium or UC medium. 
One day after seeding, scaffolds were placed in a Bose Electroforce Bio-Dynamic 
bioreactor (Fig. 1a). Subsequently the bioreactor chamber was filled with 200 ml 
RPMI supplemented with 10% FCS, 2mM glutamine, 100 U/ml penicillin and 100 
ug/ml streptomycin and cultured under dynamic conditions. A cyclic uniaxial 
strain was applied with a continuous 0.3 µm/sec cycle strain (20% full stretch 
followed by folding in 4 h) (Fig. 1b). Control scaffolds were cultured under static 
conditions in a T75 flask. After 6 days of culture, scaffolds were harvested and 
processed for evaluation.
Figure 1. Overview of the experimental setting with a strip of scaffold clamped in the Bose Electroforce 
Bio-Dynamic bioreactor (arrow) (a). Overview bioreactor program with a continuous 0.3 µm/sec cycle 
strain (20% full stretch and fold within 4 h) (b). Scanning electron microscopic pictures of the used 
type I collagen scaffold (250x); c and d represents the air and pan side, respectively, showing a typical 
honeycomb structure.
Scanning electron microscopy
Scanning electron microscopy (SEM) was performed on isolated cells (in triplicate) 
and cells cultured on scaffolds (once for every static/dynamic sample). Materials 
were washed three times for 1 h with PBS and fixed for at least 1 h in 2% (v/v) 
glutaraldehyde (Merck, Kenilworth, New Jersey, US) in 0.1 M phosphate buffer 
(PB), pH 7.4 at 21°C. Scaffolds were washed three times (1 h) using 0.1 M PB. For 
dehydration scaffolds were washed for at least 1 h in increasing concentrations 
of ethanol (30%, 50%, 70%, 100% (v/v)) and one additional o/n washing step in 
100% ethanol. Scaffolds were critical point dried (CPD) using liquid CO2. After 
drying, gold sputtering was performed prior to SEM analysis (JEOL JSM-6310; 
Tokyo, Japan).
Reverse transcriptase polymerase chain reaction (RT-PCR)
Biopsies from scaffolds (one for every static/dynamic sample) with cultured cells 
were minced, immersed in 0.5 ml Trizol and stored (-80°C). RNA was isolated by 
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chloroform and isopropanol precipitation and treated with DNase I. RT-reaction 
was performed in Perkin Elmer thermal cycler using Super Script II Reverse 
Transcriptase according to the manufacturer’s description (Life Technologies; 
Carlsbad, US). In brief, cDNAs were amplified by semi-quantitative real-time 
PCR using SYBR-Green PCR Master Mix (Roche; Basel, Switzerland) using a Light 
Cycler®480 Real Time PCR System. Finally, gene expression levels of alpha smooth 
muscle actin (ACTA2), calponin (CNN1), desmin (Desm) and type III collagen 
(Col3A1) were examined and HPRT (housekeeping gene) was used as a control 
(see Table 1 for primer sequences).
Immunohistochemistry
For histological evaluation, the scaffolds were embedded in Tissue-Tek (O.C.T. 
Compound) and snap frozen in dry-ice cooled isopentane. Cryostat sections (5 
μm) were cut and fixed for 10 min in 100% acetone (-20°C) followed by a blocking 
step of 30 min with 10% (v/v) goat serum in 1% (w/v) bovine serum albumin/
phosphate buffered saline (BSA/PBS). Sections were incubated with one of the 
following mouse anti-human antibodies: alpha smooth muscle actin (α-SMA, 
Sigma-Aldrich; St. Louis, US; 1:8 000), desmin (BioGenex; Fremont, US; 1:200), 
calponin-1 (CNN1, Abcam; Cambridge, UK; 1:100), RCK103 (Cytokeratin 5 and 
others, Nordic MUbio; Susteren, The Netherlands; 1:1) and rabbit anti-bovine type 
I collagen (EMD Millipore, Germany; 1:100), all diluted in 1% (w/v) BSA/PBS, for 
1 h. After washing (PBS, 3 times), sections were incubated with goat-anti-mouse-
Alexa 594 (1:200) and goat-anti-rabbit-Alexa 488 (1:200) for 1 h. After rinsing with 
PBS (3 times), slides were incubated with 4’,6-diamidino-2-phenylindole (DAPI; 
1:200) for 20 min and 21°C. Finally, slides were mounted with fluorescent mounting 
medium (Dako; Glostrup, Denmark) and evaluated. Porcine bladder tissue was 
used as control tissue. Primary antibody was omitted as negative control. All anti-
human primary antibodies had porcine cross-reactivity or were tested for cross-
reactivity on porcine bladder tissue.
WST-1 proliferation assay
After culture, a transverse part of every scaffold (10x3 mm) was incubated in 500 
μl medium with 50 μl cell proliferation reagent WST-1 (Roche; Basel Switzerland). 
After 2 h the absorbance at 450 nm was determined.
Results
Characterization scaffold
Scanning electron microscopy (SEM) analysis of the type I collagen scaffold 
showed a highly porous and interconnective network with pores ranging between 
50 - 100 μm for both the air and pan side (Fig. 1c and d). The degree of crosslinking 
of the scaffolds was 72 ±12% by TNBS analyses.
Characterization of bladder-derived smooth muscle and urothelial cells
Primary urothelial cell cultures formed cobblestoned epithelioid monolayers. 
Phenotypic analysis revealed a homogeneous RCK103-positive cell population 
(Cytokeratin 5 and others) (Online Resource 1a and b). Isolated SMC showed 
a typical spindle cell shape and expressed α-SMA (Online Resource 1c and d), 
smoothelin, and desmin over a number of passages. UC contamination in the 
SMC culture was negligible as judged by RCK103 staining. There were no SMC 
present in the used UC culture.
Evaluation of bioreactor cultured scaffolds 
Microscopic evaluation (H&E staining) of the constructs revealed a much 
denser SMC layer on the scaffold surface when uniaxial strain was applied (Fig. 
2a and b) compared to static culture conditions. Phenotypic analysis showed 
α-SMA expression, regardless of culture conditions. However, relatively more 
α-SMA positive cells were present in the SMC seeded scaffold cultured under 
dynamic conditions compared to static culture conditions (Fig. 2c and d). 
The immunohistochemical analyses demonstrated more intense desmin and 
calponin1 staining in the dynamic cultured SMC (Fig. 2e, f, g and h). Although 
a limited number of data is available, the RT-PCR data showed similar results, 
with a trend of higher expression of ACTA2, CNN1 and desmin levels in dynamic 
cultures (Fig.3). WST-1 cell proliferation assays of the SMC seeded scaffolds 
cultured under dynamic conditions showed increased cell proliferation compared 
to static cultures (Fig. 4) SEM analysis revealed SMC alignment when the seeded 
construct was exposed to mechanical stimulation (Fig. 5a and b).
UC lined the honeycomb and lamellae structures of the scaffold more 
prominent when cultured under static conditions compared to the UC cultured 
under dynamic stress (Fig. 6). Phenotypic analysis revealed strong expression of 
RCK103 regardless of the culture conditions (Fig. 6c and d). As expected, urothelial 
cells did not express any of the determined markers (data not shown). WST-1 
showed no differences in UC proliferation between static and dynamic culture. 
Finally, SEM analysis showed more ruptures in the confluent UC layer which was 
exposed to uniaxial strain, compared to the static cultures (Fig. 5c and d).
Discussion
One of the biggest challenges in tissue engineering is to create (preconditioned) 
templates that adequately mimic the native tissue at the phenotypic and 
organizational level. For bladder tissue engineering, cell seeded bladder dome-
shaped scaffolds have been used in patients with variable results [13]. Until now, 
no method has proven to generate superior functional scaffolds for bladder 
tissues. Mechanical stimulation during scaffold preparation may improve the 
functional outcome. It has been used to condition engineered tissue based on 
the assumption that mimicking the physiological conditions of the native tissue 
improves its function once implanted to correct or replace lost tissue. In this study 
we show that mechanical stimulation of a porcine cell seeded collagen scaffold 
using cyclic uniaxial strain, mimicking the filling and emptying of the bladder
 5
Chapter 5 The effect of a cyclic uniaxial strain on urinary bladder cells
102 103
 
Figure 2. Representative Hematoxylin & Eosin (H&E) staining and immunofluorescence staining of 
the smooth muscle cell (SMC) seeded constructs cultured under static (a, c, e, and g) and dynamic (b, 
d, f, and h) conditions. a and b H&E staining, c and d α-SMA, E and F Calponin1 and g and h Desmin 
staining. Green: collagen, blue: nuclear DAPI stain, red: cell surface marker.
Figure 3. Quantitative RT-PCR data for α-SMA (ACTA2), calponin1 (CNN1), desmin (Desm) and 
collagen (Col3A1) of smooth muscle cell (SMC) seeded scaffold which were cultured under static and 
dynamic conditions. The relative expression of the different scaffolds was corrected for the internal 
HPRT control and the static conditions were set to 1. Bars represent the mean ± SD for 3 (SMC) 
separate experiments. None of the tested markers was expressed by the UC.
Figure 4. Proliferation (WST-1 cell proliferation assay) of urothelial cell (UC) and smooth muscle 
cell (SMC) seeded scaffold which were cultured under static and dynamic conditions. The relative 
expression of the static conditions were set to 1. Bars represent the mean ± SD for 2 (UC) or 3 (SMC) 
separate experiments.
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Figure 5. Representative scanning electron microscopy (SEM) analysis of the smooth muscle cell 
(SMC) and urothelial cell (UC) seeded constructs.  a and b SEM of SMC cultured under static (a) and 
dynamic (b) conditions. c and d SEM of UC cultured under static (c) and mechanical condition (d). 
Please note aligned SMC in (b). Red arrows point to small ruptures (d)
Figure 6. Representative Hematoxylin & Eosin (H&E) staining and immunofluorescence staining 
of the urothelial cell (UC) seeded constructs cultured under static (a and c) and dynamic (b and d) 
conditions. a and b H&E staining and c and d cytokeratin staining. Green: collagen, blue: nuclear 
stain (DAPI), red: cytokeratin.
results in increased smooth muscle cell growth, improved cell distribution, and 
more importantly SMC alignment, mimicking SMC organization in muscle fibers. 
Southgate et al. [14] showed that pig and human bladders have anatomical and 
biological similarities, making porcine derived bladder cells an adequate model 
for developing tissue engineering strategies. 
Collagen-based scaffolds have been used extensively for bladder tissue 
engineering in (pre)clinical studies: immune responses are lacking and this 
natural biomaterial is highly cyto- and biocompatible. Nevertheless, despite these 
favorable characteristics implementation of collagen-based scaffolds is hampered 
by the poor and slow ingrowth of SMC after implantation [15, 16]. Whereas collagen 
scaffolds are replaced by newly formed tissue in 3-4 weeks, SMC ingrowth is 
limited to the rim of the defect. Enhanced interconnectivity of collagen scaffolds 
by decreasing the collagen density can lead to an improved SMC distribution [17]. 
Here we show that another possibility to improve SMC distribution is scaffold 
conditioning through pre-seeding and dynamic culturing of the construct. The 
current stimulation protocol was based on a pilot experiment where we compared 
slow, fast and “bladder like” stimulation protocols. The cellular distribution 
and cell density were superior. Most likely, the rapid stretch and or release 
induced too rapid material deformations, leading to cell detachment. Since we 
are using this technique to prepare in vitro conditioned scaffolds to function in 
the bladder, it may be that a “bladder like” protocol would be more effective. A 
possible refinement to prevent cell loss could involve a distinct filling (stretch) 
and extended emptying (release) phase.
Conditioning of the seeded construct by uniaxial stimulation resulted in 
SMC alignment. Moreover, SMC growing under mechanical stimulation showed 
higher α-SMA, desmin and calponin1 expression compared to static cultures 
as judged by PCR. Moreover, α-SMA, desmin and calponin1 levels were higher 
by immunohistochemistry. This is in agreement with Ahvaz et al. [18] who also 
observed increased α-SMA and calponin1 expression in SMC which were subjected 
to continuous stretch-relaxation cycles. Remarkably, the same investigators 
reported decreased α-SMA and calponin1 expression using a different (synthetic) 
substrate [10]. In experiments lasting 6 hours, calponin1 and α-SMA were down 
regulated during smooth muscle cell stimulation [19]. These discrepancies 
may be related to differences in cell source, passage number, medium type, 
mechanotransduction frequencies or physical and chemical properties of the 
scaffolds.
It has been hypothesized that mechanical stimuli also trigger surface stretch 
receptors and adhesion sites of cells, resulting in the activation of genes which are 
responsible for the synthesis and secretion of extracellular matrix components, 
such as collagens [20]. Since we used bovine derived collagen as a template for our 
cells, we were unable to investigate the production of type I collagen. When we 
analyzed type III collagen production, we did not observe any influence of culture 
conditions on type III collagen expression. This contrasts with the observation 
that in static cultures and non-compliant bladders the type III collagen production 
is decreased [21, 22]. It is possible that longer culture times are required to observe 
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increased collagen production. Other investigators have demonstrated that after 
longer culture periods (up to 14 days) type I and III collagen production levels 
increased in dynamic cultures [23].
The urothelium has an important osmotic barrier function: it protects the 
submucosa from environmental harm, mainly the toxic components of the urine. 
In our studies minor morphological and proliferation differences were observed 
between static and dynamic cultures, albeit that small cracks were present in 
the dynamic cultured urothelium. The small distortions that we observed in the 
UC layer are most likely due to the strain exerted on the collagen. Apparently 
SMC can accommodate this strain better than the UC. The absence of an adjacent 
lamina propria and/or fibroblasts in our in vitro model may indeed explain our 
observations. In the urinary bladder the UC are anchored on this superficial 
layer which contains both type IV collagen and elastin. Construction of collagen 
scaffolds in which UC and SMC are intimately connected will require a longer 
culture period. Alternatively, myofibroblasts could be used or dynamic culturing 
of SMC followed by a static culture of UC. 
Augmentation cystoplasty with gastrointestinal tissue is a relatively safe 
and effective way to restore bladder capacity. However, this treatment can be 
associated with several complications including infections, stone formation, 
metabolic abnormalities and carcinogenesis. Tissue engineering may provide an 
alternative approach, but current methods have shown substantial side effects 
and suboptimal results. This may be related to the lack of mechanical stimulation 
during preparation, which can lead to fibrosis and poor compliance [13, 24]. The 
bladder is continuously filled and emptied, resulting in continuous loading of the 
tissue. By mimicking these dynamics during preparation of tissue engineered 
constructs a better outcome may be achieved. In addition, scaffold survival is 
heavily dependent on the formation of a new vascular bed. This is especially 
important when considering that large constructs are needed for relevant 
augmentation. To solve this, multiple smaller scaffolds instead of one large 
scaffold may be used (Roelofs et al., submitted). Thus, implantation of multiple 
conditioned scaffolds may be an attractive alternative for bladder augmentation 
using gastro-intestinal tissue; an assumption that needs to be tested in patients.
A potential drawback of the current study is that we only examined the effects 
of linear stretching on the cells while bladder filling causes a multi-directional 
strain. Whether multidirectional conditioning leads to a different outcome is 
unclear and bioreactor experiments along these lines may be of use. Moreover, 
a more physiological filling and contraction profile may be needed to create 
an optimally conditioned template. Finally, healthy bladder cells may not be 
available, and a different cell source may be required. Recently, stem cells derived 
from urine or adipose tissue have been successfully differentiated to functional 
smooth muscle cells for bladder tissue engineering applications. In addition, 
these stem cells can be harvested from the patient relatively easy, providing an 
autologous cell source [25, 26].
In summary, our results show that conditioning of collagen-based scaffolds by 
mechanical stimulation leads to more SMC with a more differentiated phenotype 
which may bypass difficulties related to poor SMC in-growth and muscle 
development in tissue engineered bladders. This brings us closer to our goal to 
engineer flexible tissues such as urinary bladder as an alternative to current graft 
tissues.
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Appendix 1
Online Resource 1. Representative immunofluorescence staining and Scanning Electron Microscopy 
(SEM) of isolated porcine urothelial cells (UC) and bladder smooth muscle cells (SMC). UC stained 
with RCK103 (a), and αSMA expressing SMC (c) demonstrating homogenous cell populations. 
Scanning electron microscopic pictures of the used UC (b) and SMC (d) (250x)
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Abstract
Introduction: Tissue engineering may become an alternative to current 
bladder augmentation techniques. Large scaffolds are needed for clinically 
significant augmentation, but can result in fibrosis and graft shrinkage.
The purpose of this study was to investigate the use of multiple scaffolds 
instead of one large scaffold, to enhance bladder tissue regeneration and 
bladder capacity. Secondly, acellular collagen, collagen-heparin, and collagen-
heparin scaffolds with growth factors were used and the biological activity of 
the different scaffolds was compared in a large animal model.
Materials and methods: Scaffolds were made of bovine type I collagen with 
or without heparin (Ø = 3.2 cm). Collagen-heparin scaffolds were loaded with 
growth factors VEGF, FGF2 and HB-EGF. Three identical scaffolds prepared 
from collagen (COL-group), collagen with heparin (COLHEP-group), or 
collagen-heparin with growth factors (COLHEPGF-group) were implanted 
in one porcine bladder. The outcome was compared with sham operated 
animals (Sham-group), in which no scaffold was used. Urodynamic evaluation 
was performed prior to surgery and 3 months after bladder reconstruction, 
together with histological evaluation. 
Results: Survival rate was 92%, 12 animals completed the study, 3 of every 
group, 1 animal developed peritonitis due to urine leakage and was sacrificed. 
The regenerated area was largest in the COLHEP-group, and least in the COL-
group (p=0.002). Histological evaluation revealed a normal urothelial layer 
and good angiogenesis in all groups, and comparable ingrowth of smooth 
muscle cells. 
Urodynamics showed no statistically significant differences in bladder 
capacity and compliance between groups. Bladder capacity and compliance 
was very high in this animal model, which made it impossible to study the 
increase due to augmentation. 
Conclusions: Implantation of multiple collagen-heparin scaffolds in 
one bladder is feasible in a porcine model, resulting in tissue almost 
indistinguishable from native tissue involving all cell layers of the bladder. 
Collagen scaffolds with heparin incorporated resulted in a larger area of 
regenerated tissue. To reach clinically significant augmentation, multiple 
larger collagen-heparin scaffolds, with or without growth factors, need to be 
tested to study the largest possible diameter of scaffold and number of used 
scaffolds still resulting in well vascularized tissue.
Introduction
Bladder augmentation is often indicated in children whose bladder has a small 
capacity or low compliance. The main causes are congenital anomalies such as 
bladder exstrophy, a neuropathic bladder caused by a myelomeningocele, or 
posterior urethral valves.1 Gastrointestinal tissues are most often used to augment 
the bladder. However, the use of gastrointestinal tissues can be problematic: it is 
not always sufficiently available, and its use can lead to metabolic disturbances, 
infections, excessive mucus production, stone formation, perforation and even 
malignancies [1-4]. Several studies have shown that tissue-engineered constructs 
can be used to regenerate bladder tissue, including urothelium, smooth muscle, 
vessels and nerve fibers, in various animal models [5-7]. A substantial improvement 
in bladder capacity was found in the first clinical trial by Atala et al., who showed 
the feasibility of tissue engineering of the human bladder. Particularly promising 
results were seen with constructs consisting of collagen and a synthetic polymer, 
seeded with urothelial and smooth muscle cells (SMCs), and wrapped in 
omentum [8]. Unfortunately, these results could not be reproduced in a phase 
2 study in which 10 patients with spina bifida were treated with this technique 
[9]. Augmentation of the bladder of five patients with bladder exstrophy with an 
acellular small intestinal submucosa (SIS) scaffold improved bladder capacity. 
However, the primary clinical endpoint of improved dry intervals was not reached 
[10]. These studies clearly show that improvements of the technique are needed 
to enhance clinical outcome, which is one of the essential steps which need to be 
undertaken before it can be tested again in a clinical trial [11].
Tissue regeneration in large constructs is hampered by a lack of oxygen and 
nutrition delivery to the infiltrating cells and inadequate removal of waste products 
[12, 13]. The diffusion distance from supplying blood vessels is approximately 
150-200 µm [13], necessitating rapid and extensive angiogenesis. In the current 
study the feasibility of implantation of 3 smaller scaffolds instead of one large 
scaffold, to reach the same surface area of regenerated tissue while reducing the 
problem of oxygen and nutrition delivery in large scaffolds, was examined. We 
hypothesized that the shorter distance of the vascularized border of the native 
tissue to the center of the scaffold would reduce the vascularization time of this 
area, and consequently the period of limited oxygen and nutrient delivery, and 
improve tissue regeneration. 
Growth factors (GFs) play an important role in proliferation, migration and 
differentiation of several cell types. The inclusion of GFs in large grafts may 
therefore assist in quicker and better acceptance [12, 14, 15]. Vascular endothelial 
growth factor (VEGF), an important factor in angiogenesis, combined with 
fibroblast growth factor 2 (FGF2) enhances blood vessel formation and maturation 
[12]. Collagen scaffolds loaded with heparin were used to bind these GFs, together 
with heparin-binding epidermal growth factor (HB-EGF) which is known to 
play a role in urothelial regeneration [14-17]. This combination of growth factors 
improved regeneration of bladder tissue in a large animal model for diseased 
bladder, resulting in better ingrowth of urothelium and SMCs, and enhanced 
angiogenesis [15]. In the current study collagen-heparin scaffolds loaded with 
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these growth factors were compared to a collagen scaffold, a collagen scaffold 
with heparin alone, and a sham-operated control group. 
Materials and methods
Preparation and characterization of scaffolds
Type I collagen was purified from bovine Achilles tendon as previously described 
[18]. A 0.67% (w/v) type I collagen suspension in 0.25 M acetic acid was shaken 
overnight at 4ºC and homogenized on ice using a Potter-Elvehjem homogenizer 
(Louwers Glass and Ceramic Technologies, Hapert, The Netherlands). Air bubbles 
were removed by centrifugation at 100g for 15 min at 4ºC. The suspension was 
poured into 6-well plates (4 mL per well), frozen at -20ºC, and lyophilized. For 
cross-linking, scaffolds were pre-incubated with 50 mM 2-morpholinoethane 
sulfonic acid (MES) pH 5.0 containing 40% ethanol for 30 min at 20ºC. After 
removal of this solution, scaffolds were incubated with 33 mM 1-ethyl-3-(3-
dimethyl aminopropyl) carbodiimide (EDC) and 6 mM N-hydroxysuccinimide 
(NHS) in 50 mM MES pH 5.0 containing 40% ethanol for 4 h at 20ºC with or 
without 0.25% heparin (Diosynth, Oss, The Netherlands). Scaffolds were washed, 
frozen and lyophilized. This resulted in round collagen scaffolds with a diameter 
of 3.2 cm. Subsequently, 70% ethanol was used to disinfect the scaffolds, followed 
by washings with sterile PBS. To bind the GFs, collagen-heparin scaffolds were 
aseptically incubated with FGF2, VEGF and HB-EGF (all human recombinant; 
R&D Systems, Minneapolis, MN, USA). First, scaffolds were incubated in 7 ml 
PBS containing 3.5 μg/ml FGF2 for 1 h. Next, VEGF and HB-EGF, each 3.5 μg/ml 
PBS, were added and incubated overnight at 20°C. Finally, scaffolds were washed 
in PBS and used immediately. 
The number of primary amine groups was analyzed using a 
2,4,6-trinitrobenzene sulfonic acid assay to determine the degree of crosslinking 
[19, 20]. Heparin content was determined by a hexosamine assay with 
p-dimethylamino-benzaldehyde, using a standard curve of heparin [21]. GF 
content was assessed using Western blot analysis [14]. Scaffold ultrastructure was 
visualized using a JEOL JSM-6310 scanning electron microscopy (SEM) apparatus 
by operating at 15 kV, after gold-coating the specimens.
Surgical procedure
This study was approved by the Animal Ethics Committee of the Radboud 
university medical center.
Thirteen female Landrace pigs with a mean weight of 48.5 kg (ranging from 
41-59 kg) were operated at age 3 months. No significant difference in weight existed 
within and between groups. Animals were housed individually for two weeks after 
surgery, with a restricted diet and free access to water. After two weeks the animals 
were housed in a group. Animals were pre-medicated with intramuscular (IM) 
injection of midazolam (1 mg/kg, Roche, Woerden, The Netherlands), atropine 
(50 µg/kg, Pharmachemie BV, Haarlem, The Netherlands) and ketamine (10 mg/
kg, Eurovet Animal Health BV, Bladel, The Netherlands). General anesthesia 
was induced by intravenous (IV) injection of propofol (2-3 mg/kg, B. Braun, 
Melsungen, Germany), followed by tracheal intubation, and maintained with 
0.5-1% isoflurane (Nicholas Piramal, London, UK) and midazolam (0.6 mg/kg/h, 
IV). For analgesia, flunixin (2.2 mg/kg, Intervet, Boxmeer, The Netherlands) and 
sufentanil (5 µg/kg bolus, Janssen Cilag BV, Tilburg, The Netherlands) were given 
IV, followed by a maintenance dosage sufentanil of 10 µg/kg/h. Vecuronium (0.2 
mg/kg, N.V. Organon, Oss, The Netherlands) was given IV as muscle relaxant, 
and maintained with 0.4 mg/kg/h.
Video urodynamic evaluation was performed using the MMS Solar system 
(MMS, Enschede, The Netherlands) and a Philips BV-25 C-arm and image 
identifier (Philips, Eindhoven, The Netherlands). A double lumen 6Fr catheter 
(Medtronic, Heerlen, The Netherlands) was placed in the bladder. A double 
lumen 9Fr catheter (Bel Medical B.V., Zwolle, The Netherlands) was placed in the 
rectum. The bladders were slowly filled with iodinated contrast fluid (Xenetix® 
300 (Guerbet Nederland BV, Gorinchem, The Netherlands) diluted with PBS 1:1). 
Urethral leakage did not occur during urodynamic measurements, so bladder 
filling was stopped at a maximal pressure of 40 cm H2O and bladder capacity was 
evaluated at 20 cm H2O. One or two representative evaluations were performed 
in each animal.
Figure 1. Representative macroscopic overview of the implantation procedure. A. The bladder was 
exposed and 3 cm long incisions were made. B. In the experimental groups collagen scaffolds were 
sutured into the defects. C. In the control animals the defects were primarily closed.
Subsequently a laparotomy was performed under sterile conditions to expose 
the bladder (Fig. 1a). Three incisions of 3 cm were made in the bladder, along the 
vascularization from the lateral side to the middle of the bladder. Animals were 
randomly assigned to one of the four groups. Three identical collagen scaffolds 
(COL-group), collagen-heparin scaffolds (COLHEP-group), or collagen-heparin 
scaffolds with growth factors (COLHEPGF-group) were sutured into the defects 
using 5-0 poliglecaprone (Monocryl®, Ethicon Inc. NJ, USA) running sutures 
(Fig. 1b). In the sham-group the bladder was closed in one layer using a 5-0 
poliglecaprone running suture (Fig. 1c). Four 5-0 polypropylene (Prolene®, Ethicon 
Inc.) nonresorbable marking sutures were placed at the edges of the scaffold. A 12Fr 
silicon catheter (Coloplast, Amersfoort, The Netherlands) was used as suprapubic 
catheter. The bladder was filled to ensure that no urinary leakage occurred 
along the suture line. The peritoneum was closed using 4-0 poliglecaprone. The 
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abdominal wall was closed using 0 polyglactin (Vicryl®, Ethicon Inc.) interrupted 
sutures for the fascia and 1-0 polyglactin for the skin. The suprapubic catheter was 
fixed to the skin using 1-0 polyglactin sutures, and was removed after 2 weeks. 
Buprenorphine (10 µg/kg, IV, Schering Plough, Segre, France) was given once, and 
flunixin (2.2 mg/kg, IM) for three days as postoperative analgesia. Amoxicillin 
(10mg/kg, IM, Aurobindo Pharma BV, Zwijndrecht, The Netherlands) was given 
twice daily for 3 days. 
Functional evaluation
Animals were evaluated after 3 months. Animals were anesthetized and 
urodynamic evaluation was performed as described above. Thereafter the animals 
were sacrificed with IV pentobarbital (60 mg/kg, AST Pharma, Oudewater, The 
Netherlands). The bladder was removed, filled with 300 ml PBS, inspected, and 
the size of the regenerated tissue was measured between marking sutures (Fig. 2). 
The regenerated area was assumed to be of elliptical shape, the surface area was 
calculated using the formula (0.5 x diameter 1) x (0.5 x diameter 2) x π. Kidneys 
were examined for signs of infection, hydronephrosis, or stone formation.
Figure 2. Macroscopic overview 3 months post-surgery. A. The bladders were filled with 300 ml of 
saline to ensure equal exposure between samples for measurements. B. Implantation sites were 
recognized by the four marking sutures. C. The luminal side of the bladder was exposed, showing the 
three areas where the scaffolds were implanted (arrows).
Histological staining
Tissue samples were obtained from the regenerated tissue (COL-group, COLHEP-
group and COLHEPGF-group) and the scar tissue (sham-group), fixed in 4% (v/v) 
buffered formalin and paraffin-embedded. Sections (4 μm) were cut in the center 
of the tissue along the longest axis and stained with hematoxylin & eosin (H&E). 
Multiple levels were analyzed using H&E staining and a representative level was 
chosen for immunohistochemistry and the Masson trichrome/Verhoeff stain. 
For immunohistochemistry, sections were deparaffinized in xylene, followed by 
graded series of ethanol and re-hydration in PBS. Slides were immersed in 1% 
(v/v) H2O2/PBS for 30 min at room temperature to block endogenous peroxidase. 
Antigen retrieval methods and primary antibodies are shown in Table 1. Slides 
were pre-incubated with 5% goat serum, incubated with the antibody of interest: 
pancytokeratin , Cytokeratin 7, smooth muscle actin or smoothelin, washed 
and incubated with poly-HRP-anti mouse IgG (Immunologic, Duiven, The 
Netherlands) which was pre-incubated with 10% swine serum for 30min at RT. For 
vimentin and desmin staining, slides were peroxidase blocked and pre-incubated 
with 5% horse serum. After primary antibody incubation for 1.5 hour, sections were 
washed and  incubated with a biotin-labeled secondary antibody (30 min, horse-
α-mouse, 1:200, Vector laboratories, Burlingame, California, USA). Next, the slides 
were washed and incubated with peroxidase-labeled streptavidin/biotin complex 
(1:100 Avidin reagent and 1:100  Biotin reagent, 30 min pre-incubation, Vector 
Laboratories, Burlingame, California, USA) for 45 min followed by washings in 
PBS. All stainings were developed with Bright-DAB (Immunologic) for 10 min and 
counterstained with hematoxylin (Klinipath, Duiven, The Netherlands).
Histological evaluation was performed microscopically by LR, PdJ and PG 
and scored independently in a blinded fashion. Quantitative analysis of smooth 
muscle cell ingrowth was performed using ImageJ (NIH, USA). Using a ‘rolling ball 
method’ (50 px), background was corrected for desmin stained slides. The browns 
were extracted and converted to binary, followed by plotting the pixel intensity 
along the native muscle and the regenerated tissue. The intensity thereby is higher 
when more muscle tissue is present (Fig. 3). The distance of muscle ingrowth 
was determined. In addition, the area under the curve (number of positive pixels, 
derived from curves as shown in Fig. 3) was analyzed to approximate the amount 
of muscle tissue in the regenerated and native tissue. This was standardized to 
show the average amount of pixels per mm of tissue (AUC / mm).
Renal tissue of all pigs was processed and examined for inflammation or 
dilated nephrons by H&E staining.
Statistical analysis
Data analysis was performed with IBM SPSS statistics version 22 (IBM, New York, 
USA), using the one-way ANOVA test, followed by the LSD post hoc test.  P < 0.05 
was considered statistically significant.
Results
Scaffolds
The collagen scaffolds consisted of homogenously distributed honeycomb-like 
pores with an average size of 100-150 µm (see Hosper et al [22]. who used identical 
scaffolds). After crosslinking, primary amine groups were reduced by 46 ± 6% 
for collagen scaffolds and 48 ± 8% for heparinized collagen scaffolds. Heparin 
bound to heparinized collagen scaffolds was 12 ± 5%. The GF content bound per 
mg collagen-heparin scaffold were 0.2 ± 0.2 µg for VEGF, 0.7 ± 0.2 µg for FGF2, and 
0.8 ± 0.3 µg for HB-EGF. Results are given as mean ± SD.
Animal surgery
Overall survival rate was 92%. One out of 13 pigs had a peritonitis due to urinary 
leakage and was sacrificed. At autopsy we found a rupture of the scaffold at the 
border where it was sutured. One other animal was sacrificed one day before the 
intended date of sacrifice because of illness, no clear diagnosis was made after 
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autopsy. This animal was included in histological analysis. Both animals were 
from the COLHEPGF-group. Three months after operation the mean weight was 
108.3 kg (range 90-120 kg), no significant differences existed within and between 
groups. This was an increase of 123% (Table 2).
Figure 3. Overview of muscle quantification process. From the original image, only the brown colors 
(desmin positive cells) were extracted. Next, the image was converted to a binary image. Finally, 
a profile was plotted which showed the pixel intensity along the tissue. Higher intensity indicates 
a higher number of desmin positive cells. X indicates the native muscle tissue. * Indicates the 
anastomosis site. Note the change of morphology and decreasing intensity towards the center.
Functional evaluation
All pigs voided normally, without signs of incontinence or urinary tract infection. 
Catheterization was impossible in one animal before operation and two animals 
at 3 months. On urodynamic evaluation none of the pigs showed detrusor 
overactivity. No statistically significant differences in capacity were found 
between groups (Table 2).
No structural abnormality of the bladders, e.g. no diverticula or leakage were 
seen when the bladders were filled after sacrifice (Fig. 2a). 
Macroscopic evaluation
No scaffold remnants were visible in the scaffold groups (Fig. 2b). The bladder 
wall appeared slightly thinner at the implantation site in these groups. A small 
scar was visible in the sham group. The native bladder had a normal appearance in 
all groups, without signs of stone formation (Fig. 2c). The sum of the regenerated 
area is shown in Fig. 4a and Table 2. The largest amount of tissue was regenerated 
in the COLHEP-group, which was statistically significant compared to the COL-
group (p=0.002), but not compared to the COLHEPGF-group (p=0.083). No 
significant difference was seen between the COL-group and COLHEPGF-group 
(p=0.215). All kidneys appeared normal.
Histological evaluation
Figures 5-7 show representative sections from the different study groups.
Sham group
A confluent, normal appearing multilayered lining of urothelial cells was 
observed, containing a basal layer and umbrella cells. The architecture of the 
tissue was generally like native tissue, including smooth muscle formation. Only 
few fibroblasts and myofibroblasts were found in the wound (data not shown).
Regenerated bladder tissue in scaffold groups
The histological results are shown in Table 3. The regenerated tissue showed a 
confluent, well differentiated, urothelial layer in all groups (Fig. 5a,b, 6a,b and 
7a,b) (data cytokeratin 7 not shown). Submucosal tissue consisted of connective 
tissue with fibroblasts, myofibroblasts and dense collagen (Fig. 5a,d,e; 6a,d,e; 
7a,d,e). Directly under the urothelium the multilayered structure of vimentin- 
and α-SMA-positive cells, similar to native bladder tissue, was visible in 
approximately half, and all animals, respectively. No difference was seen between 
groups (Fig. 5d,e; 6d,e; 7d,e). Fibrosis was comparable between groups, and 
slightly more evident in the COLHEP-group, with slightly denser extracellular 
matrix (ECM) and slightly more fibroblasts and myofibroblasts. Angiogenesis was 
visible throughout the entire regenerated area and comparable between groups 
(Table 3). Mature blood vessels were present, evidenced by vimentin positive 
cellular linings and the presence of erythrocytes (Fig. 7G). In the COL-group and 
the COLHEPGF-group hardly any scaffold remnants remained. In the COLHEP-
group scaffold remnants were visible, mainly at the serosal side (Fig. 5a,c, 6a,c and
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Figure 4. Results of the quantitative and statistical analysis. A. Macroscopic surface area (cm2) was 
determined. The surface area of COL (n=9), COLHEP (n=9) and COLHEPGF (n=6) were significantly 
smaller (p < 0.001 for all) than the implanted scaffolds. The surface area of COLHEP was significantly 
larger (p = 0.002) than COL but not larger than COLHEPGF (p = 0.083). No significant difference 
was seen between COL and COLHEPGF (p = 0.215). B. The AUC / mm (pixels) was determined as a 
measure for the amount of muscle present per mm tissue based on the number of positive pixels. 
In all cases significantly less muscle was found (p < 0.001) than in native muscle tissue, but no 
differences between groups were observed (p > 0.05). COL (n=7), COLHEP (n=8), COLHEPGF (n=6), 
native (n=12). C. Histological defect size was determined by quantitative analysis. COLHEP (n=8) 
was significantly larger than COL (p = 0.01, n=8) and COLHEPGF (p = 0.003, n=6). No significant 
differences were seen between COL and COLHEPGF (p = 0.596). No significant differences were 
found regarding the distance of muscle ingrowth (p > 0.05). Whiskers represent the min-max range 
in all figures.
7a,c). Inflammatory cells were mainly visible around scaffold remnants, mainly 
consisting of lymphocytes. Slightly more inflammatory cells were observed in the 
COL-group. SMC ingrowth was present throughout almost the entire regenerated 
tissue in most animals of the COL and COLHEPGF group, appearing as fascicles 
or separate cells. While the distance of ingrowth was similar between all groups, 
the ingrowth in the center of the new tissue was limited in the COLHEP group 
due to the larger overall surface area. (Fig. 5a,f, 6a,f and 7a,f) (data smoothelin not 
shown). SMC ingrowth occurred from the borders inwards, originating from the
Figure 5. Representative histological overview of COL group after 3 months. A. Overview of the 
native and full regenerated tissue (between dashed lines). B. The luminal side was covered with a 
normal appearing multilayered urothelium. C. A moderate immune response (lymphocytes) could 
be observed locally near scaffold remnants. D. Only some vimentin positive cells were observed, 
indicating a well progressed regeneration process. E. Muscle tissue was observed in the middle of 
the regenerated tissue, with only few myofibroblasts. F. Desmin positive cells indicating maturing 
muscle tissue. G. Small elastic fibers were present in the newly formed tissue. Scale bars A = 2 mm, 
B-F = 500 um, G = 125 um. * indicates the lumen of the bladder.
native detrusor muscle. No clear difference in the amount of ingrowth of SMCs 
was visible between groups on microscopic evaluation. Quantitative analysis of 
smooth muscle ingrowth showed comparable number of SMCs per mm regenerated 
tissue (Fig. 4b). In view of the larger regenerated area of the COLHEP-group, a 
larger total amount of SMCs was present in the regenerated area of this group. 
The distance of ingrowth of these cells (when evaluating length of ingrowth from 
the anastomosis inwards) was comparable between groups (Fig. 4c). 
Elastic fibers were scarcely found between the newly formed muscle fibers, 
and slightly more in the COLHEP-group (Fig. 5g) indicated by purple/black fibers 
in the Masson trichrome/Verhoeff stain. Nerve fibers were sporadically seen, only 
at the borders of the regenerated tissue, no differences between groups were seen 
(Fig. 6g).
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Figure 6. Representative histological overview of COLHEP-group after 3 months. A. Overview 
of the native and full regenerated tissue (between dashed lines). B. The luminal side was covered 
with a normal appearing multilayered urothelium. C. A moderate immune response (lymphocytes) 
could be observed near scaffold remnants (arrows). D. More vimentin positive cells were found in 
the COLHEP-group compared to the COL- and COLHEPGF-group. E. αSMA staining was also more 
intense in the COLHEP-group compared to the COL- and COLHEPGF-group. F. Desmin positive 
cells indicating maturing muscle tissue. G. Small nerve fibers could be observed in the regenerated 
tissue. Scale bars A = 2 mm, B,D-F = 500 um, C,G = 125 um. * indicates the lumen of the bladder. 
Kidney tissue
No abnormalities were found in kidney tissue (data not shown). 
Discussion
In this study we evaluated regeneration of bladder tissue in a large animal model 
and used multiple smaller scaffolds instead of one large scaffold. We showed 
the feasibility of this technique, and were able to regenerate bladder tissue that 
was almost indistinguishable from native bladder tissue with ingrowth of all 
essential components of the bladder wall and no necrosis in the scaffold areas. 
The urothelial layer was completely regenerated in all groups, vasculature was 
present in the whole tissue, and SMCs were growing into the regenerated area, as 
well as sporadic small nerve fibers.
 
Figure 7. Representative histological overview of COLHEPGF group after 3 months. A. Overview of 
the native and full regenerated tissue (between dashed lines). B. The luminal side was covered with 
a normal appearing multilayered urothelium. C. A moderate immune response (lymphocytes) could 
be observed near scaffold remnants (arrows). D. Only some vimentin positive cells, indicating a well 
progressed regeneration process. E. Muscle tissue was observed in the middle of the regenerated 
tissue, with some myofibroblasts. F. Desmin positive cells indicating maturing muscle tissue. G. 
Extensive angiogenesis of small and larger vessels was observed. Scale bars A = 2 mm, B,D-F = 500 
um; C,G = 125 um. * indicates the lumen of the bladder.
Macroscopic evaluation showed that the largest quantity of tissue was 
regenerated in the COLHEP-group. This was statistically significantly higher 
compared to the COL-group, but not compared to the COLHEPGF-group. The 
larger amount of regenerated tissue in the COLHEP-group might be explained 
by lesser contraction during regeneration due to the highly negative charge of 
the incorporated heparin with its sulfate and carboxylic groups. The negative 
charge may protect collagen from proteolysis, and has an inhibitory effect on 
the macrophage adhesion, hereby delaying degradation of the collagen scaffold 
which may reduce contraction [14, 23]. This also explains the larger amount of 
scaffold remnants at time of evaluation in the COLHEP-group. This slower 
degradation process of the collagen scaffold may have resulted in improved 
regeneration of bladder tissue due to a slower remodeling process. The larger 
number of myofibroblasts may explain the larger amount of collagen produced 
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in the regenerated tissue. Earlier evaluation is needed to determine whether 
myofibroblast content or delayed scaffold degradation cause the improved 
regeneration.
In contrast to previous findings, GF-loading did not show a beneficiary 
effect in this study when bladder regeneration was evaluated after 3 months. 
In previous work we observed improved ingrowth of urothelium, SMCs and 
improved vasculature 1 month after implantation with a collagen scaffold loaded 
with the same GFs as used in the current study [15]. In the previous study only a 
beneficial effect on SMC ingrowth was seen after 3 months [15]. This suggests that 
initially the GFs have a stimulatory effect on ingrowing cells, but this effect seems 
to wane. The availability and activity of growth factors most likely declined after 
a given time although GFs were bound to the scaffolds through the use of heparin, 
which also stabilizes GFs and protects them against proteolytic degradation, 
creating a sustained release system [24]. Pieper et al. studied the in vitro release 
profile of FGF2 from a collagen scaffold loaded with heparan sulfate in PBS [24]. 
Following an initial burst release of 13% at day 1, 53% was gradually released 
during 4 weeks of incubation. Kanematsu et al. showed similar release profiles 
of FGF2 loaded to a bladder acellular matrix (BAM) scaffold in PBS or urine in an 
in vitro study [25]. Furthermore, biological activity was maintained even after 
4 weeks when implanted in the subcutis of mice [25]. Clearly, the subcutis and 
bladder are incomparable, in the bladder the implanted scaffolds are exposed to 
urine flow, which could increase the wash out of GFs. Data on in vivo release 
kinetics and activity of GFs incorporated in a collagen scaffold implanted in the 
bladder are lacking, and particularly important long-term results. Our results of 
the current and previous study suggest that the beneficial effects of GF loading 
can be achieved even in an environment with high urine flow, but that this effect 
is limited. Furthermore, COLHEP scaffolds may have attracted and bound growth 
factors from the wound environment and hereby improved regeneration. Indeed, 
heparin can bind a width variety of proteins and growth factors involved in 
wound healing, like TGF- β [ESKO][26]. However, by incorporating growth factors 
in a scaffold it is possible to guide regeneration in a favorable way. For instance, 
TGF-β plays an important role in wound healing, the isoform β1 was considered 
to increase fibrosis, while TGF-β isoform 3 may result in scarless wound healing. 
Incorporation of these growth factors may be optional, although the exact 
mechanism of TGF-β still needs to be elucidated [27].
In the current study we used 3 smaller scaffolds to reach the same regenerated 
surface area as with 1 larger scaffold. This decreases the area of tissue remodeling 
per scaffold to overcome the problem of angiogenesis in large scaffolds. Hereby, 
the vascularized border of the native tissue will be closer to the center of the 
scaffold, shortening the time until this area will be vascularized and reducing 
the distance for cellular ingrowth. It may be possible to implant more than 3 
scaffolds to improve the augmentation of the bladder. However, one should take 
in account the sideways alignment of bladder vasculature, which may mean that 
scaffolds cannot be implanted next to each other, otherwise regeneration may be 
hampered by insufficient delivery of nutrients and oxygen for regeneration. We 
used scaffolds of 3.2 cm in diameter to make this study comparable to previous 
work in which we also used scaffolds of this size [15, 28, 29]. The normal functional 
capacity of a human bladder is approximately 300 ml, at which the bladder has a 
surface area of 216 cm2. The total area of implanted scaffolds was 21 cm2, which 
is 10% of the functional capacity of a normal human bladder. To reach clinically 
significant augmentation, the largest possible diameter and number of scaffolds 
still resulting in well vascularized tissue need to be studied. 
With larger scaffolds, the strength of the scaffolds may need to be improved. 
In the current study we had one animal with urinary leakage due to a rupture of 
the scaffold at the side of the sutures. Inclusion of a degradable polymer may be 
a possible solution. Different polymers have already been tested for this purpose, 
with favorable results of a combination of collagen with Vicryl [30]. Additionally, 
incorporation of autologous urothelial and smooth muscle cells may improve 
tissue regeneration. However, harvesting, culturing and seeding of cells is time 
and cost consuming. Furthermore, when these cells are harvested from diseased 
bladders they may behave dissimilar to normal cells, making their use for tissue 
engineering questionable [29].
We used a porcine model because pigs are comparable sized to humans, have 
similar abdominal anatomy and results of smaller animal models often cannot be 
extrapolated to humans [31]. Urodynamic evaluation showed very high bladder 
capacities in the studied animals, and it was not possible to study the increase of 
capacity due to the augmentation. Tu et al [32]. found comparable urodynamic 
outcomes in their porcine study on bladder tissue engineering. We conclude that 
the porcine model is inappropriate for studying bladder augmentation by tissue 
engineering due to the very high compliance and capacity of porcine bladders. 
Alternatively, goat or sheep models may be more useful for this purpose [31].
Conclusions
Implantation of multiple collagen-heparin scaffolds for bladder augmentation may 
be a good alternative compared to one large scaffold. We show that this approach 
is feasible in a porcine model, resulting in tissue almost indistinguishable from 
native tissue involving all cell layers. Collagen scaffolds with heparin incorporated 
resulted in a larger area of regenerated tissue, which was statistically significant 
when compared to the COL-group. To reach clinically significant augmentation, 
multiple larger collagen-heparin scaffolds, with and without growth factors, need 
to be tested to study the largest possible diameter of scaffold and number of used 
scaffolds still resulting in well vascularized tissue. This needs to be performed 
in a large animal model that is better representative for humans, preferably in 
preclinical models using dysfunctional/diseased bladders.
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Antigen Antibody Source   Dilution Antigen 
retrieval
Cytokeratin 7 RCK105 MUbio BV 1:10 A
Pancytokeratin AE1/AE3 AE1/AE3 Thermo Fisher scientific 1:800 B
Vimentin V-9 BioGenex 1:2000 C
α-smooth muscle actin 1A4 Sigma-Aldrich 1:15000 C
Desmin [33] BioGenex 1:200 C
Smoothelin R4A Santa Cruz Biotechnology 1:150 A
S100 Z0311 Dako 1:10000 A
Table 1. Antibodies used for immunohistochemical evaluation. A: Heat mediated in sodium citrate 
buffer (10 mM; pH 6.0; 10 min; 100°C); B: with 0.1% pronase (30 min at room temperature); C: without 
antigen retrieval.
Animal Animal weight (kg) Bladder capacity (ml) Regenerated area (cm2)
COL Preop Mean 3 m Mean In-
crease
Preop Mean 3 m Mean In-
crease
Area Mean SD Con-
traction 
1 43
49.7
90
105.3 112%
NA*
580
850
1268 150%
10.9
8.3 2.3 61.0%2 47 108 460 1063 6.6
3 59 118 700 1890 7.3
COLHEP
1 44
44.7
103.5
109.2 144%
880
718
NA*
1400 177%
12.1
14.0 3.9 34.0%2 46 115 770 NA* 11.4
3 44 109 505 1400 18.5
COLHEPGF
1 41
49.5
Died
115 132%
650
611
Died
1456 155%
NA
10.6 1.5 49.8%
2 50 120 720 1238 9.6
3 53 NA+ 580 NA+ NA
4 54 110 495 1675 11.7
Sham
1 46
49.7
94
104.5 110%
350
383
915
1137 199%2 47 115 350 1300
3 56 NA 450 1195
Table 2. Overview of characteristics before surgery and at the evaluation time point after 3 
months. No significant differences in weight existed within and between groups. No statistically 
significant differences in bladder capacity were found between groups. The largest amount of tissue 
was regenerated in the COLHEP-group, which was statistically significant compared to the COL-
group (p=0.002) (also see Fig. 4a), but not compared to the COLHEPGF-group (p=0.083). Several 
values are not available due to drop-out before 3 months or technical failure, NA = not available, * = 
catheterization impossible, + = sacrificed. Preop = pre-operative; 3 m = 3 months after operation; SD 
= standard deviation.
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COL-group COLHEP-group COLHEPGF-group
Urothelium ++ ++ ++
Angiogenesis ++ ++ ++
Vimentin-positive cells +/- + +/-
α-SMA-positive cells + ++ +
SMCs + + +
ECM +/- +/- +/-
Inflammation + +/- +/-
Scaffold remnants Sp +/- Sp
Elastic fibers Sp +/- Sp
Nerves Sp Sp Sp
 
Table 3. Overview of microscopic scoring of histological results. COLHEP showed more vimentin and 
α-SMA positive cells than COL or COLHEPGF as well as more scaffold remnants and elastic fibers. ECM 
was also slightly more visible in COLHEP, although not visible in table due to round off in categories. More 
inflammation was seen in COL compared to COLHEP and COLHEPGF. No other differences were found. 
++ = abundant, + = present, +/- = limited, Sp = sporadically present.
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Abstract
Repair of long ureteral defects often requires extensive surgical procedures 
and graft tissue which is associated with various complications, e.g. graft 
site morbidity or lack of suitable tissue. Tissue engineering might provide 
an alternative therapeutic approach in these cases. Reinforced tubular 
collagen-Vicryl scaffolds (l = 5 cm, lumen Ø = 6 mm, thickness = 3 mm) were 
developed with or without vascular endothelial growth factor and basic 
fibroblast growth factor and evaluated in a pre-clinical porcine model. The 
reinforced scaffolds were successfully implanted in 20 pigs and functional, 
macroscopic and microscopic evaluation was performed at one and three 
months. Two animals without scaffold implantation served as control. All 
animals survived until their predetermined evaluation time point and grafted 
scaffolds showed urothelial regeneration, smooth muscle cell ingrowth 
and neovascularization. Loopogram and macroscopic evaluation revealed 
constriction of the scaffold lumen and hydroureteronephrosis. Enhanced 
muscle ingrowth was observed in growth factor loaded scaffolds, but this 
was not significant. We conclude that reinforced collagen-Vicryl scaffolds are 
mechanically suitable for ureteral repair, but further optimization to prevent 
strictures is required.
Introduction
Ureteral traumas account for approximately 3% of all urogenital traumas and are 
mainly of iatrogenic cause. Of these, gynaecological surgeries account for about 
73% of all ureteral injuries, mainly during hysterectomy [10-12]. When recognized 
during surgery, primary repair is often possible. However, in 33-88% of the cases 
injury is not recognized in time, potentially leading to urinoma, sepsis and even 
kidney loss [13, 14]. The repair of long defects, where end-to-end anastomosis is not 
feasible, is often challenging for the surgeon. Depending on the type and location 
of the injury, different procedures such as a Boari flap, transureteroureterostomy, 
and ileal interposition are used [15, 16]. A shortage of suitable donor tissue can 
complicate the repair. Therefore, various biomaterials have been studied as an 
alternative to the current techniques in the past three decades, but high failure 
rates were observed [17].
In a previous study we evaluated the regenerative capacity of collagen 
based tubular scaffolds in the reconstruction of the porcine ureter. The lack 
of mechanical strength complicated the surgical procedure and regeneration 
outcome [18]. To reinforce the tubular scaffolds, a Vicryl mesh was introduced 
in the collagen to generate a reinforced construct, which was then loaded with 
growth factors (vascular endothelial growth factor (VEGF) and basic fibroblast 
growth factor (bFGF)) to improve the cellular ingrowth. The aim of this study was 
to investigate the regenerative outcome of ureteral repair after introduction of a 
large defect, using reinforced scaffolds in a porcine model.
Materials and Methods
Reinforced scaffold production
Type I collagen was purified from bovine Achilles’ tendons using a previously 
described protocol (Figure 1)[19]. Commercially available Vicryl meshes (Ethicon) 
were tubularized using Vicryl sutures (Ø = 8 mm). Tubular reinforced 0.5% (w/v) 
collagen-Vicryl constructs (l = 5 cm, lumen Ø = 6 mm, wall = 3 mm) were prepared 
by freezing homogenized collagen with the Vicryl mesh in a cylindrical mold, 
followed by freeze-drying [20]. Carbodiimide cross-linking was used to cross-link 
the constructs, with or without 0.25% (w/v) heparin (Diosynth). Constructs were 
packaged in blisters containing 70% (v/v) ethanol and were sterilized by 25 kGy 
γ-irradiation (Synergy Health). A 2,4,6-trinitrobenzene sulfonic acid assay and 
hexosamine assay was used to determine the degree of collagen cross-linking and 
to quantify the amount of bound heparin, respectively. Ultimate tensile strength of 
collagen was analyzed by elongating five wet collagen strips (10 x 30 mm) and four 
Vicryl meshes (10 x 30 mm) at 2 mm per second using a BiodynamicTM bioreactor 
(Bose). The ultra-structure of the scaffold was characterized by scanning electron 
microscopy (Figure 1d). 
Growth factor loading
One hour before surgery, the heparin loaded scaffolds were incubated with 0.5 
µg/ml recombinant human VEGF-165 and 0.5 µg/ml recombinant human bFGF 
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(both R&D systems) in 3 ml PBS. The scaffolds were washed 3 times with PBS 
for approximately 15 min before implantation. Western blot analysis was used to 
quantify the concentration of loaded growth factors [21].
Figure 1. A. Wrapped reinforced scaffold in 70% ethanol. B. Macroscopic view of the reinforced 
scaffold. C. The reinforced scaffolds retain an open lumen under their own weight. D. Scanning 
electron microscopy (SEM) of the cross section of a reinforced scaffold. A highly porous structure is 
visible with good integration of the collagen and the Vicryl (black arrows). 50x magnification.
Animals
All procedures were performed according to the Institute of Laboratory Animal 
Research guide for Laboratory Animals [22]. The Nijmegen Medical Center animal 
ethics committee approved the study protocol (RU-DEC-2012-320). In total, 22 
female Landrace pigs weighing around 50 kg were used. They were housed in 
groups at the Institute’s farm with a restricted diet and free access to water. The 
pigs arrived at the animal laboratory at least 24h before every procedure. The 
pigs were weighed before surgery and were pre-medicated by intramuscular 
injection of 10 mg/kg ketamine (Eurovet Animal Health), 1 mg/kg midazolam 
(Roche) and 50 µg/kg atropine sulfate (Pharmachemie). All pigs were subjected 
to a scaffold implantation (n=20) or primary anastomosis of the ureter (n=2), and 
were evaluated one (n=12) or three months (n=10) post-implantation. 
Pre-operative preparation
Intravenous fluids (lactated Ringer’s solution) and anesthesia (2.5 mg/kg propofol 
(B.Braun)) were administered through the auricular vein. Pigs were intubated 
and 2 L/min O2/N2O (2:1) containing 0.5% isoflurane (Baxter), combined 
with a bolus of 0.3 mg/kg midazolam (Roche) and 5 μg/kg sufentanyl citrate 
(Janssen-Cilag) was administered. Anesthesia was maintained with 0.6 mg/
kg/h midazolam (Roche), 10 μg/kg/h sufentanyl citrate, 0.2 mg/kg Vecuronium 
bromide (Organon) and 25 mg/kg atropine sulfate. Pigs were placed on a heating 
pad and covered with a sterile surgical blanket after the surgical area was shaved, 
washed and disinfected using iodine. Electrocardiography, pulse oximetry, CO2 
and temperature registration provided continuous monitoring during surgery. 
Before surgery, the bladder was catheterized (12 Ch Nelaton catheter).
Surgical procedure
A 10 cm right flank incision was made 5 cm below the spine and parallel to the 
lower rib. The retroperitoneal space was entered after division of the muscle layers. 
Subsequently, the ureter was located and mobilized. Approximately 5 cm of the 
ureter was removed and the ureteral ends were spatulated. Reinforced scaffolds, 
with or without growth factors, were placed over a 7 FR/22-32 cm multi-length 
double J ureteral stent (Inlay Optima, Bard medical), which was then positioned 
in the kidney and urinary bladder. Using interrupted 6-0 monocryl (Ethicon) 
sutures, a tension free anastomosis was created. The anastomosis sites and the 
scaffold were then covered with fibrin glue (Tisseel, Baxter). Approximately 
1 cm from the anastomosis site, two 6-0 prolene sutures were placed on either 
side as reference. In two control animals, the ureter ends were spatulated and 
anastomosed without placing a scaffold. Finally, the fascia (0 Vicryl), 4 muscle 
layers (2-0 Vicryl), subcutis (2-0 Vicryl) and skin (1 CT) were closed (all sutures 
from Ethicon). The animals were followed closely for signs of discomfort and 
leakage from the anastomosis. 
Neo-ureter evaluation
One and three months after the implantation procedure, the animals were sacrificed 
by an overdose of intravenous pentobarbital after sedation with midazolam/
ketamine (Roche, Eurovet Animal Health) and evaluated radiologically. Iodinated 
contrast fluid in a 1:1 dilution with saline (Aguettant) was injected into the pyelum 
followed by a loopogram to evaluate lumen size and accessibility. The urinary 
tract was harvested and evaluated macroscopically. Specimens of the neo-ureter, 
ureters and the kidneys were harvested and fixed in 4% (v/v) formaldehyde in PBS 
(Boom) overnight for evaluation.
Immunohistochemistry
All tissues were embedded in paraffin, cut and stained with hematoxylin (Klinipath) 
and eosin (Merck). Additionally, immunohistochemistry for Pancytokeratin 
(Fisher Scientific), Smoothelin (Santa Cruz Biotechnology), desmin (Biogenix), 
α-smooth muscle actin (αSMA, Biogenix) and vimentin (Fisher Scientific), and 
Masson’s Trichrome was performed on transverse sections of the neo-ureter. 
For immunohistochemistry, sections were blocked in 1% (v/v) H2O2 (Merck) in 
PBS. Antigen retrieval for Pancytokeratin and Smoothelin was performed using 
microwave treatment with sodium citrate (pH 6). Sections were then incubated 
with 5% (v/v) goat serum (Bodinco) for 10 min. Primary antibodies (pancytokeratin 
(1:800), desmin (1:400), vimentin (1:1 000), αSMA (1:8 000) and Smoothelin (1:75)) 
were incubated for 1 h. Secondary antibody (Poly-Horseradish peroxidase-goat-
anti-mouse/rat/rabbit IgG, Immunologic) was pre-incubated with 10% (v/v) swine 
serum (prepared in house) for 30 min, followed by an additional 30 min incubation 
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on the slides. Finally, 3,3’-Diaminobenzidine (bright-DAB, Immunologic) was 
used to develop the slides and sections were counterstained with hematoxylin for 
5 s. All antibodies and goat serum were diluted in PBS with 1% (v/v) Bovine serum 
albumin (BSA, Sigma-Aldrich). 
Transverse neo-ureter sections and affected kidneys were scored for 
hydronephrosis, neo-ureter development and immune response by two 
independent evaluators (PdJ, PG). In addition to independent scoring of the 
slides, quantitative analysis was performed on desmin stained neo-ureter slides 
to quantify smooth muscle tissue ingrowth. Briefly, using ImageJ, desmin stained 
slides were corrected for background using a ‘rolling ball method’ (50 px) and 
converted to binary. Next, the pixel intensity along the native muscle and neo-
ureter was plotted. This data represents the amount of smooth muscle ingrowth 
from the native ureter tissue into the neo-ureter. 
Results
Scaffold characterization
The tubular scaffolds were highly porous and the Vicryl mesh was fully integrated 
into the collagen scaffold (). The collagen was stabilized by EDC/NHS cross-
linking, which resulted in a 49% (no heparin) and 61% (with heparin) free amine 
group reduction. Incorporating the Vicryl mesh greatly improved handling 
properties: the lumen stayed open and both ends could easily be sutured. The 
tensile strength of the Vicryl meshes was around 20x stronger than the cross-
linked collagen structure (collagen: 1.46 ± 0.41 N, Vicryl: 29.78 ± 8.41 N). The 
heparinized scaffolds contained 20 wt% of heparin. Western blot analysis showed 
that an average of 10.0 ng VEGF/ mg collagen and 50.3 ng bFGF/ mg collagen 
were bound per scaffold at the time of implantation. Each scaffold contained 
approximately 35 mg of collagen, therefore we estimated that a total of 0.35 µg 
VEGF and 1.76 µg BFGF was delivered at the implantation site.
In vivo evaluation
Figure 2 shows an overview of the implantation procedure. All animals survived 
until the pre-determined time point (one or three months). In both control 
animals urinary leakage was observed due to inadequate healing of the end-to-
end anastomosis upon evaluation at one month. Both control animals could not 
be further evaluated due to the extent of the leakage. In three animals a urinoma 
was observed after one month (n = 1 with growth factors, n = 2 without growth 
factors). One additional animal grafted with a scaffold without growth factors 
presented with a small encapsulated urinoma after three months. The other 
animals did not show any urine leakage, diverticula or fistula formation. All grafted 
animals developed constriction of the neo-ureter, including the anastomoses. The 
double-J stent remained in situ during the entire experiment, but the proximal 
part of the stent migrated from the kidney to the proximal ureter, possibly due to 
dilatation of the proximal ureter. The ureters were open even when the construct 
constricted. In all cases, the loopograms revealed a lumen which matched the size 
of the double-J stent (Figure 3c). One month post-grafting of the growth factor 
loaded scaffolds the lumen of the regenerating tissue had a red appearance, but 
this was not apparent three months post-grafting (figure 3d-g). All kidneys of the 
anastomosed ureters showed signs of hydronephrosis as evidenced by a whitish 
appearance, distension and dilatation of the kidney.
Figure 2. Overview of the surgical procedure. A. A flank incision next to the lower rib was used to 
approach the ureter. B. The ureter was localized and mobilized. C. Approximately 5 cm of the ureter 
was removed. D. A reinforced scaffold was placed over a 7 Fr. Double-J stent and sutured to the 
spatulated ends of the ureter.
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Figure 3. A. The urinary tract was harvested at the evaluation time point. A dilated ureter and 
hydronephrotic kidney was observed. B. Implantation location shows signs of tissue contraction and 
a small diverticulum. C. Loopogram three months after implantation of a scaffold without growth 
factors. Left: Proximal ureter. Right: Distal ureter. Arrow indicates the implantation site. The 
proximal ureter shows dilatation, while the distal ureter has a normal diameter. The implantation 
site shows narrowing of the lumen, leaving a negative imprint of the double-J stent. D-G. Macroscopic 
view of implantation area after dissection. Dotted lines indicate the lumen. D. One month, growth 
factor loaded. E. One month, no growth factors. F. Three months, growth factor loaded. G. Three 
months, no growth factors. 
Histology
Microscopic scoring was performed by two independent researchers (PdJ, PG, 
Table 1), focusing on the appearance of the urothelium and submucosa layers of 
the neo-ureteral tissue and the affected kidney. Figure 4 shows representative 
samples of the different groups. 
1M 3M
-GF +GF -GF +GF
Urothelium
Hyperplasia +/- +/- sp -
Squamous - sp sp sp
Intact +/- +/- ++ ++
Umbrella cells - +/- sp sp
Cell layers + + + +
Basal layer +/- + +/- +
Granulocytes sp +/- +/- +/-
Matrix present - - sp sp
Submucosa
ECM organization + + ++ ++
Neovascularization + + + +
Muscle ingrowth +/- +/- + +*
Myofibroblasts + +
Scaffold remnants +/- + +/- +/-
Granulocytes +/- +/- +/- +/-
Lymphocytes ++ ++ + ++
Macrophages +/- +/- +/- +/-
Giant cells + +/- +/- +/-
Kidney Hydronephrosis + +/- ++ +++
Table 1. Microscopic evaluation by two independent researchers (PdJ, PG). Urothelium was 
evaluated for being continuous, different cell types and possible abnormal cell growth. The 
submucosa was evaluated for organization of the tissue, including extracellular matrix organization, 
neovascularization and muscle ingrowth. Immune response was also studied. Finally, hydronephrosis 
of the kidney was evaluated. Scores between researchers were averaged. Scoring possibilities: - (not 
present), sp (sporadically present), +- (somewhat present), + (present), ++ (abundant), +++ (very 
abundant). +* indicates a higher scores than +, but lower than ++.
One month
By one month neo-ureters were intact with signs of regeneration. The control 
animals could not be analyzed due to extensive urine leakage.
Urothelium
A single layered urothelium was formed throughout most of the lumen of all neo-
ureters as judged by the presence of a pancytokeratin-positive cell layer regardless 
of the addition of growth factors. However, the urethral basal cell layer was more 
identifiable and occasionally umbrella cells were observed when growth factor 
loaded scaffolds were used. Sporadically squamous differentiation as well as more 
granulocytes were observed in the remodeled growth factor loaded scaffolds, 
albeit that the number of granulocytes was still rare. 
Submucosa
The extracellular matrix tended to align the lumen of the neo-ureter, irrespective 
of growth factor loading. Neo-vascularization was observed as well as the initiation 
of smooth muscle tissue ingrowth into the neo-ureter, but no differences were 
found between the groups. More collagen remnants were found in the growth 
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factor loaded scaffolds. Vicryl remnants were absent, and the immune response 
was similar in all animals, mainly consisting of lymphocytes and a limited influx 
of granulocytes and macrophages. Interestingly, more giant cells were observed 
in the group without growth factors, even though less collagen remnants were 
observed.
Figure 4. Histological overview of the regenerated ureter. A. Masson Trichrome stained example of 
a longitudinal section across the native ureter. Scalebar = 5mm B. Smoothelin staining at the 
anastomosis indicating development of new muscle. C. A moderate immune response with mainly 
lymphocytes. D. Pancytokeratin staining in the middle of the new tissue, indicating formation of 
urothelium. E. Native smooth muscle tissue, clearly showing normal muscle architecture. F. Immune 
response at one month. Mainly lymphocytes and some giant cells were found. By three months, this 
response became much weaker (C) G-I. Anastomosis at three months with growth factors, stained 
for pancytokeratin staining (G), desmin (H) and smoothelin (I). The luminal side was covered with a 
(multilayered) urothelium. Desmin positive cells were found further into the new tissue than 
smoothelin, indicating the formation of new and maturing muscles in the new tissue. Scalebars B-I 
= 500µm. * Indicates the lumen.
Kidney
All kidneys showed signs of hydronephrosis, although the kidneys connected 
to ureters with growth factor loaded constructs showed more intact glomeruli, 
tubuli and less fibrosis.
Three months
By three months the remodeled scaffold started showing tissue organization, as 
evidenced by a well-organized extracellular matrix, growing muscle layer and 
urothelial lining. 
Urothelium
The neo-ureter was completely covered by at least one single layer of cytokeratin-
positive cells. The basal cell layer was more clearly identifiable in the growth factor 
loaded group, but no difference was seen in the amount of umbrella cells. Also, 
the number of granulocytes and squamous cells was similar. Scaffold remnants 
were sporadically observed in both groups. 
Submucosa
In both groups the extracellular matrix was well organized in parallel with the 
lumen. Myofibroblasts were abundant in the neo-ureter, whereas the amount of 
neo-vascularization and scaffold remnants and the number of giants cells did not 
change in comparison to 1 month post-implantation. The inflammatory response 
appeared to be lower in the group treated without growth factors, as evidenced 
by reduced lymphocyte infiltration. Granulocyte and macrophage infiltration 
remained unchanged. More importantly, the smooth muscle layer had continued 
to develop and was growing into the regenerating new tissue as thin, stretched 
bundles. These smooth muscle bundles appeared more evident in the remodeled 
growth factor loaded scaffolds. 
Kidney
In contrast to one month post-grafting, hydronephrosis was more pronounced 
in all animals. Kidneys harvested from animals grafted with scaffolds without 
growth factors sporadically showed regions with intact tubuli and glomeruli, 
whereas with growth factor most of the normal morphology had disappeared.
Quantification of muscle ingrowth
Desmin stained slides were used to quantify the total ingrowth of the smooth 
muscle cells in the neo-ureter (figure 5). The mean length of the neo-ureter for 
the non growth factor loaded scaffolds and growth factor loaded scaffolds was 
11.9 ± 5.3 mm and 11.3 ± 4.6 mm respectively by three months. Average smooth 
muscle cell ingrowth was 2.0 ± 1.7 mm without growth factors and 2.4 ± 1.0 mm 
with growth factors from both sides. Relative to the total defect size, the ingrowth 
of muscle tissue was 32 ± 15 % without growth factors and 50 ± 34 % with growth 
factors. 
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Figure 5. Quantitative analysis. An example is shown for a sample from the three month group 
without growth factors. After background correction of the original image, the browns (desmin 
positive tissue) were extracted from the image. Next, the image was converted to binary. Finally, a 
profile plot of the pixel intensity along the construct was prepared. Intensity increases with increased 
desmin staining on the slide. The plots of all samples were used to quantitatively determine the 
total defect size and ingrowth of smooth muscle tissue from both sides (dotted lines). No significant 
influence on the use of growth factors was found.
Discussion
Compared to tissue engineering of the urethra, urinary bladder and urinary 
diversions, the ureter is relatively understudied. This might be attributed to a 
lower number of lesions, a positive-results bias or a lack of cross-over from 
other studies in which tissue engineered tubular organs were evaluated [23]. In 
addition, while several studies on tubular scaffolds were published, they were 
not specifically designed or evaluated for ureter repair or only for onlay repair. 
Nevertheless, there is a need for tissue engineered constructs when large defects 
need to be repaired.
The reinforced tubular scaffolds with predetermined mechanical properties, 
consisting of collagen and Vicryl mesh, with and without growth factors, were 
successfully anastomosed in pig ureters, creating a watertight and tension free 
neo-ureter. The introduction of a Vicryl mesh increased the mechanical strength 
of the tubular constructs up to 24 times greatly improving the surgical handling. 
More importantly, no early complications were seen in the animals as a result of 
inadequate stability, in contrast to tubular grafts that consisted of collagen only 
[18]. Consequently, all animals survived until the predetermined evaluation time 
points without major short-term complications.
Already after one month the Vicryl woven mesh was completely degraded 
without a major inflammatory response. This is in accordance with a recent 
study in which different polymers were tested for bladder regeneration and the 
collagen-Vicryl construct turned out to be the most suitable candidate construct 
for urogenital tissue engineering [24]. Although the clinical outcome of the 
scaffold grafting was favorable, the tubular scaffolds were created by manually 
tubularizing commercially available Vicryl meshes, which is not truly compatible 
with clinical practice. Therefore, Vicryl tubes should be produced by e.g. 
electrospinning, knitting and winding to achieve clinical implementation by high 
throughput production. This will also allow further fine-tuning of the construct 
properties.
To enhance the biological characteristics of the construct growth factors 
VEGF and bFGF were included to stimulate cell ingrowth from the adjacent 
native ureters and tissues [25]. The ingrowth of smooth muscle tissue and the 
formation of a urothelial barrier are the most important outcome measure as it 
plays a critical role in the peristalsis of the ureter and preventing tissue damage. 
Considering that a fully regenerated musculature is essential for the autonomous 
ureteral peristalsis, the presence of smooth muscle cells was quantified using 
image analysis of desmin stained slides. The objective image analysis allowed 
accurate determination of the total size of the remodeled implanted construct 
and the distance of smooth muscle ingrowth, both good indicators of construct 
contraction and muscle development in the newly formed tissue. The results 
indicated a trend towards increased muscle ingrowth when growth factors were 
added, however, the effect was not significant. Regarding the urothelium, we 
observed the formation of a partial and complete single layered urothelium at 
one month and three months respectively, regardless of growth factor loading. 
Interestingly, there was extensive graft shrinkage from 50 mm (implanted 
scaffold) to 11.9 ± 5.3 mm (no growth factors) and 11.3 ± 4.6 mm (growth factors), 
which may have played a role in the formation of hydronephrosis. Even though 
VEGF and bFGF should increase angiogenesis in acellular collagen scaffolds [26], 
our results did not reveal major differences between growth factor loaded and non 
growth factor loaded constructs even though the growth factor concentrations 
were supranatural: They were in the ng/mg range, compared to natural pg/
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mg range [27]. The lack of effect may be attributed to the delivery method. We 
used heparin sulfate to concentrate the heparin-binding growth factors bFGF 
and VEGF in the construct. Although heparin enabled effective loading of the 
scaffolds, the binding affinity may have been too low. The immediate urinary flow 
after implantation may have caused an unfavorable fast release. It is therefore 
likely that the growth factor exposure was limited and probably only effective 
during early stage wound healing. In order to accomplish sustained growth factor 
delivery, alternative delivery methods should be considered. These could include 
covalent binding to the collagen, hydrogels such as fibrin and polymeric carriers 
that protect the growth factors from the urinary flow [28-30].
To assess the functional outcome of the neo-ureters we investigated the 
kidneys at all evaluation points. Hydroureteronephrosis was observed in all pigs 
as a result of contraction of the inner lumen of the construct.  This led to urine 
retention in the upper urinary tract probably creating increased pressure in the 
kidney and proximal ureter. Three possible underlying causes may include: (i) A 
lack of peristaltic movement in the large scaffold after implantation. This may 
have prevented adequate urine transport past the regeneration area. Restoring 
the peristaltic activity may be key in prevention of urine retention in the upper 
urinary tract and regeneration of the muscular layers should be prioritized when 
attempting to regenerate the ureter. (ii) A potential tension on the anastomosis 
due to retraction of the ureter and contraction during wound healing. Replacing a 
certain sized defect by a longer scaffold may prevent this. (iii) Despite the favorable 
anatomy, the pig has unavoidable drawbacks in relation to this application; e.g. 
high growth rate, quadrupedal stance, high intra-abdominal pressures, and rapid 
wound healing with extensive fibrosis [31, 32]. The wound healing and contraction 
may have caused strictures around the double-J stent, disabling the urinary flow 
which ultimately resulted in hydroureteronephrosis. Alternatives to the pig model 
might include goats, sheep and dogs. These animals are more mobile than pigs, 
which may improve urine drainage. Also, their wound healing shows less fibrosis 
as supported by the fact that a stoma can be maintained e.g. in goats, but not in 
pigs [33, 34]. However, there will always be dissimilarities between the clinical 
and pre-clinical situation, e.g. local drain or a nephrostomy catheter could be 
placed more easily in the clinical situation to drain a urinoma or prevent large 
amounts of urine from passing the anastomosis site. 
The inflammatory response appeared to be more profound (chronic) when 
scaffolds were loaded with growth factors as indicated by a higher number of 
lymphocytes three months post-grafting. Additionally, scaffold remnants were 
observed. This difference in scaffold clearance and resulting inflammatory 
response may have been caused by the heparin sulfate. After the growth factors 
were washed out, the heparin may have protected the collagen from proteolysis 
due to its high negative charge delaying matrix degradation [35]. In agreement 
with our previous results, the presence of multinucleated giant cells indicated a 
foreign body response against the scaffold. This was probably due to the relatively 
high degree of cross-linking (49% (no heparin), 61% (heparin)) and the inclusion 
of the synthetic polymer [36, 37]. 
Until recently, the field of ureteral tissue engineering was dominated by tubular 
materials such as small intestinal submucosa, collagen, and Gore-Tex without 
cells. There is a trend towards the use of more smart and biodegradable materials 
with or without mesenchymal stem cells and/or pre-implantation techniques. 
The regenerative outcome of the tubular mechanically enhanced scaffolds 
studied here was comparable with previous studies in which collagen sponges and 
SIS patches were used [23]. Our results were superior to studies using Gore-Tex 
or acellular matrix, which did not induce cellular ingrowth [38, 39]. Inclusion of 
mesenchymal and adipose-derived stem cells seeded on a mechanically suitable 
degradable material has shown promising results for ureteral tissue engineering 
[40, 41]. Relatively large defects (> 3cm) were repaired in rabbits, which supports 
the current view that cellular constructs are required when repairing defects 
that warrant more than one cm tissue [42]. By incorporating these stem cells, 
strictures were avoided and smooth muscle cell and urothelial cell regeneration 
was greatly improved. 
Another potential method to reduce tissue contraction and thereby 
hydronephrosis may be to pre-implant the constructs in a different, highly 
vascularized tissue. This way the initial tissue contraction takes place in a more 
controlled environment, without the toxic influences of urine [43]. Recent studies 
have shown the successful application of these techniques by implanting the 
tissue in non-functional locations [44-46], as well as using them for ureteral 
repair afterwards [41, 47]. Pre-implantation before functional implantation may 
therefore improve the outcome of the reconstruction. 
Conclusions
Reinforced collagen-Vicryl scaffolds might be a suitable base material for ureteral 
repair and may provide an alternative to current graft tissue and reconstructive 
surgeries in the future. We observed both urothelial lining and smooth muscle cell 
ingrowth with an average of 32% and 50% of the total neo-ureter by three months, 
which indicates the potential of the material. However, a more appropriate animal 
model should be chosen to more adequately mimic the human situation, and a 
more suitable method for sustained delivery of growth factors in case of ureteral 
repair should be explored. 
Acknowledgements
We would like to acknowledge the European Urological Scholarship Programme 
(EUSP) for granting Vasileios Simaioforidis. We would also like to acknowledge 
the staff of the Radboud Central Animal Laboratory and the RIMLS MIC center 
for the SEM facilities. 
 7
Chapter 7 Ureteral reconstruction with reinforced collagen scaffolds in a porcine model
150 151
References
1. Orabi, H., et al., Tissue engineering of urinary bladder and urethra: advances from 
bench to patients. TheScientificWorldJournal, 2013. 2013: p. 154564.
2. Lumen, N., W. Oosterlinck, and P. Hoebeke, Urethral reconstruction using buccal 
mucosa or penile skin grafts: systematic review and meta-analysis. Urologia 
internationalis, 2012. 89(4): p. 387-94.
3. Dublin, N. and L.H. Stewart, Oral complications after buccal mucosal graft harvest for 
urethroplasty. BJU international, 2004. 94(6): p. 867-9.
4. Langer, R. and J.P. Vacanti, Tissue engineering. Science, 1993. 260(5110): p. 920-6.
5. Place, E.S., N.D. Evans, and M.M. Stevens, Complexity in biomaterials for tissue 
engineering. Nature materials, 2009. 8(6): p. 457-70.
6. Ma, P.X., Biomimetic materials for tissue engineering. Advanced drug delivery reviews, 
2008. 60(2): p. 184-98.
7. Freed, L.E., et al., Biodegradable polymer scaffolds for tissue engineering. Bio/
technology (Nature Publishing Company), 1994. 12(7): p. 689-93.
8. Guo, S. and L.A. Dipietro, Factors affecting wound healing. Journal of dental research, 
2010. 89(3): p. 219-29.
9. Bianco, P. and P.G. Robey, Stem cells in tissue engineering. Nature, 2001. 414(6859): p. 
118-21.
10. Dowling, R.A., J.N. Corriere, and C.M. Sandler, Iatrogenic Ureteral Injury. Journal of 
Urology, 1986. 135(5): p. 912-915.
11. Elliott, S.P. and J.W. McAninch, Ureteral injuries: External and iatrogenic. Urologic 
Clinics of North America, 2006. 33(1): p. 55-+.
12. Siram, S.M., et al., Ureteral trauma: patterns and mechanisms of injury of an uncommon 
condition. American Journal of Surgery, 2010. 199(4): p. 566-570.
13. Vakili, B., et al., The incidence of urinary tract injury during hysterectomy: A prospective 
analysis based on universal cystoscopy. Am J Obstet Gynecol, 2005. 192(5): p. 1599-
1604.
14. Ostrzenski, A., B. Radolinski, and K.M. Ostrzenska, A review of laparoscopic ureteral 
injury in pelvic surgery. Obstetrical & Gynecological Survey, 2003. 58(12): p. 794-799.
15. Peters, P.C. and A.L. Sagalowsky, Genitourinary trauma, in Campbell’s Urology, P.C. 
Walsch, et al., Editors. 1992, WP Saunders: Philadelphia, USA. p. 2571-2594.
16. Png, J.C. and C.R. Chapple, Principles of ureteric reconstruction. Curr Opin Urol, 
2000. 10(3): p. 207-12.
17. Kloskowski, T., et al., Tissue engineering and ureter regeneration: is it possible? Int J 
Artif Organs, 2013. 36(6): p. 392-405.
18. de Jonge, P.K., et al., Recent advances in ureteral tissue engineering. Curr Urol Rep, 
2015. 16(1): p. 465.
19. Pieper, J.S., et al., Preparation and characterization of porous crosslinked collagenous 
matrices containing bioavailable chondroitin sulphate. Biomaterials, 1999. 20(9): p. 
847-58.
20. Koens, M.J., et al., Organ-specific tubular and collagen-based composite scaffolds. 
Tissue Eng Part C Methods, 2011. 17(3): p. 327-35.
21. Burnette, W.N., “Western blotting”: electrophoretic transfer of proteins from sodium 
dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic 
detection with antibody and radioiodinated protein A. Anal Biochem, 1981. 112(2): p. 
195-203.
22. Worlein, J.M., et al., The Eighth Edition of the Guide for the Care and Use of Laboratory 
Animals (2011); Implications for Behavioral Management. American Journal of 
Primatology, 2011. 73: p. 98-98.
23. Simaioforidis, V., et al., Ureteral tissue engineering: where are we and how to proceed? 
Tissue Eng Part B Rev, 2013. 19(5): p. 413-9.
24. Sloff, M., et al., Novel tubular constructs for urinary diversion: A biocompatibility study 
in pigs. J Tissue eng Regen Med, 2015. Accepted for publication.
25. Nuininga, J.E., et al., Urethral reconstruction of critical defects in rabbits using 
molecularly defined tubular type I collagen biomatrices: key issues in growth factor 
addition. Tissue Eng Part A, 2010. 16(11): p. 3319-28.
26. Nillesen, S.T., et al., Increased angiogenesis and blood vessel maturation in acellular 
collagen-heparin scaffolds containing both FGF2 and VEGF. Biomaterials, 2007. 28(6): 
p. 1123-31.
27. Pallua, N., et al., Content of the growth factors bFGF, IGF-1, VEGF, and PDGF-BB in 
freshly harvested lipoaspirate after centrifugation and incubation. Plast Reconstr Surg, 
2009. 123(3): p. 826-33.
28. Richardson, T.P., et al., Polymeric system for dual growth factor delivery. Nat Biotechnol, 
2001. 19(11): p. 1029-34.
29. Lee, K., E.A. Silva, and D.J. Mooney, Growth factor delivery-based tissue engineering: 
general approaches and a review of recent developments. J R Soc Interface, 2011. 8(55): 
p. 153-70.
30. Wong, C., et al., Fibrin-based biomaterials to deliver human growth factors. Thromb 
Haemost, 2003. 89(3): p. 573-82.
31. Swindle, M.M. and A.C. Smith, Comparative anatomy and physiology of the pig. 
Scandinavian Journal of Laboratory Animal Science, 1998. 25: p. 11-21.
32. Dalmose, A.L., et al., Surgically induced urologic models in swine. J Invest Surg, 2000. 
13(3): p. 133-45.
33. Pugh, D.G. and N. Baird, Sheep & Goat Medicine. 2012, Elsevier Health Sciences.
34. Geutjes, P., et al., Tissue engineered tubular construct for urinary diversion in a 
preclinical porcine model. J Urol, 2012. 188(2): p. 653-60.
35. Smetana, K., Jr., et al., Macrophage recognition of polymers: effect of carboxylate 
groups. Journal of Materials Science: Materials in Medicine, 1993. 4(5): p. 526-529.
36. McNally, A.K. and J.M. Anderson, Macrophage fusion and multinucleated giant cells of 
inflammation. Adv Exp Med Biol, 2011. 713: p. 97-111.
37. Anderson, J.M., A. Rodriguez, and D.T. Chang, Foreign body reaction to biomaterials. 
Semin Immunol, 2008. 20(2): p. 86-100.
38. Baltaci, S., et al., Failure of ureteral replacement with Gore-Tex tube grafts. Urology, 
1998. 51(3): p. 400-3.
39. Sabanegh, E.S., Jr., J.R. Downey, and A.L. Sago, Long-segment ureteral replacement 
with expanded polytetrafluoroethylene grafts. Urology, 1996. 48(2): p. 312-6.
 7
Chapter 7 Ureteral reconstruction with reinforced collagen scaffolds in a porcine model
152 153
40. Zhao, Z.K., et al., Differentiation of adipose-derived stem cells promotes regeneration 
of smooth muscle for ureteral tissue engineering. Journal of Surgical Research, 2012. 
178(1): p. 55-62.
41. Liao, W., et al., Construction of Ureteral Grafts by Seeding Bone Marrow Mesenchymal 
Stem Cells and Smooth Muscle Cells Into Bladder Acellular Matrix. Transplantation 
Proceedings, 2013. 45(2): p. 730-734.
42. Chen, F., J.J. Yoo, and A. Atala, Experimental and clinical experience using tissue 
regeneration for urethral reconstruction. World Journal of Urology, 2000. 18(1): p. 67-
70.
43. Adamowicz, J., et al., Urine Is a Highly Cytotoxic Agent: Does It Influence Stem Cell 
Therapies in Urology? Transplantation Proceedings, 2012. 44(5): p. 1439-1441.
44. Xu, Y.D., et al., Autologous urothelial cells transplantation onto a prefabricated capsular 
stent for tissue engineered ureteral reconstruction. Journal of Materials Science-
Materials in Medicine, 2012. 23(4): p. 1119-1128.
45. Shi, J.G., et al., Tissue engineering of ureteral grafts by seeding urothelial differentiated 
hADSCs onto biodegradable ureteral scaffolds. Journal of Biomedical Materials 
Research Part A, 2012. 100A(10): p. 2612-2622.
46. Fu, W.J., et al., New ureteral scaffold constructed with composite poly(L-lactic acid)-
collagen and urothelial cells by new centrifugal seeding system. Journal of Biomedical 
Materials Research Part A, 2012. 100A(7): p. 1725-1733.
47. Zhang, J., et al., Ureteral Reconstruction Using Autologous Tubular Grafts for the 
Management of Ureteral Strictures and Defects: An Experimental Study. Urologia 
Internationalis, 2012. 88(1): p. 60-65.
 7
Chapter 7 Ureteral reconstruction with reinforced collagen scaffolds in a porcine model
Clinical protocol levels are 
required in laboratory animal 
surgery when using medical 
devices: Experiences with 
ureteral replacement surgery in 
goats
Paul de Jonge1, Marije Sloff1, Heinz-Peter Janke1, Barbara Kortmann1, Robert de 
Gier1, Paul Geutjes1, Egbert Oosterwijk1 and Wout Feitz1,2
1 Department of Urology, Radboud Institute for Molecular Life Sciences, Radboud 
university medical center, Nijmegen, The Netherlands
2 Amalia Children‘s Hospital, Radboud University Medical Center, Nijmegen, The 
Netherlands
Laboratory Animals, 2017; doi:10.1177/0023677217696520
156 157
Abstract
In large animal studies it is common to test medical devices that are or could 
also be used in patients. In this short report we describe the use of a ureteral 
J-stent for the evaluation of biodegradable tubular constructs for tissue 
reconstruction and the regeneration of the ureter in Saanen goats. Similar 
to a previous study in pigs, the ureteral J-stent was blindly inserted until 
some resistance was met. During evaluation of the goats after three months, 
we observed perforation of the renal cortex by the stent in four out of seven 
animals. These results indicated that blind stent placement was not possible 
in goats. In four new goats, clinical protocols were followed using X-ray 
and iodinated contrast fluids to visualize the kidney and stent during stent 
placement. With this adaptation the stents were successfully placed in the 
kidneys of all four goats with minimal additional effort. It is likely that other 
groups in other fields ran into similar problems that could have been avoided 
by following clinical protocols. Therefore, we want to stress the importance 
of following clinical protocols for the use of medical devices in animals to 
prevent unnecessary suffering and to reduce the number of animals needed. 
The application of new surgical techniques often requires evaluation in large 
laboratory animals to study its effectiveness and safety [1]. This is especially 
important in emerging fields such as tissue engineering and regenerative medicine. 
Tissue engineering aims to replace damaged organs and tissues by providing an 
alternative to autologous donor tissue or when standard surgical procedures are 
not possible [2]. One tissue engineering application that we are interested in, is 
replacing a long segment of the ureter with a tubular template after trauma or 
iatrogenic injury [3]. To prevent obstruction and kidney damage a ureteral stent 
is placed during surgery. This stent facilitates sufficient urine transport during 
the initial wound healing phase, which is accompanied by tissue contraction and 
scar formation. A “J” tail curl at the ends helps to keep the stent in the correct 
place [4]. In previous pig studies by our group, blind insertion of this stent into 
the proximal ureter/pyelum of the kidney was uneventful [5].
Recently, we have switched from young Landrace pigs to adult goats as our 
animal model for ureter reconstruction as the pigs were growing too fast (30 kg 
weight gain in 3 months). The rapid growth was also associated with fast wound 
healing as evidenced by fast skin closure in a stoma model, which may have 
influenced the regenerative outcome [6]. Despite the smaller overall size of the 
kidneys, pyelum and ureteral diameter, stenting was easily performed in cadaver 
material in preparation for the animal experiment. 
Initially, seven female Saanen goats weighing 50-70 kg were used in this 
study (based on power analysis). The study was approved by the Nijmegen Medical 
Center animal ethics committee (RU-DEC-2014-223) and all procedures were 
performed according to the Institute of Laboratory Animal Research guide for 
Laboratory Animals [7]. As catheterization was required, only female goats were 
used due to the curved urethra in male goats. The goats were housed in groups at 
the Institute’s farm with free access to water and a restricted diet. The goats were 
sedated per institute’s protocol prior to surgery and treated with analgesia and 
antibiotics afterwards. In all goats, the right ureter was located and mobilized 
through a flank incision. The ureter was cut, spatulated and the ureteral stent 
(4.7Fr/22-32 cm multi-length double J stent, Inlay Optima, Bard medical) was 
blindly inserted into the proximal ureter until some resistance was met as 
indicator for correct positioning. At that point, the guide-wire was removed to 
allow the proximal “J” to curl inside the pyelum. The tissue engineered template 
was positioned over the stent and the stent was then inserted into the distal 
ureter and urinary bladder. Finally, the tissue engineered template was connected 
to both spatulated openings of the ureter by end-to-end anastomosis. 
After three months the goats were sacrificed by an overdose of pentobarbital 
for evaluation. We noticed that the stents had perforated the kidney in 4/7 treated 
goats (Figure 1). In one case this resulted in a large urinoma on top of the kidney, 
while in the other three cases inflammation in the kidneys was noted. This 
clearly is an unwanted result; the wound healing results are unreliable and it may 
have caused unnecessary suffering for the goats.  Upon close inspection of the 
harvested tissue, it was obvious that the kidney tissue of the goats is much softer 
than that of pigs. This may have been missed in the cadaver study due to the room 
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temperature and the clotting of blood in the highly vascularized kidney, which 
may have increased the stiffness and resistance of the kidney. In addition, due to 
the small size of the renal calyces and pyelum, it was difficult for the “J” end of the 
stent to correctly curl inside the kidney. Therefore, it is more likely that the stent 
penetrated the kidney cortex during placement.
In routine human clinical practice, ureteral stents are almost always inserted 
using contrast fluids and X-ray guidance [7]. This allows visualization of the kidney 
and correct positioning of the stent inside the pyelum can be verified. In view 
of the observed kidney perforations we used iodinated contrast fluids (Xenetix) 
and C-arm X-ray guidance to position the ureteral stent in an additional four 
goats (Figure 2). By following this clinical protocol, we managed to successfully 
position the stent with a minimal increase in surgery time. When the ureteral 
stent penetrated the renal cortex (Figure 2(b)), we were able to adjust the position 
until the stent was correctly placed (Figure 2(c)). This way we avoided unwanted 
side effects and the regeneration of the ureter progressed as initially intended in 
the experiment. 
It is likely that other groups in different fields have similar experiences 
with the use of medical devices in their experiments. Based on our experience 
with ureteral stenting in goats, we advise to always use routinely applied clinical 
techniques when using medical devices in animals. This refinement is often fast 
and easy to perform and will prevent unnecessary suffering of animals and reduce 
the number of animals required due to technical failures.
Figure 1. a. Macroscopic view of the right kidney after perforation by the ureteral catheter (white 
arrowhead). b. X-ray scan without iodinated contrast fluids. Stent is clearly visible in the system and 
perforates the renal cortex (white arrowhead). c. X-ray scan with iodinated contrast fluids. Contrast 
fills the kidney calculi and the stent can be seen in the renal cortex outside of the calculi (white 
arrowhead).
Figure 2.a. X-ray scan of the right kidney (white circle) with iodinated contrast fluids to visualize 
the renal calculi before inserting the stent during surgery. b. After inserting the stent, the tip 
was perforating the renal cortex (white arrowhead), indicating a misplaced stent. c. The stent was 
retracted and repositioned. This time the stent curled nicely inside the calculi (white arrowhead) and 
no penetration of the renal cortex was seen, confirming successful stent placement.
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Abstract
Introduction: Repair of long ureteral defects often requires long graft tissues 
and extensive surgery. This is associated with complications including a lack 
of suitable tissue and graft site morbidity. Tissue engineering may provide an 
attractive alternative to the autologous graft tissues. In this study, ureteral 
repair using (pre-implanted) tubular collagen-Vicryl templates was evaluated 
in a new goat model. 
Materials and methods: Tubular templates were prepared from tubularized 
Vicryl meshes and 0.7% type-I collagen (length = 6 cm, inner diameter = 6 
mm, wall thickness = 3 mm). In total, twelve goats were used and evaluated 
after three months. Eight goats were implanted with the collagen-Vicryl 
templates and in four goats the templates were first pre-implanted in the 
subcutis and subsequently used as ureteral graft. 
Results: Template implantation was successful in 92% of the goats (11/12). 
During follow-up, 82% of the animals (9/11) survived without signs of 
discomfort. Two animals were sacrificed prematurely due to kidney 
perforation by the stent and urine leakage. Two other animals presented with 
stenosis of the neo-ureter due to stent migration. After pre-implantation, 
the templates were remodeled mostly to autologous tissue with similar 
mechanical characteristics as the native ureter. Goats grafted with pre-
implanted templates presented with predominantly healthy kidneys, while 
the goats grafted with the collagen-Vicryl templates presented with fibrotic 
and inflamed regions in the kidneys. 
Conclusion: The use of pre-implanted tissue templates showed favorable 
results compared to direct functional implantation of the templates. Partial 
remodeling towards autologous tissue and similar mechanical characteristics 
likely improved the integration in the ureteral tissue. Pre-implantation of 
tissue engineered templates should therefore be considered when two-stage 
procedures using a nephrostomy catheter are indicated or when planning 
allows for additional time to treatment.
Introduction
Ureteral trauma can lead to severe problems, including urinoma, sepsis and 
even kidney loss. While these traumas are relatively rare, they do account for 
approximately 3% of all urogenital traumas. Iatrogenic injury is the main cause, 
with hysterectomy during gynecological surgeries accounting for about 73% of 
all injuries to the ureter [1-3]. Primary repair is often possible when the injury is 
recognized, but in 33-88% of the cases injury is not recognized during the surgery 
[4, 5]. Depending on the time between treatment, the type, and the location of the 
injury, different treatment options are available. Primary end-to-end anastomosis 
is often only possible shortly after the injury or in very short distance injuries. 
More severe damage requires extensive and challenging procedures, such as a 
Boari flap, transureteroureterostomy or ileal interposition [6, 7]. Especially when 
donor tissue like the ileum is used, the complication rate is as high as 40% and 
almost all patients need an intervention to treat obstruction after surgery [8], 
emphasizing the need for alternative approaches. Tissue engineering may be a 
new source of graft tissue, but in the past 3 decades failure rates have been high, 
despite the use of many biomaterials and approaches [9]. 
Collagen is a biomaterial of interest because of its availability, plasticity and 
low antigenicity [10]. In previous studies in pigs we evaluated tubular templates 
prepared from collagen only, with or without cells and reinforced collagen-
Vicryl tubes, with or without growth factors to repair ureteral deficits. While 
regeneration of the ureter was possible, the kidneys suffered from the procedure. 
Rapid wound healing and strong fibrosis were hypothesized to be the main factors 
causing hydronephrosis [11, 12]. Interestingly, in a recent urostomy study in pigs 
pre-implanted and subsequently translocated templates showed a more favorable 
outcome than direct implantation [13]. In the current study, mature goats with a 
slower wound healing process were used to study (pre-implanted) collagen-Vicryl 
templates for ureter tissue engineering. 
Methods
Template preparation
Vicryl meshes (Ethicon) were tubularized around a stainless-steel mandrel with 
Vicryl sutures (Ø = 8 mm). Tubular 0.7% (w/v) type I collagen (Collagen solutions, 
Eden Praire, USA) –Vicryl templates (l = 7 cm, lumen Ø = 6 mm, wall = 3 mm) were 
prepared as follows: homogenized collagen was cast in a cylindrical mold. Next, 
the Vicryl mesh and a 6 mm stainless-steel mandrel was inserted, followed by 
freezing and freeze-drying as described [14]. After lyophilization the collagen was 
cross-linked using Carbodiimide [15] and final hybrid templates were lyophilized 
a second time and packaged in blisters. All production steps were performed in 
a commercial cleanroom (EMCM). The final product was sterilized by ethylene 
oxide (Synergy Health). The degree of cross-linking was determined using a 
2,4,6-trinitrobenzene sulfonic acid assay in triplicate. Template ultra-structure 
was characterized by scanning electron microscopy (JEOL JSM-6310). 
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Mechanical characterization
Tensile ring tests were performed to investigate the (bio)mechanical properties 
of the hybrid templates and autologous tissues. Wet ring specimens of l: 10mm 
of hybrid templates (N = 4), pre-implanted templates (N = 4) and midsections of 
goat ureteral tissue (N = 9) were mounted between customized hooks (hook-to-
hook distance: 6mm) of a tensile tester (Z2.5 TN, Zwick/Roell) equipped with a 
2.5kN load cell. Test specimens were pre-conditioned radially (50mm/min) by 
stretching 10x to 50% strain. Afterwards, uniaxial load was applied until rupture. 
Force/displacement data were normalized to the test specimen dimensions to 
compute a stress/strain curve. The initial elastic modulus was calculated from 
the first slope of the curve. The ultimate tensile strength (UTS) and maximum 
strain at break were defined as the maximum stress and strain before failure. Data 
analysis was performed with SPSS statistics version 22 (IBM) using the one-way 
ANOVA test and Bonferroni post hoc analysis. P<0.05 was considered statistically 
significant. 
Animals
The Nijmegen Medical Center animal ethics committee approved the study 
protocol (RU-DEC-2014-223). All procedures were performed according to the 
Institute of Laboratory Animal Research guide for Laboratory Animals [16]. In 
total twelve mature female Saanen goats, weighing 45-65 kg were used. They were 
housed in groups at the Institute’s farm with a restricted diet and free access 
to water. The goats were transported to the animal laboratory the day before 
every procedure. Eight goats received a hybrid template, while in four other 
goats the template was pre-implanted in the subcutis first. Goats were sedated 
trough intravenous injection of 5 µg/kg medetomidine (Domitor, Orion Pharma) 
and 5 µg/kg propofol (Fresenius Kabi). Goats were intubated and anesthesia was 
maintained using 1,5% isoflurane (Pharmachemie). Subcutaneous injection of 0,5 
mg/kg Meloxicam (Novem, Boehringer Ingelheim) was administered for analgesia. 
Intravenous antibiotics were administered (Amoxicilline, 10 mg/kg, Aurobindo 
pharma). During recovery, intra muscular injections of 5 µg/kg buprenorphine 
(AST Farma), 10.000 IE/kg benzylpenicilline (Procpen 30, DoPharma) and 15 
µg/kg atipamezole (Orion Pharma) were given. Post-operatively, subcutaneous 
injection of 0,5 mg/kg Meloxicam and intramuscular injection of 10.000 IE/kg 
benzylpenicilline was given daily for three days. 
Surgical procedure
Pre-implantation
One month before ureter reconstruction, two hybrid templates (l = 7 cm) were 
subcutaneously implanted in four goats on the right flank. A 5-cm incision was 
made approximately 3 cm from the lower rib. Two separate pockets were created 
by spreading the subcutaneous tissue using long scissors towards the hind leg. 
Hybrid templates were placed over a silicon tube (Ø = 6 mm) and were fixed to 
the tube using a 2-0 Vicryl suture on both ends. Next, the hybrid templates were 
placed and fixed in the pockets using 2-0 Vicryl sutures. Finally, the subcutis and 
skin were closed using 2-0 Vicryl sutures. 
Functional implantation
A flank incision (l = 10 cm) was made in the right flank of the goats 5 cm below 
the spine in parallel to the lower rib next to the pre-implantation scar. The 
muscle layers were separated in the direction of the muscle fibers to enter the 
retroperitoneal space. The ureter was located and mobilized. Next, the ureter was 
stripped from the fatty layers for better visibility. The ureter was transected 5-11 
cm from the kidney and both ends were spatulated. Hybrid templates or pre-
implanted templates (l = 6 cm) were placed over a 4.7 Fr/22-32 cm multi-length 
double-J stent (Inlay Optima, Bard medical) followed by stent positioning in the 
kidney and bladder. Following technical complications related to stent placement, 
a C-arm was used to determine correct positioning of the stent in the kidneys for 
the final five goats [17]. A tension free anastomosis was created using 6-0 monocryl 
sutures (Ethicon). A 6-0 prolene suture placed in the ureter approximately 1-cm 
from the anastomosis site on both sides as markers. Fibrin glue (Tisseel, Baxter) 
was used to cover the anastomosis sites and templates to prevent leakage. The 
individual muscle layers, the subcutis and skin were closed (2-0 Vicryl). The 
animals were followed closely for signs of discomfort. 
Blood tests
After observed technical complications, blood creatinine, CRP and sedimentation 
was analyzed in four animals to detect possible kidney failure and inflammation. 
Samples were retrieved pre-operatively, post-operatively and then weekly for up 
to one month. Samples were analyzed by the clinical chemistry lab of the Radboud 
university medical center. 
Evaluation
The goats were sacrificed by an overdose of intravenous pentobarbital 
approximately three months after the implantation procedure to study medium-
term tissue regeneration. The urinary tract was harvested and evaluated 
macroscopically. Next, the size of the internal ureter and kidney morphology was 
investigated by radiology using iodinated contrast fluid (Iomeron 300, Bracco 
Imaging). Finally, tissue specimens of the neo-ureter, ureters, kidneys and urinary 
bladder were harvested for histological evaluation. Specimens were fixed in 4% 
(v/v) formaldehyde in PBS (Boom) overnight and embedded in paraffin. The goats 
in which kidney perforation occurred with extensive urine leakage had unreliable 
tissue regeneration results and were omitted from further analysis (Table 1). 
Immunohistochemistry
Sections of 4 µm were cut and stained with hematoxylin (Klinipath) and eosin 
(Merck) for morphological analysis. Pre-implanted templates and neo-ureter 
tissue after grafting were stained for pancytokeratin (AE1/AE3, Fisher Scientific), 
desmin (33, Biogenix), α-smooth muscle actin (αSMA, 1A4, Biogenix) and Verhoeff/
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Masson’s Trichrome (Pathology, Radboudumc). In brief, antigen retrieval was 
performed using microwave treatment in sodium citrate (pH 6, 10 min boiling 
and subsequently cooling to RT) for pancytokeratin immunohistochemistry 
(IHC). Peroxidase activity was blocked by incubation in 1% (v/v) H2O2 (Merck) 
in PBS for 30 min. Next, sections were incubated with 10% (v/v) rabbit serum 
for 10 min, followed by 1 h incubation with primary antibodies: pancytokeratin 
(1:400), desmin (1:200), αSMA (1:16000). Secondary antibody (polyclonal rabbit 
anti-mouse immunoglobulins/HRP (Dako) was incubated for 30 min (1:100). 
Then, 3,3’-Diaminobenzidine (bright-DAB, Immunologic) was used to develop 
the slides. Finally, sections were counterstained using hematoxylin for 5s. All 
antibodies and goat serum were diluted in PBS containing 1% (v/v) bovine serum 
albumin (BSA, Sigma-Aldrich). 
Qualitative analysis 
Pre-implanted tissues were investigated for template degradation, inflammation 
and vascularization. Kidney sections were investigated for the occurrence of 
inflammation and fibrosis, morphology of tubuli and glomeruli. Neo-ureter 
sections were investigated for template degradation, tissue development (muscle, 
urothelium, vasculature), fibrosis and inflammation. All sections were evaluated 
in a blinded fashion. 
Results
Templates
Structure 
SEM analysis showed highly porous honeycomb structures typical for collagen-
based templates (Figure 1). The tubularized Vicryl meshes were successfully 
integrated in the collagen as evidenced by collagen attaching to the Vicryl. 
Carbodiimide cross-linking stabilized the collagen resulting in a 49% free amine 
group reduction. After pre-implantation, the templates were remodeled by host 
tissue and well vascularized. Collagen and Vicryl were partially degraded and a 
dense tissue layer formed on the inside and outside surrounding the remnants of 
the templates (Figure 1). 
Mechanical properties
All templates showed a ‘’J’’ shaped stress-strain curve in tensile ring tests 
(supplementary figure 1). Templates showed an initial high elasticity followed by an 
uprising slope indicative of a rising stiffness before total failure. Hybrid templates 
showed a significantly higher initial (p<0.0001) and ultimate tensile strength 
(p<0.0001) compared to the other templates (figure 2). The difference between the 
initial tensile strength and ultimate tensile strength of pre-implanted templates 
and goat ureteral segments was not significant (p=0.8 and p=0.13 respectively). 
Figure 1. Material characterization. A. Macroscopic view of a dry collagen-Vicryl template. B. Cross-
sectional scanning electron microscopy image of a collagen-Vicryl template showing an open porous 
structure and good integration of the Vicryl mesh (arrow head). Scalebar = 500µm. C. Templates were 
placed over a silicon mandrel before pre-implantation in the subcutis. D. Macroscopic view after 
one month of pre-implantation in the subcutis showing tissue encapsulation and vascularization. E. 
Histological cross-section of pre-implanted template. Scalebar = 2000µm. F. Magnification of cross-
sectional overview. * indicates the Vicryl mesh. X indicates collagen remnants. A dense tissue layer 
formed on the inside, sealing the template. Scalebar = 250µm. 
Animal surgery
Success rate of the implantation procedure was 92% (11/12). One animal was 
sacrificed during surgery as the ureter wall ruptured and the ureter retracted, 
resulting in a defect >10 cm that could not be repaired. During follow-up, 82% 
(9/11) survived without signs of discomfort. Two animals were sacrificed before 
the predetermined endpoint of three months due to rapid weight loss and signs 
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of discomfort. Upon necropsy kidney perforation by the stent and subsequent 
urine leakage from the kidney was observed. In two animals that reached the 
endpoint, the stent had perforated the kidney. One animal belonged to the group 
with hybrid templates, while the other received a pre-implanted template. Based 
on this experience, x-ray guided stent placement was introduced in the next five 
animals, after which no kidney perforation was observed. Two of these animals 
presented with stent migration which led to stenosis of the neo-ureter. Five 
animals had no major complications. Results per animal are summarized in table 
1. Figure 3 shows the templates during implantation surgery. 
Figure 2. Biomechanical analysis. A. Initial modulus of collagen-Vicryl hybrid template, pre-
implanted template and native tissue. Hybrid templates show a significantly higher initial modulus 
compared to pre-implanted (p<0.0001) and native tissue (p<0.0001). No difference was found 
between pre-implanted templates and native tissue (p=0.8). B. Ultimate tensile strength and strain 
at the failure point of collagen-Vicryl hybrid template, pre-implanted template and native tissue. 
Hybrid templates show a significantly higher ultimate tensile strength compared to pre-implanted 
(p<0.0001) and native tissue (p<0.0001). No difference was found between pre-implanted templates 
and native tissue (p=0.13). No differences were found regarding strain at failure for any of the 
specimens (p>0.99). 
Macroscopic evaluation
The appearance of the right kidneys was normal, regardless of the treatment 
modality (Figure 4A-B, F). The shape, size and color resembled the control 
kidneys, albeit that small patches of dyschromia were observed sporadically, as 
well as a slightly thicker renal capsule. The proximal ureter was slightly dilated 
and the area of implantation showed signs of fibrosis in the animals grafted with 
the hybrid templates. The size of the regenerated tissue was approximately 1.5 cm 
in both groups compared to the 6 cm graft. Small diverticula were observed at 
the anastomosis site when hybrid templates were used. Additionally, when hybrid 
templates were used collagen remnants were found between the ureteral stent 
and the new tissue which resembled a gel like substance. When pre-implanted 
templates were used remnants were absent.
X-ray evaluation 
No differences between the appearance of the right kidney connected to the 
reconstructed ureter and the left (control) kidney was observed (Figure 4). The 
calyces were clearly distinguishable. The pyelum and proximal ureter were slightly 
dilated on the treated side. Small diverticula were observed in the group without 
pre-implantation at the anastomosis site. 
Figure 3. Surgical procedure. A. Implantation of a collagen-Vicryl template between two spatulated 
ureter ends. B. Implantation of template between two spatulated ureter ends after pre-implantation.
Blood analysis 
Blood creatinine was slightly elevated (95.0 ± 8.5 µmol/l) in all analyzed animals 
as a result of the surgery. Creatinine levels returned to normal (64.8 ± 10.1 µmol/l, 
based on pre-operative measurements) in all goats in the week thereafter. No 
changes were found for CRP (<1 mg/l) and sedimentation rate (2 mm/hour) at any 
time point in any of the analyzed goats.
Histological evaluation
Three goats could be included for histology in both groups (table 2). The other 
goats had compromised regeneration due to complications with stenting (kidney 
perforation or stent migration), which resulted in excessive urine leakage (kidney 
perforation) or stenosis of the ureter (stent migration) and were therefore excluded 
from further analysis. 
Hybrid template group
Kidneys
Morphological analysis of the kidney connected to the reconstructed ureter 
revealed fibrotic areas and inflammation in the renal cortex (Figure 4G). In two 
goats, fibrosis and inflammation was also observed near the calyces.
Neo-ureter
Integration of the hybrid template was poor (Figure 5A). Although only a small 
amount of template remnants was found in the neo-ureter, many remnants 
were found extruded in the ureteral lumen (Figure 5B). The newly formed 
tissue consisted mainly of connective tissue with α-sma positive cells in parallel 
alignment to the ureteral lumen and extensive vascularization. Epithelial lining 
was absent as judged by the lack of panCK-positive cells (Figure 5C,D). Smooth 
muscle cell ingrowth was limited to the anastomosis sites as evidenced by the 
minimal amount of desmin positive cells growing into the neo-ureter (Figure 
5E,F). A small diverticulum (<1 cm2) was observed in two animals near the 
anastomosis site.
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Figure 4. Evaluation overview 3 months after implantation. A. Macroscopic view of the urological 
tract after implantation of a collagen-Vicryl template in the right ureter. B. Macroscopic view of 
the urological tract after implantation of a pre-implanted template in the right ureter. C. X-ray 
image of the ureter and kidney after implantation of a collagen-Vicryl template. Arrowhead shows 
implantation site. D. X-ray image of the ureter and kidney after implantation of a pre-implanted 
template. Arrowhead shows implantation site. E. X-ray image of left ureter and kidney (control). F. 
Cross-section of both kidneys after implantation of a pre-implanted template showing no differences 
between treated and control kidney. G. Histological view of the kidney after implantation of a 
collagen-Vicryl template showing influx of inflammatory cells (X). H. Histological view of the kidney 
after implantation of a pre-implanted template showing healthy kidney tissue. G,H. scalebar = 250 
µm. 
 
Figure 5. Histological analysis 3 months after implantation of a collagen-Vicryl template. A. Overview 
of the regenerated area. Newly formed tissue can be found between dashed lines. * indicates a small 
diverticulum. X indicates template remnants. Scalebar = 5 mm. B. Collagen remnants were found 
in the lumen of the ureter as indicated by X. C. PanCK staining of normal tissue. D. PanCK staining 
in the regenerated tissue. PanCK-positive cells were sparsely present. E. Desmin staining at the 
anastomosis site (native tissue right of dashed line, new tissue left of dashed line) indicates limited 
muscle cell ingrowth. F. Masson-Verhoeff staining confirms limited muscle ingrowth as muscle 
morphology changes from spindle like bundles in the native tissue (right) to small patches in the 
new tissue (left). Muscle and epithelium in red, ECM in green. B-F. Scalebar = 250 µm.
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Pre-implantation group
Kidneys 
Morphologically the kidney tissue on the treated side was similar to native 
kidney tissue of the untreated side (Figure 4H). The tubuli and glomeruli were 
almost completely intact and changes were minimal. In one goat slight influx 
of inflammatory cells was observed in the renal cortex. In another goat slight 
inflammation in one of the calyces was seen, while in the third goat inflammation 
was absent. 
Neo-ureter
The pre-implanted template integrated well in the ureter. The newly formed ureter 
tissue had a similar wall thickness compared to the native ureter (Figure 6A). 
Smooth muscle tissue ingrowth was limited to the anastomosis sites as evidenced 
by minimal desmin positive cell ingrowth into the neo-ureter (Figure 6C). A 
single layered epithelium was observed throughout most of the luminal area as 
indicated by panCK-positive cells (Figure 6B,D). The new tissue consisted mainly 
of connective tissue with α-sma positive cells and extensive vascularization 
(Figure 6E). There was mild inflammation, particularly around the anastomosis 
site. The template was mostly degraded as evidenced by the minimal collagen and 
Vicryl remnants (table 2). No diverticulum was observed in any of the animals. 
Discussion
There is a clear need for alternative treatments options for large ureteral defects 
when conventional surgical techniques cannot be used or donor tissues is not 
available. Nevertheless, ureteral tissue engineering is an understudied field in 
urogenital tissue engineering, possibly due to the lower number of patients in 
need for alternatives compared to other urogenital tissues such as the urethra or 
the urinary bladder [18, 19]. In this study we repaired an induced ureteral defect 
with (pre-implanted) hybrid templates in adult goats. The main goal of a ureter 
reconstruction is to salvage the disconnected kidney to prevent kidney loss and 
restore the urinary tract. Therefore, the most important outcome of successful 
ureteral reconstruction is minimal kidney damage. In this large animal model we 
show that ureteral defect can be repaired with a tissue engineering approach (6 
cm long implant) with presumably minimal damage to the kidney. After ureteral 
repair with either direct grafting of a hybrid template or after pre-implantation of 
this template, blood creatinine levels returned to pre-operative values within one 
week and remained stable afterwards, indicating good overall kidney function. 
However, morphological analysis of the tissue with a pre-implanted template 
were superior to direct implantation of hybrid templates, suggesting that pre-
implantation followed by translocation is superior. Although blood creatinine 
levels normalized and histological analysis showed minimal kidney damage after 
reconstruction, future studies should include comprehensive functional studies, 
e.g. measure the glomerular filtration rate (GFR) to show potential differences in 
clearing rate between the left and right kidney [20]. Moreover, although follow-up 
Figure 6. Histological analysis 3 months after implantation of a pre-implanted template. A. Overview 
of the regenerated area. Newly formed tissue can be found between dashed lines. Scalebar = 5 mm. 
B. PanCK staining at the anastomosis site. Morphology changed from normal to single layered 
epithelium. C. Desmin staining at the anastomosis site indicates limited muscle cell ingrowth. D. 
PanCK staining in the regenerated tissue. A single layered epithelium was observed throughout most 
of the regenerated tissue. E. αSMA staining in the regenerated tissue shows alignment of fibroblasts 
in the extracellular matrix. B-E. Scalebar = 250 µm.
of animals was twelve weeks, a reasonably long follow-up period, true long-term 
follow-up of at least one year is needed to adequately mimic the human situation. 
Pre-implantation procedures have previously shown promising results in 
tissue engineering, including ureteral reconstruction [21, 22]. Here we show the 
ability to create tissue tubes that were well vascularized and in which the initial 
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inflammatory response had largely subsided before functional implantation. 
Through the insertion of a silicon mandrel the lumen was maintained during 
this initial remodeling, preventing a change in template dimensions. After 
functional implantation, the connective tissue that covered the lumen of the 
neo-tissue templates may have protected the surrounding tissue from the toxic 
urine, preventing absorption of urine into the template remnants [23]. Without 
pre-implantation, the template can act as a sponge that absorbs urine which may 
have a detrimental effect on the remodeling process by constantly irritating the 
surrounding tissue. After the remodeling phase the pre-implanted tissue had 
similar mechanical properties compared to the native ureter in contrast to the 
significantly stiffer hybrid templates. This higher stiffness may have led to a 
compliance mismatch that can cause local tissue stiffening and disturbed flow 
profiles resulting in hyperplasia [24, 25]. The combination of a high stiffness and 
constant exposure of the regenerating tissue to urine may have contributed to 
the formation of diverticula, extrusion of collagen into the lumen and slower 
remodeling of the tissue. The compromised regeneration may also influence 
kidney outcome due to higher ureteral pressures. 
Interestingly, collagen sponges have previously shown good results in 
other urogenital tissue engineering applications, such as urethra replacement 
and urinary bladder augmentation [26, 27]. This difference may be explained 
by constant exposure to urine in the ureter compared to intermittent exposure 
during voiding in the urethra and folding of the urinary bladder when empty. 
Moreover, the anatomical characteristics are different, e.g. the urethra is tightly 
surrounded by fascia and other penile tissues while the ureter is positioned freely 
in the retroperitoneal space which makes it susceptible to mechanical stresses. 
Here we studied adult goats instead of young pigs and showed a much more 
favorable outcome regarding the kidney. Due to their size, we previously used 
young pigs (3-6 months old) for ureter reconstruction studies [28]. Their fast 
growth and rapid wound healing may have negatively impacted the remodeling 
of the neo-ureter and resulted in hydronephrosis; an undesired outcome. Adult 
goats have a similar size and weight to these young pigs, but have the wound 
healing capacity of adult animals. By using adult animals, we may have better 
mimicked adult human tissue regeneration. 
Smooth muscle tissue regeneration in the neo-ureter was limited compared 
to pigs. While smooth muscle tissue is important for ureter functionality, the 
regeneration of this tissue after ureteral defect repair may not be as important 
as initially hypothesized when only part of the contractile function is lost. In 
addition, the presence of the double-J catheter may have made muscle regeneration 
redundant as it guarantees urine flow. Therefore, this catheter should be removed 
when studying longer time points. In the current study, the pre-implanted tissue 
tube functioned adequately as ureter segment to maintain kidney integrity and 
function within the study time frame. Interestingly, graft shrinkage from 6 to 
1.5 cm length had no detrimental effect on the kidneys. This may be related to 
the greater mobility of goats compared to pigs which may improve the flow of 
urine. In general, the goat model appears to be a good alternative to the pig model 
when studying ureter reconstruction. However, the size of the kidney pyelum 
and the inner diameter of the ureter are much smaller than that of humans 
and pigs. In contrast to previous studies, no resistance was noticed when the 
guidewire perforated the kidney. Consequently, double-J stent positioning was 
problematic in some cases, necessitating the use of human clinical protocol levels 
using X-ray and iodinated contrast fluids [17]. Additionally, the small size of the 
ureter complicated anastomosis of the relatively oversized templates to the ureter. 
Smaller diameter templates may need to be considered for future experiments to 
better match template dimensions to the ureter. 
While pre-implantation of the templates showed promising results for ureteral 
repair, this method has a major drawback: In general, this type of reconstruction 
is mostly unforeseen and requires fast intervention. I.e., it may not be possible 
to pre-implant a template and wait for one month in all patients. Nevertheless, 
for severe and long ureteral defects a two-stage repair using a percutaneous 
nephrostomy catheter to drain urine during is a standard treatment option [29]. 
The time between the two stages could be used for pre-implantation. However, 
investigating this method is complicated in animals due to their mobility which 
may lead to early elimination of the nephrostomy catheter. Alternatively, different 
templates that do not require pre-implantation to be watertight and mimic the 
native tissue properties could provide a solution. Decellularization of native 
tissues may be an attractive alternative to investigate [30-32]. In addition to being 
watertight and having similar tissue properties, beneficial bio-active compounds 
such as growth factors may remain in the tissue to stimulate wound healing and 
remodeling.  
Conclusion
Ureteral reconstruction using pre-implanted hybrid templates is superior to 
direct grafting in a goat model. This study showed that matching mechanical 
characteristics to the native tissue is superior to using stiffer templates and leads 
to better wound healing and tissue regeneration. Pre-implantation of tissue 
engineered templates should be considered when two-stage procedures are 
indicated or when the surgery can be planned. Finally, functional kidney analysis 
should be performed and longer follow-up should be studied to determine long-
term outcome of ureteral defect repair using tissue engineering.
Acknowledgements
We would like to acknowledge the staff of the Radboud Central Animal Laboratory 
and the RIMLS MIC center for their support and the use of their facilities. 
 9
Chapter 9 Ureteral reconstruction in goats using tissue engineered templates and subcutaneous pre-implantation
176 177
References
1. Dowling, R.A., J.N. Corriere, and C.M. Sandler, Iatrogenic Ureteral Injury. Journal of 
Urology, 1986. 135(5): p. 912-915.
2. Elliott, S.P. and J.W. McAninch, Ureteral injuries: External and iatrogenic. Urologic 
Clinics of North America, 2006. 33(1): p. 55-+.
3. Siram, S.M., et al., Ureteral trauma: patterns and mechanisms of injury of an uncommon 
condition. American Journal of Surgery, 2010. 199(4): p. 566-570.
4. Ostrzenski, A., B. Radolinski, and K.M. Ostrzenska, A review of laparoscopic ureteral 
injury in pelvic surgery. Obstetrical & Gynecological Survey, 2003. 58(12): p. 794-799.
5. Vakili, B., et al., The incidence of urinary tract injury during hysterectomy: a prospective 
analysis based on universal cystoscopy. Am J Obstet Gynecol, 2005. 192(5): p. 1599-
604.
6. Peters, P.C. and A.L. Sagalowsky, Genitourinary trauma, in Campbell’s Urology, P.C. 
Walsch, et al., Editors. 1992, WP Saunders: Philadelphia, USA. p. 2571-2594.
7. Png, J.C. and C.R. Chapple, Principles of ureteric reconstruction. Curr Opin Urol, 
2000. 10(3): p. 207-12.
8. Armatys, S.A., et al., Use of ileum as ureteral replacement in urological reconstruction. 
J Urol, 2009. 181(1): p. 177-81.
9. Kloskowski, T., et al., Tissue engineering and ureter regeneration: is it possible? Int J 
Artif Organs, 2013. 36(6): p. 392-405.
10. Cen, L., et al., Collagen tissue engineering: Development of novel biomaterials and 
applications. Pediatric Research, 2008. 63(5): p. 492-496.
11. Dalmose, A.L., et al., Surgically induced urologic models in swine. J Invest Surg, 2000. 
13(3): p. 133-45.
12. Swindle, M.M. and A.C. Smith, Comparative anatomy and physiology of the pig. 
Scandinavian Journal of Laboratory Animal Science, 1998. 25: p. 11-21.
13. Sloff, M., et al., Tubular Constructs as Artificial Urinary Conduits. The Journal of 
urology, 2016. 196(4): p. 1279-86.
14. Koens, M.J., et al., Organ-specific tubular and collagen-based composite scaffolds. 
Tissue Eng Part C Methods, 2011. 17(3): p. 327-35.
15. Pieper, J.S., et al., Development of tailor-made collagen-glycosaminoglycan matrices: 
EDC/NHS crosslinking, and ultrastructural aspects. Biomaterials, 2000. 21(6): p. 581-
93.
16. Worlein, J.M., et al., The Eighth Edition of the Guide for the Care and Use of Laboratory 
Animals (2011); Implications for Behavioral Management. American Journal of 
Primatology, 2011. 73: p. 98-98.
17. Jonge, P.K.J.D.d., et al., Clinical protocol levels are required in laboratory animal surgery 
when using medical devices: experiences with ureteral replacement surgery in goats. 
Laboratory Animals. 0(0): p. 0023677217696520.
18. Simaioforidis, V., et al., Ureteral tissue engineering: where are we and how to proceed? 
Tissue Eng Part B Rev, 2013. 19(5): p. 413-9.
19. Versteegden, L., et al., Tissue Engineering of the Urethra: A Systematic Review and 
Meta-analysis of Preclinical and Clinical Studies. European urology, 2017.
20. Stevens, L.A., et al., Assessing kidney function--measured and estimated glomerular 
filtration rate. The New England journal of medicine, 2006. 354(23): p. 2473-83.
21. Liao, W., et al., Construction of Ureteral Grafts by Seeding Bone Marrow Mesenchymal 
Stem Cells and Smooth Muscle Cells Into Bladder Acellular Matrix. Transplantation 
Proceedings, 2013. 45(2): p. 730-734.
22. Zhang, J., et al., Ureteral Reconstruction Using Autologous Tubular Grafts for the 
Management of Ureteral Strictures and Defects: An Experimental Study. Urologia 
Internationalis, 2012. 88(1): p. 60-65.
23. Adamowicz, J., et al., Urine is a highly cytotoxic agent: does it influence stem cell 
therapies in urology? Transplantation proceedings, 2012. 44(5): p. 1439-41.
24. Crapo, P.M. and Y. Wang, Physiologic compliance in engineered small-diameter arterial 
constructs based on an elastomeric substrate. Biomaterials, 2010. 31(7): p. 1626-35.
25. Brugaletta, S., et al., Vascular compliance changes of the coronary vessel wall after 
bioresorbable vascular scaffold implantation in the treated and adjacent segments. 
Circulation journal : official journal of the Japanese Circulation Society, 2012. 76(7): 
p. 1616-23.
26. Roelofs, L.A., et al., Bladder Regeneration Using a Smart Acellular Collagen Scaffold 
with Growth Factors VEGF, FGF2 and HB-EGF. Tissue Eng Part A, 2016. 22(1-2): p. 83-
92.
27. Nuininga, J.E., et al., Urethral reconstruction of critical defects in rabbits using 
molecularly defined tubular type I collagen biomatrices: key issues in growth factor 
addition. Tissue Eng Part A, 2010. 16(11): p. 3319-28.
28. de Jonge, P., et al., Ureteral reconstruction with reinforced collagen scaffolds in a 
porcine model. J Tissue Eng Regen Med, 2016.
29. Goodwin, W.E., W.C. Casey, and W. Woolf, Percutaneous trocar (needle) nephrostomy 
in hydronephrosis. Journal of the American Medical Association, 1955. 157(11): p. 891-4.
30. Gilbert, T.W., T.L. Sellaro, and S.F. Badylak, Decellularization of tissues and organs. 
Biomaterials, 2006. 27(19): p. 3675-83.
31. Matsunuma, H., et al., Constructing a tissue-engineered ureter using a decellularized 
matrix with cultured uroepithelial cells and bone marrow-derived mononuclear cells. 
Tissue engineering, 2006. 12(3): p. 509-18.
32. Chun, S.Y., et al., Identification and characterization of bioactive factors in bladder 
submucosa matrix. Biomaterials, 2007. 28(29): p. 4251-6.
 9
Chapter 9 Ureteral reconstruction in goats using tissue engineered templates and subcutaneous pre-implantation
178 179
Supplementary figure 1. Representative stress-strain curves of the tensile ring tests showing a 
typical “J” shape. A. Hybrid construct. B. Pre-implanted construct. C. Goat ureter (midsection).
Supplementary figure 2. Outcome of blinded histological scoring of representative sections of the 
templates after pre-implantation, after functional implantation and the kidney on the treated side. 
- = not present, sp =- sporadically present, +- = somewhat present, + = present, ++ = abundant.
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Time in 
experiment
Survival Distance 
implant to 
kidney
Neo 
ureter 
size
Observations Included 
for 
histology
No pre-implantation
Goat 1 0 days Sacrificed 
in surgery
- - Ureter ruptured in surgery 
during suturing, defect 
become too long to repair
No
Goat 2 84 days Survived 5 cm 1.5 cm Double-J penetrated 
kidney, hydronephrosis
No
Goat 3 67 days Sacrificed 
2 weeks 
early 
8 cm 1.5 cm Double-J penetrated kidney No
Goat 4 42 days Sacrificed 
6 weeks 
early
11 cm - Reached humane endpoint 
(6 kg weight loss, signs 
of discomfort), Double-J 
penetrated kidney, urinoma 
on top of kidney
No
Goat 5# 91 days Survived 7 cm 1.5 cm Small diverticulum at 
anastomosis site (<1cm2)
Yes
Goat 6# 91 days Survived 7.5 cm 2.0 cm Small diverticulum at anas-
tomosis site (<1cm2)
Yes
Goat 7# 94 days Survived 7 cm 1.5 cm Double-J stent migrated 
to neo-ureter site, fistula 
around neo-ureter 
(5-10cm2), neo-ureter 
obstructed
No
Goat 8# 94 days Survived 6 cm 2.0 cm Double-J stent migrated 
to bladder, complete 
obstruction of neo-ureter, 
weight loss* (20 kg).
Yes
Pre-implantation
Goat 9 27 + 85 days Survived 7 cm 3.5 cm Double-J stent penetrated 
kidney, urinoma on top of 
kidney, distal part of the 
stent in ureteral sheets 
instead of ureteral lumen
No
Goat 10 28 + 84 days Survived 7 cm 1.5 cm No complications Yes
Goat 11 31 + 81 days Survived 10.5 cm 1.5 cm No complications Yes
Goat 12# 31 + 84 days Survived 9 cm 2.0 cm No complications Yes
Table 1. Outcome of the surgical procedure for each goat. For pre-implantation, the time in 
experiment is split to show pre-implantation + implantation times in experiment. Technical 
problems with double-J stents caused them to penetrate the kidney cortex in goats 2,3,4 and 9. These 
goats were excluded for further analysis as this may have influenced the regeneration results. *Goat 
8 unexpectedly appeared to be pregnant during the experiment. Weight loss probably resulted from 
carrying the young, as no other signs of discomfort were observed. # indicates goats in which x-ray 
was used for stent positioning.
No pre-implantation Pre-implantation
Pre-implanted tissue Collagen remnants NA +
Vicryl remnants NA +-
Inflammation NA +
Vascularization NA +-
New ureter tissue Collagen remnants +- +-
Vicryl remnants +- +-
Inflammation +- +-
Vascularization ++ ++
Muscle ingrowth +- +-
Epithelial lining - +
Kidney Normal morphology +- ++
Inflammation + +-
Fibrosis + -
Table 2. Outcome of blinded histological scoring of representative sections of the templates after pre-
implantation, after functional implantation and the kidney on the treated side. NA = not applicable, 
- = not present, +- = somewhat present, + = present, ++ = abundant. Supplementary figure 2 shows a 
dot plot of the individual scores.
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Summary
Reconstruction of large urogenital defects remains a challenging procedure that 
often require donor tissues such as local skin flaps, buccal mucosa or bowel tissue. 
While repair is often possible, it is associated with severe side effects like donor 
side morbidity, metabolic abnormalities and recurrences of the original problem. 
This thesis focused on the development of tissue engineered medical devices as an 
alternative to autologous donor tissue. Reconstructive surgery using biomaterials 
was initiated around the seventies. In the nineties, this field started to grow 
rapidly and the term “tissue engineering” was introduced [1]. Tissue engineering is 
a fast growing discipline that aims to replace or repair damaged organs and tissue 
[2]. The engineered constructs temporarily support the damaged organ or tissue 
and ideally are gradually replaced during wound healing and tissue remodeling. 
Depending on the tissue, the constructs can be designed to specifically meet the 
requirements of the local environment such as mechanical properties and the 
degradation speed. Although many approaches, including different biomaterials, 
cells and growth factors have been studied since then, clinical translation for 
urogenital applications is still limited. Only in rare cases, where routine clinical 
practice has failed repeatedly, are tissue engineered alternatives considered [3-
5]. This thesis described the current state-of-art for ureteral and urethral tissue 
engineering, followed by the development and evaluation of new flat and tubular 
collagen based constructs.
A (systematic) literature overview of the state-of-art
The first part of the thesis provides an overview of ureteral tissue engineering in 
animal models, followed by a complete overview of urethral tissue engineering in 
animal models and patients. 
Chapter 2 shows that initial attempts at reconstructing the ureter involved 
large animal models using pigs and dogs. Large defects were created followed 
by repair using collagen sponges, decellularized bowel tissue and even non-
degradable Gore-Tex. The constructs were mostly implanted without seeding cells. 
While there was evidence of tissue regeneration as evidenced by urothelial and 
muscle cell regrowth, most animals presented with fibrosis of the ureter causing 
strictures and hydronephrosis. These results show that ureteral reconstruction 
may be viable using tissue engineering, but new methods are required to overcome 
current complications. 
In chapter 3 recent advances in ureteral tissue engineering are reviewed, 
showing a shift from acellular tissue towards the application of cells on 
decellularized tissue and collagen sponges. The use of mesenchymal stem 
cells showed promising results compared to primary cells. Additionally, pre-
implantation at a non-functional location improved vascularization and stem 
cell differentiation. The low number of new publications shows that ureteral 
reconstruction remains challenging and understudied. 
Interestingly, clinical application of urogenital tissue engineering is rare even 
though there is extensive pre-clinical literature for organs like the urethra. In 
chapter 4, a systematic review on urethral tissue engineering was performed to 
investigate why clinical translation is limited and which approaches proved to be 
most successful. This review provided a comprehensive overview of all published 
literature followed by meta-analysis to study the effect of different approaches. 
Remarkably, the use of cells significantly reduced the chance of developing side 
effects in animal models, but not in clinical studies. Other design choices, such as 
the type of biomaterial or the animal model did not significantly affect the chance 
for developing side effects, having a functional urethra or completing the study. 
Quality analysis of the studies revealed that pre-clinical study design needs to 
improve to better facilitate clinical translation. Proper control groups, as well as 
blinding and randomization need to be applied. In addition, the outcome of each 
individual animal should be reported. 
New hybrid biomaterials in urogenital tissue engineering
In the second part, the use of newly developed tubular and flat collagen based 
(hybrid) constructs in vivo and in vitro is presented. In chapter 5 the effect of 
mechanical stimulation on the proliferation and differentiation of primary porcine 
smooth muscle and urothelial cells was studied. Primary cells were isolated from 
the urinary bladder of pigs and cultured on flat collagen scaffolds. Static culture 
was compared to dynamic culture in a bioreactor system. This system simulated 
the filling and voiding of the bladder to provide a mechanical strain to the cells. 
Dynamic culture resulted in higher proliferation and alignment of smooth muscle 
cells. No significant differences between smooth muscle cell specific marker 
expression was observed and no differences for any outcome was observed for 
urothelial cells. Considering the alignment, preconditioning of templates with 
smooth muscle cells under dynamic conditions may improve smooth muscle cell 
ingrowth in tissue engineered tissues, which is currently a major challenge. 
Besides the ingrowth of smooth muscle cells, vascularization of the 
constructs is a major challenge as there is limited time before necrosis occurs. In 
chapter 6 multiple smaller flat collagen scaffolds were implanted into the bladder 
of pigs instead of one large scaffold to increase the total bladder volume. The use 
of multiple smaller scaffolds instead of one large scaffold reduced the distance of 
tissue ingrowth while facilitating a similar increase in bladder surface. To further 
enhance the vascularization of these scaffolds, growth factors were included 
using heparin. Primary closure, collagen only and collagen with heparin scaffolds 
were used as controls to study the effect of adding growth factors. Implantation 
of multiple flat collagen scaffolds showed to be a feasible technique for bladder 
augmentation. The largest surface area of regenerated tissue was accomplished 
using collagen and heparin scaffolds without growth factors. No differences were 
observed after adding growth factors, which was likely due to a burst release and 
fast growth factor wash-out due to continuous urine exposure. 
Tubular collagen constructs were developed for ureteral reconstruction. 
An initial trial in pigs (chapter 4) revealed the need to enhance the mechanical 
properties of the collagen. To improve the tensile strength of collagen, knitted 
Vicryl meshes were incorporated (chapter 7). In addition, growth factors were 
added to improve the vascularization. The Vicryl meshes greatly improved the 
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mechanical properties of the scaffolds avoiding complications related to scaffold 
rupture. The increased load of synthetic material did result in a more pronounced 
immune response, causing excessive fibrosis and hydronephrosis. Similar to the 
use of growth factors in the bladder augmentation study, no significant long term 
beneficial effect was observed when growth factors were added. This suggests 
the need for optimization of growth factor delivery and local suppression of the 
immune system.
While ureteral reconstruction was possible in the pig model, there were 
complications that may have been specifically related to the animal choice. For 
practical reasons, young pigs were used. These pigs grow very fast, which may 
have influenced the wound healing process and may have led to extensive fibrosis 
and stricture formation. In chapter 8 the first experience in adult goats are 
described. Adult goats were chosen as the new species as they have a similar size 
and abdominal anatomy to young pigs and humans. Moreover, goats are more 
mobile than pigs and the use of adult animals better simulates the wound healing 
of the clinical situation. The surgical procedure was uneventful in the new model, 
but perforation of the renal cortex by the ureteral stent was observed in four out 
of seven goats during evaluation after three months. Upon close inspection, the 
pyelum of the kidneys appeared to be too small for blind stent placement. This 
necessitated the use of clinical protocols for stent placement, which involves the 
use of iodinated contrast fluids and X-ray visualization. An additional four goats 
were successfully treated using these new protocols. This relatively small and easy 
refinement to the surgical protocol greatly improved the quality of the procedure. 
It is important to always use clinical protocols when dealing with laboratory 
animals to avoid unnecessary suffering and reduce the number of animals needed. 
Finally, chapter 9 describes the results of the ureteral reconstruction in goats. 
Hybrid collagen-Vicryl constructs were implanted in the goat ureter similarly to 
the pig study (chapter 7). Instead of using growth factors, pre-implantation in 
the subcutis was performed for four weeks to improve vascularization and to 
enable partial remodeling in a non-functional location. Mechanical properties 
of pre-implanted tissue were very similar to the native tissue. In contrast, the 
collagen-Vicryl constructs were much stiffer. Pre-implanted constructs integrated 
better with the native tissue as, unlike direct implantation, no diverticula or 
template extrusion into the lumen was observed. Microscopic results were 
similar regarding smooth muscle regeneration, but urothelium regenerated 
better after pre-implantation. Moreover, when pre-implanted grafts were used 
the kidney outcome was superior: Macroscopic and microscopic morphology was 
predominantly normal, fibrosis was absent and only slight inflammation was 
observed, compared to a compromised morphology, fibrosis and inflammation 
when tubular grafts were immediately placed. This may be explained by the better 
match in tissue properties and the formation of a tissue barrier that may have 
protected the surrounding tissue from urine. This study showed the importance 
of matching construct properties to tissue properties and showed the viability of 
pre-implantation. 
Conclusions
This thesis describes the current state-of-art in urogenital tissue engineering by 
using narrative and systematic reviews. Trends in tissue engineering were identified 
and suggestions were provided to improve the clinical translation. Importantly, 
pre-clinical study design needs to be improved, specifically by using proper 
control groups, blinding and randomization. Furthermore, this thesis describes 
the development and in vitro and in vivo evaluation of collagen based tissue 
constructs for bladder augmentation and ureteral repair. Regenerative outcome 
was manipulated by either using cells, growth factors or pre-implantation. From 
these, pre-implantation showed the most promising results and may be required 
for the successful application of tissue engineering in the clinical setting. 
Future perspectives
Translating pre-clinical knowledge to clinical applications is a critical next step 
in the field of tissue engineering. To reach clinical translation, it is clear that 
pre-clinical study design should be improved as shown in chapter 4 of this thesis 
on urethral tissue engineering. Most importantly, future studies should include 
current standard treatment, such as free skin flaps, buccal mucosa or bowel tissue. 
Another remarkable observation was the type of tissue engineered constructs 
that was studied in a clinical setting. Where there is a lot of variety in pre-
clinical studies, mainly decellularized tissues without added cells were studied 
in the clinic. Another important aspect in study design is the duration of the pre-
clinical experiments. Currently, most studies have a pre-determined endpoint of 
3 or 6 months, which only shows short-term complications. Patients that receive 
these devices however, need functional organs for many years. Therefore, longer 
endpoints (> 12 months) should be considered to improve clinical translation. In 
addition, this allows better understanding of the tissue remodeling over time. 
Currently, a lot of effort is put into optimizing biomaterials like collagen 
to mimic the native tissue properties, e.g. by using different concentrations, 
by incorporating synthetic materials or by adding growth factors. While tissue 
engineering allows for diverse construct design, it is next to impossible to mimic 
native tissue due to its sheer complexity. Decellularized materials may ease this 
process as the native tissue, including its morphology and mechanical properties, 
can remain largely intact if properly treated [6]. Organ specific tissue may be 
harvested from allogenic or xenogeneic origin and treated to remove cells and 
DNA fragments to avoid graft rejection. By maintaining most of the structural 
integrity, construct properties can be very similar to the organ that is being 
treated for better integration of the graft. As the extracellular matrix is tissue and 
cell type specific, the use of these decellularized tissue may guide tissue ingrowth 
and improve the regeneration of tissue that currently shows slow regeneration 
(e.g. smooth muscle tissue) and reduce fibrosis by matching tissue properties. 
Pre-implantation is another promising strategy to improve the performance 
of tissue engineered constructs. The constructs will be partially remodeled and 
vascularized at a non-functional location, which may improve graft acceptance 
when implanted to treat a defect. Different locations for pre-implantation have 
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been evaluated, including the omentum, peritoneum and subcutis [7-9]. A major 
drawback of pre-implantation is the need for an additional implantation and 
graft harvest procedure. For adequate tissue remodeling and vascular formation, 
several weeks are required. While this may be possible for several applications 
such as urethra reconstruction, it is less suitable for ureteral reconstruction. 
The nature of ureteral damage is usually acute and requires immediate surgery. 
Nevertheless, for severe and long ureteral defects a two-stage repair using a 
percutaneous nephrostomy catheter to drain urine between stages is a standard 
treatment option [10]. This time could be used for pre-implantation. However, 
investigating this method is complicated in animals due to their mobility which 
may lead to early elimination of the nephrostomy catheter. Current pre-clinical 
data suggests that pre-implantation may greatly improve the regenerative and 
functional outcome. Therefore, it should be considered for treatments that allow 
several weeks before intervention or when a two-stage procedure is indicated. 
The addition of cells to tissue engineered grafts is still a topic of debate. 
Many individual studies report positive effects, but a recent systematic review 
shows that this is not the case for all outcome measures [11]. The addition of 
cells to tissue engineered constructs is thought to improve tissue regeneration 
by excreting cytokines and stimulating tissue development and is especially 
important for defects > 1.0 cm [12]. Stem cells are of great interest as they are 
readily available from autologous sources like the bone marrow or adipose tissue. 
These cells can differentiate to multiple cell types, including smooth muscle 
cells that are important for functionality of most urogenital organs. Similarly 
to pre-implantation, the use of cells may not be viable for all interventions as 
the isolation and expansion of the cells requires several weeks and an additional 
invasive procedure is required to harvest the cells. Even though the use of cells 
complicates the procedure, current results are promising and therefore the use of 
these cells should be further investigated.
When evaluating regeneration outcome, most studies only report qualitative 
data. One or more independent researchers usually perform histological scoring 
and a single figure is added to support these results. This method of analysis is 
subject to reporting bias as only one section of the regenerating tissue is shown. 
Therefore, reporting of qualitative data should also be considered when showing 
regenerating tissue. In chapter 6 and 7 of this thesis it was attempted to quantify 
muscle regeneration to get an objective measurement of tissue remodeling and 
reduce bias. In future studies, more sections should be evaluated in such a manner, 
preferably at multiple levels throughout the construct to improve appreciation of 
3D tissue regeneration. 
Currently, most investigators use constructs that are engineered in their 
own laboratories before application in an animal model. Whether these can be 
clinically implemented can be doubtful and may also explain the dissimilarity 
between construct used in pre-clinical and clinical studies. For successful clinical 
translation, it is important that these devices can be produced in GMP facilities 
according to ISO 13485 standards [13]. It is important to take these directives into 
account when designing the constructs for pre-clinical studies and preferably 
they should be produced under these conditions. This avoids repetitive evaluation 
when the production process cannot be translated from the lab to these facilities. 
Another important consideration is sterilization of the devices. Currently, several 
options are available, including autoclavation, gamma irradiation and ethylene 
oxide gassing. Depending on the material, not every option will be possible as 
it may influence the intrinsic scaffold/ material properties or even degrade the 
product [14-16]. Collaboration with industry partners that can help to design the 
production process to meet the regulatory requirements is crucial here. 
When taking all these suggestions into consideration, significant steps can be 
taken towards clinical application of tissue engineered medical devices.
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Samenvatting
De behandeling van grote defecten aan het urogenitale stelsel blijft een uitdaging 
waarbij vaak donor weefsel zoals een huidflap, wangslijmvlies of darmweefsel 
nodig is. Ondanks dat er vaak een behandeling mogelijk is, is er een grote kans 
op bijwerkingen zoals (blijvende) pijn na het weghalen van het donorweefsel, 
metabole stoornissen of herhaling van het probleem. Het doel van dit proefschrift 
was het ontwikkelen van kunstweefsels als alternatief voor lichaamseigen donor 
weefsel. In de jaren zeventig begon het gebruik van biomaterialen toe te nemen 
in de reconstructieve geneeskunde. Toen het vakgebied in de jaren negentig snel 
begon te groeien werd de naam “tissue engineering” geïntroduceerd [1]. Het doel 
van dit snelgroeiende vakgebied is het vervangen of repareren van beschadigde 
organen en weefsels [2]. De vervaardigde constructen geven tijdelijke steun aan 
de beschadigde organen en weefsels en worden geleidelijke door het lichaam 
afgebroken en vervangen door lichaamseigen weefsel. De constructen kunnen 
specifiek ontworpen worden om aan de eigenschappen van het te repareren 
weefsel na te bootsen. Denk hierbij aan de mechanische eigenschappen en de 
snelheid waarmee het kunstweefsel wordt afgebroken. In de loop van de jaren 
zijn er veel pogingen gedaan om deze techniek naar de kliniek te brengen. 
Desalniettemin blijft ondanks het gebruik van verschillende biomaterialen, cellen 
en groeifactoren het gebruik van deze constructen binnen de urologie gelimiteerd. 
Alleen in gevallen waarbij de normale behandeling geen baat heeft, wordt tissue 
engineering overwogen [3-5]. In het eerste deel van dit proefschrift wordt de 
huidige stand van zaken besproken omtrent het gebruik van tissue engineering 
bij ureter (urineleider) en urethra (plasbuis) defecten. In het tweede deel wordt de 
ontwikkeling van nieuwe constructen op basis van collageen bestudeerd. 
Een (systematisch) overzicht van de literatuur
In het eerste deel van dit proefschrift wordt een overzicht gegeven van ureter 
tissue engineering in dierproeven. Daarna volgt een systematisch overzicht van 
urethra tissue engineering in dierproeven en klinische studies. 
Hoofdstuk 2 beschrijft de eerste pogingen om met tissue engineering de 
ureter te repareren. Hierbij werden vooral grote dieren zoals honden en varkens 
gebruikt. In deze modellen werd een groot defect gemaakt dat vervolgens 
behandeld werd met afbreekbaar collageen en darmweefsel waar de cellen uit 
werden gehaald of Gore-Tex, een niet afbreekbaar materiaal. In de meeste 
studies werden er aan deze constructen geen cellen toegevoegd. Ondanks dat 
weefsel herstel werd waargenomen op celniveau waren er veel bijwerkingen zoals 
excessieve bindweefselvorming dat voor vernauwing van de ureter en nier schade 
zorgde. Uit dit overzicht werd geconcludeerd dat de ureter mogelijk door middel 
van tissue engineering   behandeld kan worden, maar dat er nieuwe technologie 
noodzakelijk is om bijwerkingen te voorkomen. 
In hoofdstuk 3 worden de meest recente studies naar ureter tissue 
engineering beschreven. Hierin was grote verandering in de aanpak waar 
te nemen. Er werden vaker cellen aangebracht en er werden meer natuurlijk 
materialen zoals collageen of gedecellulariseerde weefsels toegepast. Het gebruik 
van stamcellen nam ook toe en gaf veelbelovende resultaten in vergelijking tot 
volwassen cellen. Daarnaast werd een nieuwe operatietechniek geïntroduceerd 
waarbij de constructen tijdelijk elders in het lichaam geplaatst werden. Met deze 
zogenaamde pre-implantatie konden de constructen van bloedvaten voorzien 
worden en konden de stamcellen uitgroeien tot volwassen cellen. Opvallend 
was het kleine aantal nieuwe publicaties. Dit geeft weer dat het ontwikkelen van 
constructen om de ureter te behandelen erg uitdagend is. 
Een interessante observatie is het gebrek aan klinische translatie, zelfs bij 
de urethra, het meest bestudeerde orgaan van het urogenitale stelsel. Om te 
onderzoeken waarom de klinische translatie beperkt is werd in hoofdstuk 4 een 
systematisch overzicht van urethra tissue engineering uitgevoerd. Op deze manier 
werd een compleet overzicht gemaakt van alle gepubliceerde studies en kon de 
effectiviteit van verschillende behandelstrategieën met elkaar vergeleken worden. 
Opvallend was dat het gebruik van cellen in dierproeven tot een significant lager 
aantal bijwerkingen zorgt, terwijl dit effect in klinische studies niet waargenomen 
kon worden. Het gebruik van verschillende soorten biomaterialen of verschillende 
diermodellen had geen significant effect op het ontwikkelen van bijwerkingen, 
functionaliteit of de studietijd volbrengen. Uit analyse van de kwaliteit van de 
studies werd duidelijk dat het ontwerp van de studies verbeterd moet worden om 
tot klinische translatie te komen. Daarnaast dienen er betere controlegroepen 
gebruikt te worden en moet blindering en randomisatie toegepast worden. Als 
laatste is het belangrijk om de uitkomst van elk individueel dier te rapporteren. 
Nieuwe hybride biomaterialen in urogenitale tissue engineering 
In het tweede deel wordt de in vivo en in vitro ontwikkeling en evaluatie van nieuwe 
tubulaire en platte (hybride) collageen constructen besproken. In hoofdstuk 
5 wordt het effect van mechanische belasting op de groei en ontwikkeling van 
varkensblaas cellen bestudeerd. Deze cellen werden geïsoleerd uit de blaas van 
een varken en vervolgens op collageen matjes gekweekt. In een speciale bioreactor 
werd een mechanische rek op de matjes aangebracht om het vullen en legen van 
de blaas te simuleren. Deze rek zorgde voor een toename van de celgroei en zorgde 
voor het gelijk richten van de cellen. Op moleculair niveau konden geen verschillen 
worden waargenomen. Op basis van deze resultaten werd geconcludeerd dat het 
toepassen van mechanische stress tijdens het kweken van de cellen op collageen 
constructen mogelijk kan zorgen voor verbeterde ingroei van spierweefsel. 
Naast de ingroei van spierweefsel is de vorming van nieuwe bloedvaten erg 
belangrijk om weefseldood te voorkomen. In hoofdstuk 6 werden meerdere 
kleinere platte collageen constructen in de blaas van een varken getransplanteerd. 
Door meerdere kleine constructen te gebruiken kon hetzelfde oppervlak 
gerepareerd worden als met een groter construct, maar bleef de afstand die 
bloedvaten in moesten groeien beperkt. Om de bloedvat groei verder te stimuleren 
werden groeifactoren aan de constructen gebonden. Het gebruik van meerdere 
platte collageen constructen bleek een optie te zijn om het blaasoppervlak 
te vergroten. Het gebruik van groeifactoren leek geen effect te hebben op het 
weefselherstel. Een mogelijke oorzaak hiervan was de methode van binding aan 
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het construct. Doordat deze relatief zwak was kan het zijn dat de groeifactoren 
door urine uit het construct gewassen werd. 
Om de ureter te repareren zijn tubulaire constructen nodig. In een pilotstudie 
in varkens (beschreven in hoofdstuk 4) werd duidelijk dat collageen alleen niet 
sterk genoeg is om gebruikt te worden voor behandeling van ureter defecten. Om 
de kracht van de constructen te versterken werd in hoofdstuk 7 een afbreekbaar 
polymeer (Vicryl) toegevoegd. Daarnaast werden wederom groeifactoren 
aangebracht in een poging bloedvat ingroei te verbeteren. Het gebruik van Vicryl 
verbeterde de mechanische eigenschappen van de constructen en zorgde dat deze 
intact bleven. Door het gebruik van synthetische materialen trad er echter een 
grotere immuunreactie op waardoor de ureter sterk vernauwde en er nier schade 
optrad. Wederom werd er geen effect gezien bij het gebruik van groei factoren. 
Deze resultaten lieten zien dat er optimalisatie nodig is voor het gebruik van groei 
factoren en dat lokaal de immuunrespons gedempt moet worden. 
In de voorgaande hoofdstukken werd het varken als diermodel gebruik. 
Ondanks de veelbelovende resultaten werden complicaties waargenomen 
die waarschijnlijk met het diermodel te maken hebben gehad. Zo werden er 
om praktische redenen jonge dieren gebruikt. Omdat jonge varkens erg snel 
groeien kan dit effect gehad hebben op de wondgenezing en hebben gezorgd 
voor de sterke bindweefselvorming vernauwing van de ureter. In hoofdstuk 8 
beschrijven we onze eerste ervaringen met een volwassen diermodel, de geit. Er 
werd voor geiten gekozen vanwege de grote gelijkenissen in gewicht en grootte 
met volwassen mensen en jonge varkens. Daarnaast bewegen geiten veel meer 
dan varkens. De operaties verliepen zonder problemen, maar bij het onderzoek na 
drie maanden bleek dat bij het plaatsen van de stent het nierkapsel doorgeprikt 
was. Om deze complicatie te voorkomen bleek het noodzakelijk te zijn om de 
stents met contrastvloeistof en röntgendoorlichting te plaatsen. Hieruit bleek dat 
het belangrijk is om ook bij dierproeven dezelfde voorzorgmaatregelen te nemen 
als bij mensen om onnodig lijden van de dieren te voorkomen. 
In de laatste studie (hoofdstuk 9) van dit proefschrift worden de resultaten 
van de geiten studie besproken. Wederom werd gebruik gemaakt van collageen-
Vicryl constructen zoals in de varkensstudie (hoofdstuk 7). In plaats van 
groeifactoren werd dit keer echter gebruik gemaakt van pre-implantatie. Door 
de constructen eerst een maand onder de huid te plaatsen konden bloedvaten 
ingroeien en werd het construct al gedeeltelijk omgevormd tot lichaamseigen 
weefsel. Het resultaat was een weefsel dat mechanische eigenschappen had die 
gelijkwaardig waren aan het ureter weefsel. Dit in tegenstelling tot de hybride 
constructen die veel stijver waren. Na pre-implantatie was de integratie in de 
ureter beter. Op celniveau werden er echter weinig verschillen waargenomen. De 
spiercellen groeiden even ver in beide type constructen. Bij de nieren waren wel 
grote verschillen waar te nemen. Waar bij het gebruik van hybride constructen 
was verbindweefseling, ontsteking en verandering van vorm waar te nemen was 
dit na pre-implantatie grotendeels normaal. Uit deze studie bleek het belang van 
het gebruik van constructen met mechanische eigenschappen die dicht bij het te 
behandelen weefsel liggen. Pre-implantatie lijkt een veelbelovende techniek om 
dit te bewerkstelligen. 
Conclusie
In dit proefschrift wordt de huidige stand van zaken op het gebied van urogenitale 
tissue engineering beschreven doormiddel van (systematische) overzichten 
van de literatuur. Nieuwe trends op het gebied van tissue engineering konden 
worden geïdentificeerd, alsmede redenen voor een beperkte klinische translatie. 
Belangrijke punten hierbij is het ontwerp van de dierproeven, specifiek het gebruik 
van de juiste controle groepen, blindering en randomisatie. Daarnaast beschrijft 
dit proefschrift de ontwikkeling van (hybride) collageen constructen voor het 
vergroten van de blaascapaciteit en het repareren van grote ureter defecten. Om 
de uitkomst te verbeteren is gebruik gemaakt van cellen, groeifactoren en pre-
implantatie. Van deze technieken lijkt pre-implantatie het meest veelbelovend en 
misschien zelfs noodzakelijk voor het gebruik in de kliniek. 
Toekomstvisie
Klinische translatie van de kennis die opgedaan is tijdens dierproeven en 
laboratoriumonderzoek is een cruciale stap die genomen moet worden in het 
vakgebied van tissue engineering. Uit hoofdstuk 4 is duidelijk geworden dat het 
ontwerp van dierproeven verbeterd moet worden om deze klinische translatie 
te bewerkstelligen. Het belangrijkste aandachtspunt is het gebruik van de 
juiste controle groepen, zoals het gebruik van een huid flap, wangslijmvlies 
of darmweefsel. Een andere opmerkelijke bevinding was het materiaal dat 
gebruikt wordt in de klinische studies. In tegenstelling tot de dierproeven, 
waar een grote variatie aan materialen wordt gebruikt, werden er voornamelijk 
gedecellulariseerde weefsels zonder toegevoegde cellen toegepast. Daarnaast is 
het aan te bevelen om de duur dat de dieren in het experiment zitten te verlengen. 
De meeste dierproeven duren momenteel drie tot zes maanden, terwijl patiënten 
nog vele jaren zullen leven na de operatie. Het is daarom aan te bevelen om ook 
langere tijdspunten (> 12 maanden) te onderzoeken. Hierdoor zullen niet alleen 
de korte termijn complicaties bekend worden, maar ook complicaties die pas later 
optreden. Daarnaast geeft dit een beter beeld van de weefselgenezing over de 
jaren.  
Er wordt momenteel veel energie gestoken in het optimaliseren van 
biomaterialen zoals collageen. Zo worden verschillende concentraties, combinaties 
van materialen en groeibevorderende eiwitten getest en gecombineerd. Hoewel 
het met tissue engineering mogelijk is om deze condities uit te proberen is 
het momenteel door de complexiteit van lichaamsweefsel onmogelijk om deze 
weefsels goed na te maken in het laboratorium. Gedecellulariseerde materialen 
kunnen een goede stap zijn aangezien de structuur en weefseleigenschappen 
grotendeels intact kunnen blijven [6]. Een mogelijkheid is het gebruik van 
orgaan specifiek weefsel van allogene of xenogene oorsprong dat behandeld is 
om alle cellen en DNA restanten te verwijderen. Doordat de weefselstructuur en 
weefseleigenschappen grotendeels intact blijven lijkt het weefsel veel op het te 
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behandelen weefsel. Dit kan zorgen voor een betere integratie van het construct. 
De structuur van het gedecellulariseerde weefsel is orgaan en celtype specifiek. 
Hierdoor kunnen deze weefsels de ingroei van belangrijk functioneel weefsel, 
zoals spiercellen, bevorderen. Daarnaast kan het tot een vermindering van 
bindweefselvorming zorgen. 
Een andere veelbelovende strategie is het pre-implanteren van een tissue 
engineered construct. Doordat de constructen gedurende de pre-implantatie 
periode deels vervangen worden door lichaamseigen weefsel en er bloedvat 
ingroei plaats kan vinden kunnen de eigenschappen verbeterd worden. Er zijn 
verschillende plekken onderzocht waar het weefsel tijdelijk geplaatst kan worden, 
bijvoorbeeld in het omentum, peritoneum en de subcutis [7-9]. Een groot nadeel 
van pre-implantatie is de lange tijd die hiervoor nodig is. Om bloedvat en weefsel 
ingroei te krijgen zijn meerdere weken nodig. Dit is voor veel behandelingen geen 
probleem aan gezien deze vaak gepland kunnen worden. Voor de ureter kan dit 
lastig zijn, aangezien ureter trauma vaak acuut is, waardoor direct behandeling 
nodig is. Desalniettemin is er bij ernstig trauma vaak een tweede procedure nodig 
waarbij de eerste alleen dient ter stabilisatie. Er wordt dan tijdelijk een katheter 
geplaatst waardoor er geen urine door de ureter loopt [10]. De tijd die nodig is 
om te stabiliseren zou gebruikt kunnen worden voor de pre-implantatie. Het 
onderzoeken van deze methode is echter gecompliceerd aangezien dieren erg 
mobiel zijn en de katheter zullen proberen te verwijderen. De huidige dierproeven 
suggereren dat pre-implantatie een grote verbetering kan geven bij het weefsel 
herstel en de functionaliteit van het urine systeem. Het is daarom aan te raden 
om pre-implantatie te overwegen als de operatieplanning dit toe laat. 
Het toevoegen van cellen is een controversieel onderwerp waar veel discussie 
over plaats vindt. Veel onderzoeken rapporteren positieve resultaten. Een recente 
systematische vergelijking laat echter zien dat dit niet voor alle uitkomsten geldt 
[11]. Cellen worden toegevoegd vanwege de hypothese dat deze groeibevorderende 
eigenschappen hebben, zoals het uitscheiden van eiwitten en het sturen van de 
uitgroei van stamcellen. Dit is voornamelijk belangrijk bij defecten > 1.0 cm [12]. 
Stamcellen worden veel onderzocht omdat deze in grote getalen te verkrijgen 
zijn van de patiënt zelf, bijvoorbeeld uit het beenmerg of vetweefsel. Daarnaast 
kunnen deze cellen uitgroeien tot een groot aantal volwassen cellen, waaronder 
spiercellen die belangrijk zijn voor de werking van het urogenitale stelsel. Het 
opkweken van deze cellen is echter een tijds- en arbeidsintensief proces, waardoor 
dit niet altijd mogelijk is bij de behandelingen van ureter defecten. Daarnaast is 
een invasieve handeling nodig om de cellen te verkrijgen. Desalniettemin zijn 
de resultaten veelbelovend en zal het gebruik van stamcellen verder onderzocht 
moeten worden. 
Momenteel wordt de uitkomst van het weefselherstel voornamelijk kwalitatief 
onderzocht, waarbij een of meerdere onafhankelijke onderzoekers een oordeel 
geven. Deze methode heeft een grote kans op vooroordelen bij de beoordeling 
aangezien maar een klein deel van het weefsel bekeken wordt. Het toepassen van 
kwantitatieve beoordeling kan deze vooroordelen verminderen aangezien het 
gehele weefsel automatisch onderzocht kan worden. In hoofdstuk 6 en 7 van dit 
proefschrift is getracht de spierweefsel ingroei kwantitatief te beoordelen om zo 
een onbevooroordeeld oordeel over de weefselregeneratie te kunnen geven. In 
toekomstige studies kan deze methode gebruikt worden om een groter aantal 
niveaus van het weefsel te beoordelen en zelfs driedimensionale reconstructies 
te maken. 
Momenteel worden de meeste constructen die gebruikt worden in 
dierproeven gefabriceerd in het laboratorium van de onderzoekers. Het is dan 
ook maar de vraag of deze constructen ooit gebruikt zullen worden voor klinische 
toepassingen. Voordat deze materialen naar de kliniek gebracht kunnen worden 
is het belangrijk dat deze onder GMP condities en volgens ISO standaarden 
gefabriceerd worden [13]. Het is niet vanzelfsprekend dat een construct dat in het 
laboratorium gemaakt kan worden ook onder deze omstandigheden vervaardigd 
kan worden. Het is daarom aan te bevelen dat er al rekening gehouden wordt 
bij het ontwerpen van de constructen dat het in de toekomst onder bepaalde 
omstandigheden gemaakt moet kunnen worden. Sterilisatie is een belangrijk 
voorbeeld hiervan. Veel materialen die gebruikt worden in dierproeven worden 
gedesinfecteerd met ethanol, terwijl ze gesteriliseerd moeten worden voor 
klinisch gebruik. Dit kan met behulp van autoclaveren, bestraling en het gebruik 
van bepaalde gassen. Echter, niet alle materialen zijn geschikt om gesteriliseerd te 
worden met deze opties aangezien ze van invloed kunnen zijn op de eigenschappen 
van de constructen [14-16]. Dit kan uiteindelijk zorgen van discrepanties tussen 
dierproefresultaten en eerste klinische proeven. Samenwerking met partners uit 
de industrie is belangrijk om te zorgen dat het productieproces mogelijk is en dat 
er voldaan kan worden aan de regelgeving. 
Wanneer de bovenstaande aanbevelingen in acht genomen worden kunnen 
er grote stappen gezet worden om tissue engineering naar de kliniek te brengen. 
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Tilly, Kees, Jeanette, Anglita, Vicky, Elze, Marion, Nicolien en Renate, ontzettend 
bedankt voor de fijne tijd op het lab. Ook wil ik Boy, Allert, Dick, Hans, Rianne, 
Caroline, Tom, Siebren en Max, de artsen en arts-onderzoekers die (soms) op het 
lab te vinden waren bedanken voor alle onvergetelijke momenten. Boy en Allert, 
met 9gag, de speld, flauwe woordgrappen en regelmatig een biertje ben ik blij 
dat ik jullie heb leren kennen. Beste Jack, bedankt dat ik bij jou op het lab mijn 
onderzoek heb kunnen doen. Je hebt een leuke club mensen bij elkaar weten te 
krijgen en houden!
Vasilis, thanks for the great teamwork during my first years at the lab. Your sense 
of humor and dedication to our projects was much appreciated. Luc, bedankt voor 
de prettige samenwerking. Ondanks dat je al even bij het lab weg was hebben we 
die laatste studie toch nog even mooi weg kunnen zetten! Barbara en Robert, heel 
erg bedankt voor jullie hulp bij de operaties. Samen met Wout hebben jullie de 
complexe ingrepen kinderspel doen lijken. 
Dit proefschrift was nooit tot stand gekomen zonder de inzet van het team op 
het CDL en de boerderij. Alex, Maikel en Wilma, ik heb met veel plezier met 
jullie samengewerkt. De sfeer bij jullie was altijd goed en de lange dagen die ik bij 
jullie heb doorgebracht voelden slechts als enkele uurtjes. Conrad, Tom en Henk, 
bedankt voor de goede verzorging van de dieren op de boerderij.
Ook ben ik dankbaar voor de prettige samenwerking met de afdeling Biochemie. 
Toin en Willeke, bedankt voor jullie input en expertise op het gebied van collageen. 
Elly, bedankt voor het wegwijs maken in de biochemie technieken. Ook hadden 
jullie een toffe club onderzoekers rondlopen: Michiel, Luuk, René, Henk, Corien 
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Luuk, aan het begin van mijn promotie zijn we samen in de “Collagen Mansion” 
gaan wonen. Wat een mooie tijd hebben we hier gehad! Heel erg bedankt voor 
de gezelligheid op deze prachtige locatie! Michiel, ik ben blij dat je als paranimf 
naast me staat vandaag. 
Frank, bedankt voor het advies dat je me als mentor hebt gegeven. Rob en Joanna, 
ik ben jullie erg dankbaar voor jullie expertise (en geduld) bij het schrijven van de 
systematic review. Het is een prachtig stuk geworden!
Stephan, Ruud, Mark H en Mark B, we kennen elkaar al ontzettend lang en ik 
ben blij dat we elkaar nog steeds regelmatig zien. Het doet me altijd goed om 
jullie te spreken na een week hard werken! Jullie vriendschap is ontzettend 
waardevol voor mij. Michiel P, René, Thomas, Jon, Michiel C, Sander, Pim, Frank 
en Stefan, bedankt voor de gezellige studietijd en leuke uitstapjes die we nog 
steeds regelmatig maken. Tractus Sanus, elke keer als ik jullie zie voelt het weer 
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alsof we in de kelder van de Horst belangrijk aan het doen zijn. Bedankt Erik, 
Evita, Michiel, Daan en Kaj! Beste bRAXIANEN, jullie zijn inmiddels met te veel 
om allemaal apart op te noemen, maar toch wilde ik jullie nog even noemen in 
dit dankwoord. Ook als ik jullie weer zie lijkt het alsof ik pas gisteren richting 
Nijmegen ben gegaan. Hetzelfde geldt voor jullie mannen van de TvB13. De 
kerstdiners in mei of november zijn nog steeds legendarisch!
Hilma, Laurent, Saydi, en Ron en Marjoleine, ik prijs mezelf gelukkig dat ik zo’n 
leuke schoonfamilie erbij heb gekregen. Bedankt voor jullie interesse in mijn 
onderzoek. 
Marthe en Tijl, mijn kleine zusje en broertje. In een poging een goed voorbeeld te 
zijn als grote broer ga ik altijd net wat harder lopen. Bedankt voor jullie luisterende 
oor en goede adviezen. Marthe, ik hoop dat je ook snel aan het dankwoord van 
je proefschrift kan beginnen! Tijl, het is een eer dat je vandaag naast mij staat als 
paranimf. Klaas en Jitske, heel fijn dat jullie deze twee gelukkig maken!
Lieve pap en mam, ik zeg het niet vaak, maar ik ben ontzettend dankbaar voor al 
jullie steun door de jaren heen. Jullie staan altijd voor me klaar en halen het beste 
in mij naar boven. Jullie zijn geweldig!
Lieve Eilien, die ene avond toch nog even op stap gaan is de beste beslissing die 
ik ooit heb genomen: Daar heb ik jou ontmoet. Bij jou kan ik altijd mezelf zijn en 
voel ik me helemaal thuis. Ik kijk uit naar alle mooie momenten die we samen 
gaan beleven. Ik hou van je!
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